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Abstract
This thesis investigates several aspects of familial Alzheimer disease (FAD). The 
specific results of the work undertaken for this thesis were: (1) The proportion of 
FAD accounted for by mutations in known genes was 68% in 31 FAD families; Those 
without mutations were ten years older and associated with APOE s4; (2) The 
phenotype of PSEN1 FAD was found to share an early age at onset and features 
broadly suggestive of AD. However the phenotype was broad and included spastic 
paraparesis in association with “cotton wool” plaques in PSENI E280G; (3) Plasma 
amyloid P peptide was found to be a potentially useful biomarker of FAD with levels 
being elevated in mutations carriers compared with non-carriers, and levels in at risk 
subjects falling halfway between the groups; (4) Cerebral atrophy in early onset AD 
was 2-8% (95% Cl 2*3—3-3) per year which rose by 0-32% per year (0-15-0*50); (5) 
Pre-symptomatic medial temporal lobe atrophy in FAD at risk family members who 
become symptomatic was demonstrated with MRI medial temporal lobe volumes 
16.6% lower in patients than controls and a higher rate of atrophy in patients than 
controls; (6) Cerebral atrophy in FAD was shown to begin in the posterior cingulate, 
temporoparietal and medial temporal cortices in presymptomatic FAD patients, a 
finding in accordance with previous cross-sectional neuropathological studies; (7) By 
contrast the onset and progression of cerebral atrophy in non-AD familial dementia 
was shown to markedly different in an presymptomatic FTLD patient with focal left 
frontal lobe onset reflecting the different clinical presentation; (8) Cerebral atrophy in 
FAD was found not to progress significantly faster than sporadic AD despite a twenty 
year age difference between the groups.
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The problem
Alzheimer’s disease (AD) is the commonest form of dementia. AD inevitably follows 
a progressive course. As age is the single biggest risk factor for the development of 
AD, rising life expectancy in the western world means that AD will increasingly 
impact not only on individuals and families, but also on society as a whole.
The aetiology of sporadic AD (SAD) is thought to result from a combination 
of environmental and genetic factors. By contrast autosomal dominant familial AD 
(FAD) is a rare genetic form of the disease that occurs in the presenium. Patients from 
families with FAD particularly lend themselves to clinical, biochemical and 
neuroimaging studies as they generally do not have the co-morbidities seen in SAD 
occurring in later age. Furthermore the development of symptoms and signs can 
reasonably be taken to be due to FAD even without neuropathological confirmation. 
However, the Dementia Research Group (DRG) collection of FAD families contained 
a number of families that had previously been screened without success for mutations 
in the recognised causative FAD genes: APP, PSEN1 and PSEN2, all of which affect 
APP processing and alter amyloid p production - a key component of neuritic plaques. 
The study of the genetics of these families allowed the determination of the 
proportion accounted for by known FAD genes, and the clinical phenotype associated 
with these mutations. Since amyloid p peptide is not only synthesised in brain, but 
also in platelets the assessment of plasma amyloid P peptide as a biomarker of FAD in 
family members could also be performed.
The pathological signature lesions of AD are extra-cellular amyloid plaques, 
and intracellular neurofibrillary tangles. It is not yet possible to assess the distribution 
or quantity of these abnormal proteins reliably in vivo. However an inevitable effect 
of neuronal loss is cerebral atrophy. This atrophy is seen at post-mortem, but may also 
be visualized in vivo using volumetric magnetic resonance imaging (MRI). In AD, 
atrophy is both global, as well as regional, with early and prominent involvement of 
medial temporal lobe structures. In order to quantify rates of brain atrophy at an 
individual level, it is necessary to compare serial scans taken from the same individual 
over time. In order to facilitate accurate comparison, these scans can be digitally 
matched (registered) to one another, with a high degree of precision. It is then 
possible to measure rates of global atrophy either by comparing the brain volumes 
directly, by assessing expansion of cerebrospinal fluid space over time, or by using an
13
automated method of brain volume change, the brain boundary shift integral (BBSI). 
Atrophy rates derived using the BBSI can distinguish groups of patients with 
Alzheimer’s disease from controls over a one year period. Using these imaging 
techniques the rate of progression of AD over a period of many years can be 
established and whether this process accelerates; the medial temporal lobe, the 
proposed area of earliest change, can be studied in at risk FAD patients during the 
time that they become affected to determine whether there is pre-symptomatic 
atrophy; furthermore using fluid registration (where the brain is treated as a viscous 
fluid rather than a rigid body) of serial MRI the site of earliest change can be 
determined in vivo without a priori decisions based on established neuroimaging and 
neuropathological knowledge. Having established the onset and progression of 
cerebral atrophy in FAD this can be compared with non-AD familial dementia to see 
whether this pattern is the same or, like the clinical presentation, different potentially 
adding to the biological plausibility of the technique. The progression of cerebral 
atrophy in FAD has not previously been compared with SAD and the Specialist 
Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery 
proved a valuable source of patients to allow this comparison.
The aim of the work undertaken for this thesis was to determine whether there 
were any novel FAD mutations in DRG families, whether these were associated with 
unusual phenotypes, and whether plasma amyloid p peptide was a useful biomarker. 
Neuroimaging studies using MRI were performed to assess how cerebral atrophy 
starts and how it progresses over time in FAD. I had the opportunity of comparing this 
with the onset of cerebral atrophy in non-AD familial dementia. I also had the 
opportunity of comparing the progression of cerebral atrophy of FAD with SAD.
Specific aims were: (1) to determine the proportion of FAD accounted for by 
mutations in known genes; (2) to determine whether there is a specific PSEN1 FAD 
phenotype; (3) to determine whether plasma amyloid P peptide is a useful biomarker 
of FAD; (4) to determine whether the progression of cerebral atrophy in early onset 
AD is linear; (5) to determine whether there is pre-symptomatic medial temporal lobe 
atrophy in FAD at risk family members who become symptomatic; (6) to determine 
where cerebral atrophy in FAD begins in at risk family members who become 
symptomatic; (7) to assess whether the onset and progression of cerebral atrophy is 
different in non-AD familial dementia; (8) to compare cerebral atrophy in FAD and 
SAD to determine whether FAD progresses more quickly.
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1. Introduction
1.1 Dementia
Dementia is a clinical syndrome characterised by a decline in both cognitive and 
social function to the extent that it interferes with the activities of daily living. A 
concise definition is provided by the American Psychiatric Association Diagnostic 
and Statistical Manual of Mental Disorders version 4 (DSM-IV) (1994). This requires 
the development of multiple cognitive deficits that include memory impairment and at 
least one of: aphasia (language disturbance), apraxia (impaired ability to carry out 
motor activities despite intact motor function), agnosia (failure to recognise or
identify objects despite intact sensory function) or executive dysfunction (i.e.
disturbance in planning, organising, sequencing, abstracting). A diagnosis of dementia 
should not be made if the cognitive deficits occur exclusively in the presence of 
delirium. Usually the disorder is progressive, but occasionally may be reversed or 
arrested when the underlying aetiology is treatable. Not uncommonly patients 
develop, or occasionally present with, depression, personality change or apathy.
The prevalence of dementia depends on the criteria used to define the 
syndrome and can vary tenfold (Erkinjuntti et al. 1997). Regardless of the criteria 
used there is a clear age related increase in incidence of dementia. Meta-analyses of 
studies done in developed countries have established dementia prevalence at around
1.5% at age 65 years, doubling every four years to reach about 30% at 80 years 
(Ritchie & Lovestone 2002). Dementia is currently the third most common cause of 
death and is predominantly a problem that affects the developed world. However, the 
larger population size and increasing longevity in the developing world means that the 
number of patients with dementia is rising faster than at any time in history and it is 
estimated that it will be the second most common cause of death by the middle of this 
century. There are many causes for the syndrome of dementia, the most common 
being Alzheimer’s disease (Ritchie & Lovestone 2002).
1.2 Alzheimer9s disease
In 1907 Alois Alzheimer reported the case of Auguste D, a 51 year old woman who 
had developed multiple cortical deficits with prominent dysphasia, dyslexia, 
dysgraphia, and agnosia in addition to a severe memory impairment and paranoid 
delusions . Neuropathological examination of her brain using the then newly available
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silver stains revealed senile plaques, consisting of dystrophic neurites, and dense 
perikaryal staining, which was termed the neurofibrillary tangle. The cerebral cortex 
was atrophic, which was assumed to be due to cell loss. Alzheimer subsequently 
wondered how senile dementia differed from normal ageing, and whether cognitive 
impairment seen in the elderly should be considered a separate entity from the 
presenile cases that he had already reported. Specific clinical features, in particular 
dysphasia, were more prominent in younger onset patients and Emil Kraepelin 
concluded that there was a difference and proposed the eponym Alzheimer’s disease. 
The disease continued to be considered a rarity confined to the presenium until the 
landmark studies of Blessed, Tomlinson and Roth (1968), who showed that the 
neuropathological substrates of senile dementia and Alzheimer’s disease (AD) were 
identical, making AD one of the most common diseases of an ageing population.
1.2.1 Epidemiology
1.2.1.1 Prevalence
There are an estimated 400,000 patients with AD in the United Kingdom (Alzheimer 
Society (2004), UK) and nearly five million in the United States of America (Hebert 
et al. 2003). The prevalence of AD increases rapidly with age from 0.3% in the 
seventh decade of life, to 3.2% in the eight decade of life, and to 10.8% in the ninth 
decade of life (Kokmen et al. 1989; Rocca et al. 1991). In view of the improved 
survival of those aged over 75 years, the number of AD patients in the USA is 
expected to triple to 13.2 million by 2050 with a concomitant increase in the 
economic and caregiver burden (Hebert et al. 2003).
1.2.1.2 Risk factors
As discussed above Alzheimer’s disease is increasingly common in late life and age 
appears to be the primary risk factor for AD. Familial clustering is recognised in 10% 
of AD patients and family history is the most important risk factor after age (Van 
Duijn et al. 1991). Some families display an autosomal dominant pattern of 
inheritance, a fact which was recognised relatively soon after Alzheimer’s original 
description of Auguste D (Lowenberg & Waggoner 1934; Schottky 1932). The 
genetics of AD, the role of Apolipoprotein E (APOE) genotype and autosomal
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dominant AD genes will be discussed in detail later. Other associations such as head 
trauma are less robust (Mayeux et al. 1993; Mehta et al. 1999; van Duijn et al. 1992).
Recently there has been much interest in the association of atherosclerosis and 
“vascular” risk factors with the development of AD (Snowdon et al. 1997). A Dutch 
prospective incidence study from Rotterdam showed a significant relationship 
between vascular risk factors and AD (Kalmijn et al. 1997; Ott et al. 1997; Ott et al. 
1998; Ott et al. 1999). In this three year longitudinal study of 6000 residents from a 
specific district of Rotterdam 126 residents developed dementia of whom 89 were 
diagnosed with AD. Atherosclerosis, cigarette smoking, hypercholesterolaemia, 
cardiovascular disease and diabetes were all associated with a significantly higher risk 
of AD. There was a doubling of risk associated with type II diabetes mellitus, the risk 
being greatest for those who were insulin requiring. Atrial fibrillation was a greater 
risk factor for AD than vascular dementia in this study, which may reflect the relative 
incidences of these two dementias. Smoking and a high fat diet were independent risk 
factors that also doubled risk, although when diet was looked at in more detail a high 
intake of total, saturated, and trans fat and cholesterol (and low intake of mono or 
poly unsaturated fats) were not associated with increased risk of dementia or its 
subtypes (Engelhart et al. 2002). Moderate alcohol consumption appeared to be 
protective (Ruitenberg et al. 2002), a finding previously demonstrated in the French 
PAQUID cohort, an epidemiological study of normal and pathological aging after 65 
years of 2950 non-demented people living at home in the south west of France 
(Commenges et al. 2000).
A Finnish epidemiological study showed that patients with a raised systolic 
blood pressure (BP) or high serum cholesterol in midlife had a significantly higher 
risk of AD in later life, and their effect appeared to be additive (Kivipelto et al. 
2001). However, the data on blood pressure are complex. Studies that report an 
association between hypertension and AD share a long observation period before 
onset of dementia. High systolic or diastolic BP at 70 years of age was predictive of 
onset of AD between the ages of 79 and 85 years in the Gothenburg Longitudinal 
Study on Aging (Skoog et al. 1996). Similarly systolic BP above 160 mmHg or 
diastolic BP above 90 mmHg measured between 1961 and 1965 was predictive of AD 
diagnosis in 1991 in the Honolulu-Asia Aging study (Launer et al. 2000). 
Longitudinal studies therefore report associations between early hypertension, but not
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concurrent hypertension and dementia. Cross sectional studies and short term 
longitudinal studies report associations between low BP and dementia (Ruitenberg et 
al. 2001). This may be because BP declines in the years preceding the onset of AD 
and that BP continues to decline during the course of the disease. A more recent study 
suggests that both very low diastolic BP (<66 mmHg) and very high systolic BP 
(>180 mmHg) were related to an increased incidence of AD in the six year 
Kungsholmen study (Qiu et al. 2003). This increased risk of AD due to low diastolic 
BP was only found in those treated with antihypertensive drugs, which suggests that 
patients at high risk of AD had a history of hypertension.
In population terms vascular risk factors are potentially very important as 
some of them may be modifiable. Supporting evidence of vascular risk factor 
assessment and appropriate treatment is now beginning to emerge (in't Veld et al. 
2001). The reduction of cholesterol seems to be particulary beneficial with a report of 
a 70% reduction in the incidence of AD (Jick et al. 2000) and a 39% lower risk of AD 
in statin users relative to nonstatin users (Zamrini, McGwin, & Roseman 2004). The 
epidemiological data are underpinned by multiple laboratory studies. A reduction in 
cholesterol levels results in both a reduction in plasma Ap peptide levels and Ap 
deposition in brain (Fassbender et al. 2001; Kojro et al. 2001; Refolo et al. 2001). In 
the study by Kojro et al. (2001) cholesterol lowering treatment of peripheral and 
neural cell lines resulted in a dramatic increase of secreted a-secretase cleaved soluble 
APP, and an accompanied reduction in secretion of Ap peptides. Similar results were 
obtained in mice by Refolo et al. (2001) who additionally observed a strong, positive 
correlation between the amount of plasma cholesterol and Ap. The mechanism of 
action of statins in the prevention of AD is unclear, but it seems that this is an effect 
beyond cholesterol lowering (for review see Crisby et al. 2002). Clearly this opens a 
novel and relatively safe therapeutic pathway for primary and secondary prevention 
and possibly treatment of AD.
1.2.2 Clinical features
Alzheimer’s disease is characterised by progressive memory impairment of insidious 
onset. Episodic or autobiographical memory is primarily affected with the early loss 
of event memory. Frequently patients have difficulty remembering familiar routes. 
Procedural memory and short term memory, as in digit span, are preserved until later
19
in the illness. Semantic memory problems, attentional deficits and executive 
dysfunction typically appear after the initial amnestic symptoms.
A collateral history from the spouse or other informant is essential as the 
patient may not be aware of the presence or severity of these deficits (anosognosia) 
and is often capable of maintaining a social fa<?ade that can mask the cognitive 
impairment. Deficits in problem solving, language, calculation and visuospatial skills 
appear relatively early in the disease and reflect dysfunction of non-memory cognitive 
domains. Atypical forms of AD are well recognised and include progressive visual 
dysfunction, progressive biparietal dysfunction, and progressive aphasia (for review 
see Galton et al. 2000).
Non-cognitive symptoms occur frequently: depressed mood can occur prior to 
or coincident with diagnosis in up to 25% of patients (Devanand et al. 1996). 
Delusions, hallucinations and aggression are a frequent management problem later on 
and are often the most distressing to patients and family members (Bums, Jacoby, & 
Levy 1990; Harvey 1996). These behavioural features are common reasons for 
institutionalisation.
Early in the disease abnormalities on neurological examination are usually 
confined to deficits of higher mental function. Dyspraxia is typical once patients are 
moderately affected. Gegenhalten may be found (Frommelt et al. 1991; Tyrrell & 
Rossor 1988), but the presence of extrapyramidal features in the absence of 
neuroleptic treatment raises the possibility of a diagnosis of dementia with Lewy 
bodies (Lippa, Smith, & Swearer 1994; McKeith et al. 1994) or possibly 
frontotemporal lobar degeneration (Foster et al. 1997; Neary et al. 1998).
Motor function and co-ordination are typically preserved until late in the 
disease. Seizures are a recognised late manifestation and may be predated by 
myoclonus, with some evidence that both these features appear more frequently in 
early onset AD (Forstl et al. 1992; Janssen et al. 2000; Mayeux, Stem, & Spanton 
1985).
After a gradual decline all testable cognitive function is lost, and the patient 
becomes mute, bedbound and usually succumbs to intercurrent medical 
complications. From the time of diagnosis, the disease runs approximately four to 16 
years until the time of death with a mean survival of ten years (Jost & Grossberg
20
1995). In recent times survival has been increasing, though this may in part reflect 
earlier diagnosis and the increasing realisation that AD may be associated with a 
prolonged amnestic prodrome (Backman, Small, & Fratiglioni 2001; Elias et al. 
2000). This relatively subtle cognitive dysfunction has generated much work to define 
the syndrome of (amnestic) mild cognitive impairment (MCI), which may represent a 
precursor state of AD (Petersen et al. 1999).
Whilst AD has a devastating effect on the patient, in certain respects it takes 
an even greater toll on their family. Family care givers commonly feel helpless, 
frustrated, exhausted and often face considerable financial difficulties. Almost half of 
family care givers become depressed (Cohen & Eisdorfer 1988). Although medical 
guidance and support can help them anticipate and prepare for some of the 
consequences of AD, family members frequently find themselves reacting to crises as 
they arise. As a result dementia care requires a multidisciplinary approach with input 
from many professionals and the voluntary sector.
1.2.3 Diagnostic clinical criteria
A definitive diagnosis of AD requires neuropathological examination of the brain to 
demonstrate neuritic plaques and neurofibrillary tangles, the hallmark lesions of AD. 
However, over the last fifteen years the reliability of ante mortem diagnosis of AD 
has improved significantly. This may in part reflect the increased interest in AD 
resulting from the development and licensing of the acetylcholinesterase inhibitors 
(AChEI), donepezil, rivastigmine and galantamine (Rogers et al. 1998; Rosier et al. 
1999; Wilcock, Lilienfeld, & Gaens 2000) and more recently the N-Methyl-D- 
aspartate (NMDA) type receptor antagonist memantine (Doody et al. 2004), but is 
largely due to the development of standardised diagnostic criteria. The most 
prominent amongst these are the research criteria developed jointly between the 
National Institute of Neurological and Communicative Disorders and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al. 
1984). The NINCDS-ADRDA criteria define diagnoses of “definite”, “probable”, and 
“possible” AD. The NINCDS-ADRDA criteria were used in the studies described in 
this thesis and unless otherwise specified AD refers to “probable” AD. The sensitivity 
and specificity of the NINCDS-ADRDA criteria discussed below have been found to
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be relatively independent of the specific criteria used for a neuropathological 
diagnosis of AD (Nagy et al. 1998).
Definite AD is reserved for the gold standard of histopathological examination 
of the brain at autopsy. Brain biopsy provides a lesser degree of diagnostic certainty 
but is included in this category. Probable AD requires the presence of dementia to be 
established by clinical examination and simple cognitive tests, and confirmed by 
neuropsychological tests. The symptoms of memory loss and other cognitive deficits 
must be progressive. A Probable AD diagnosis also requires the absence of 
disturbances of consciousness, other brain diseases and systemic illnesses that could 
explain the cognitive impairments. Impaired activities of daily living and a positive 
family history of AD are considered supportive of the diagnosis. The latter may allow 
the inclusion of patients with autosomal dominant AD with an age at onset younger 
than the minimum age of 40 years considered to be the threshold in the criteria. The 
diagnosis of Probable AD is considered unlikely when the onset is sudden and/or 
certain focal deficits are present, as distinct from the gradual and insidious decline 
expected in AD; seizures or extrapyramidal symptoms occurring early in the course of 
the disease would make the Probable AD diagnosis unlikely. Possible AD is used to 
describe those cases of dementia (or progressive isolated cognitive impairments) in 
which the onset, presentation, or clinical course is somewhat atypical, yet no other 
explanation for the impairment is found. In the event that a systemic or other brain 
disease is present the diagnosis of possible AD can still be applied providing the 
second illness is not considered to be the cause of the dementia. The criteria are listed 
in full below.
1.2.3.1 NINCDS-ADRDA criteria for Alzheimer’s disease
I. Criteria for the diagnosis of Definite Alzheimer’s disease:
> Clinical criteria for probable Alzheimer’s disease fulfilled, AND
> Histopathological evidence obtained from autopsy
II. Criteria for the diagnosis of Probable Alzheimer’s disease:
y  Dementia established by clinical examination, and documented by the 
MMSE, Blessed Dementia scale or some similar examination, and 
confirmed by neuropsychological tests
> Deficits in two or more areas of cognition
> Progressive worsening of memory and other cognitive functions
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> No disturbance of consciousness
> Onset between ages 40 and 90, most often after age 65
> Absence of systemic disorders or other brain diseases that in and of 
themselves could account for the progressive deficits in memory and 
cognition
III. Diagnosis of Probable Alzheimer’s disease is supported by:
> Progressive deterioration of specific cognitive functions such as 
language (aphasia), motor skills (apraxia) and perception (agnosia)
> Impaired activities of daily living and altered patterns of behaviour
> Family history of similar disorders, particularly if confirmed 
neuropathologically
> Normal lumbar puncture as evaluated by standard techniques
> Normal pattern or non-specific changes in EEG, such as increased slow- 
wave activity
> Evidence of cerebral atrophy on CT and progression documented by 
serial observation
IV. Other clinical features consistent with the diagnosis of Probable 
Alzheimer’s disease, after exclusion of causes of dementia other than 
Alzheimer’s disease, include:
> Plateaus in the course of progression of the illness
> Associated symptoms of depression, insomnia, incontinence, delusions, 
illusions, hallucinations, catastrophic verbal, emotional, or physical 
outbursts, sexual disorders and weight loss
> Other neurological abnormalities in some patients especially with more 
advanced disease and including motor signs such as increased muscle 
tone, myoclonus or gait disorder
> Seizures in advanced disease
> CT normal for age
V. Criteria that make a diagnosis of Probable Alzheimer’s disease uncertain 
or unlikely include:
> Sudden, apoplectic onset
> Focal neurological findings such as hemiparesis, sensory loss, visual 
field deficits, and incoordination early in the course of the illness
> Seizures or gait disturbance at the onset or very early in the course of the 
illness
VI. Clinical diagnosis of Possible Alzheimer’s disease:
> May be made on the basis of the dementia syndrome, in the absence of 
other neurological, psychiatric, or systemic disorders sufficient to cause 
dementia, and in the presence of variations in the onset, in the 
presentation or in the clinical course
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> May be made in the presence of a second systemic or brain disorder 
sufficient to produce dementia, which is not considered to be the cause 
of dementia
> Should be used in research studies if the presence of a single gradually 
progressive severe cognitive deficit is identified in the absence of other 
identifiable cause
1.2.3.2 Accuracy of NINCDS-ADRDA Diagnostic Criteria
In order to reach a specific dementia diagnosis, the physician integrates 
information from patient and caregiver interviews, medical, neurological and 
psychiatric examinations, and the results of investigations. The entire dementia 
evaluation process is often treated as though it is a single diagnostic test for the 
purpose of defining diagnostic sensitivity, specificity and predictive values.
Relative to autopsy, the Possible AD category is associated with low 
sensitivity (47-56%) and low specificity (43-61%), while the Probable AD category 
has excellent specificity (97-100%) but low sensitivity (34-47%) (Nagy et al 1998). 
The combination of the Probable and Possible AD categories results in a high 
sensitivity, ranging from 91-98%, but the specificity of the criteria remains relatively 
low, ranging from 23-61% (Jobst, Bametson, & Shepstone 1998; Nagy et al. 1998; 
Varma et al. 1999).
By definition, the distinction between Probable and Possible AD diagnoses is 
the degree to which comorbid confounders are present and the extent to which the 
symptoms and/or progression are atypical. The high specificity of a Probable AD 
diagnosis reflects the fact that AD can be reliably diagnosed when presenting in the 
classical amnestic manner. However, the poor sensitivity of the Probable AD category 
indicates that many AD patients do not present in this way. Alzheimer’s disease may 
be difficult to distinguish from other forms of dementia when other conditions are 
present or the course is atypical. A factor which is rarely considered in assessing the 
accuracy of an AD diagnosis is disease severity at presentation. The clinical 
phenotypes of different forms of dementia tend to be most evident early in the disease 
process. The trend towards earlier diagnosis of AD, however, creates a potential for 
misdiagnosis partly due to the subtlety of symptoms and partly because of the limited 
history of progression available in early stage patients and patients with MCI.
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1.2.4 Genes associated with Alzheimer’s disease
A genetic component to AD has been postulated since the recognition of familial 
cases in the 1930’s (Lowenberg & Waggoner 1934; Schottky 1932), and a family 
history is considered a supportive feature in the NINCDS-ADRDA diagnostic criteria. 
As discussed later in this thesis many families with multiple affected members have 
been reported, and in the majority of these the mode of inheritance appears to be 
autosomal dominant with an age at onset in the presenium. The latter may be a 
confounding factor in that familial clustering will be easier to recognise and the 
genetic patterns in these families may not be typical. Many diseases for which there is 
a genetic basis require specific environmental conditions to express the disease. If a 
gene has an allelic variant that is, more often than not, found among patients with a 
specific disease, then that gene is said to be associated with the disease. Not everyone 
possessing the high susceptibility allele develops the disease, and some, perhaps 
many, will also become affected for other reasons. It is often difficult to determine 
whether the associated gene is pathogenic or merely a surrogate marker for another 
genetic risk factor. These AD associated genes are termed risk genes and they are 
discussed in this section.
1.2.4.1 Apolipoprotein E gene
Good evidence now exists that Apolipoprotein E (ApoE, protein; APOE, gene) is an 
important contributor to AD susceptibilitly. Apolipoprotein E is a plasma protein 
involved in cholesterol transport encoded by the APOE gene on chromosome 19ql 3.2 
(Zannis, Kardassis, & Zanni 1993). Though ApoE is primarily produced in the liver, it 
is also synthesised by astrocytes in the central nervous system and intimately involved 
in the growth and repair of the nervous system during development or after injury 
(Ignatius et al. 1986; Pitas et al. 1987). ApoE is increased in several chronic 
neurodegenerative diseases including AD and Creutzfeldt Jakob disease (Namba et a l  
1991). Antisera to ApoE stain senile plaques, neurofibrillary tangles and cerebral 
vessel amyloid deposits (Namba et al 1991; Strittmatter et al. 1993; Wisniewski & 
Frangione 1992).
There are three common allelic variants designated APOE-e2, -s3 and -s4. 
Because everyone inherits one APOE allele from each parent, there are six possible 
APOE genotypes: APOE-e2/2, APOE-e2/3, APOE-e2/4, APOE-e3/3, APOE-e3/4, and
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APOE-e4/4. These variants result in amino acid substitutions (Arg and Cys) at 
positions 112 and/ or 158 of the isoprotein (Zannis, Kardassis, & Zanni 1993). In 
Caucasians the allele frequencies are e 2 = 0.08, e3 = 0.77 and e4 = 0.15 (Campion et 
al. 1999; Weiner et al. 1999; Zannis, Kardassis, & Zanni 1993).
It is now well accepted that the frequency of the e4 allele of APOE is
overrepresented in patients with AD. This observation was initially made in late onset
familial AD (Strittmatter et al. 1993). It was rapidly replicated and established that
sporadic late onset as well as young onset cases had approximately a threefold higher
than expected likelihood of having APOE-e4 (Poirier et al. 1993; Rebeck et al. 1993;
Saunders et al. 1993). These findings suggest that inheritance of APOE-e4 is a risk
factor in the development of AD. In addition, early studies found that APOE-s2 was
underrepresented in AD, suggesting that it is a negative or protective risk factor for
AD (Corder et al. 1994; West, Rebeck, & Hyman 1994). Corder and colleagues
(1994) initially estimated that in late onset familial AD the APOE-e4 associated risk
for dementia approached 100% by the age of 80 years. However, this observation was
derived from a highly selected patient group with a very strong family history of AD.
Since that time data from several population-based studies have demonstrated that the
risk of developing AD for an individual in the general population is much lower than
it initially appeared with a range in odds ratios associated with APOE-e4, from 1.4
(Iowa study) to 3.7 (Framingham study) (Feskens et al. 1994; Hyman et al. 1996; 
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Kuusisto et al. 1994; Myers et al. 1996). The differences in risk ratios among 
different studies might in part be due to differences in study design, population 
differences, and differences in age and gender distribution in those populations.
These same studies have also shown that the average age at onset of AD 
patients who carry one or two copies of the e4 allele is significantly lower than that of 
patients who did not inherit this allele. In a study of a clinic based population of 359 
patients with AD, the age at onset of APOE-e4/e4 patients was 67.1 ± 7.6 (mean ± 
SD) years, five years earlier than APOE-e3/e4 patients at 72.3 ± 8.3 years, and seven 
years earlier than APOE-e3/e3 patients at 73.9 ± 11.7 years (Gomez-Isla et al. 1996b). 
Thus AD patients with one or two e4 alleles do have an earlier age at onset, with a 
dose effect, a finding that has been replicated on several occasions (Blacker et al. 
1997; Meyer et al. 1998). However, as illustrated above, these ages at onset are 
broadly overlapping among APOE genotypes, and the genotype-age relationship is 
not applicable to an individual patient.
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1.2.4.2 Other risk genes
Although APOE-s4 is the risk gene that has the most robust association with AD it is 
neither sufficient nor necessary for the development of AD. Relatives of AD patients 
without an APOE e4 allele have been found to be at increased risk of AD, suggesting 
that other genes or risk factors may be involved in the pathogenesis of AD (Devi et al.
1999).
In 1998 two case control studies (Blacker et al. 1998; Liao et al. 1998) 
reported an association between the a 2-macroglobulin gene (A2M) on chromosome 
12 and late onset AD, whereas others have not been able to replicate this finding 
(Wavrant-DeVrieze et al. 1999). In a Finnish prospective population based 
clinicopathological study of late onset AD, the A2M  exon 24 AJA genotype was 
associated with a diagnosis of Definite AD, but not with Probable AD (Myllykangas 
et al. 1999). No association was found with the other A2M  polymorphism (5 base pair 
deletion upstream of exon 18), an observation confirmed in a study from Taiwan (Hu 
et al. 1999).
a2-macroglobulin is an abundant serum protease inhibitor and a major ligand 
of the low density lipoprotein related receptor protein (LRP). LRP is found in neuritic 
plaques. It binds cholesterol, several other AD related ligands, and is also the primary 
ApoE receptor in neurons. Like A2M, the LRP gene is also located on chromosome 12 
and it may itself be a risk factor for AD affecting primarily neuritic plaque 
development (Kang et al. 1997). A meta-analysis found the LRP-C allele to be 
overrepresented in definite AD patients compared to control subjects (86.7% versus 
82.8%; odds ratio 1.34; P < 0.0001) (Beffert, Arguin, & Poirier 1999). However, there 
appears to be no difference in age at onset for AD between LRP genotypes (Warwick 
Daw et al. 2000).
Linkage between chromosome 12 and AD has been demonstrated 
consistently, and since the LRP association is relatively weak, it has been suggested 
that another locus on chromosome 12 is a more likely candidate as a risk factor for 
AD, possibly at a site near to A2M  (Martin, Martin, & Borgaonkar 1998; Rogaeva et 
al. 1998; Wu et al. 1998). This further chromosome 12 candidate gene maybe the 
transcriptional factor LBP-lc/CP2/LSF, which lies just 6cM proximal to LRP and 
regulates the expression of numerous genes including A2M. A protective association 
between a G/A polymorphism in the 3’- untranslated region of this gene and SAD has
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been reported in French, British and North American populations (Lambert et a l 
2000). This protective finding has been replicated in two further SAD series, the 
earlier of which was autopsy confirmed (Luedecking-Zimmer et al. 2003; Taylor et 
al. 2001). However, further studies will be necessary to reveal the real identity of this 
gene.
Recent papers provide evidence for an AD locus on chromosome 10 
independent of APOE genotype (Ertekin-Taner et al. 2000; Myers et al. 2000). 
Interestingly the insulin degrading enzyme (IDE), which has a central role in the 
degradation and clearance of Ap, also lies on chromosome 10 (Bertram et al. 2000; 
Vekrellis et a l  2000). Although IDE maps distal to the peak of linkage shown by 
Myers et al. (2000), Bertram et al. (2000) found linkage with four out of six markers 
close to the IDE locus. Furthermore physical mapping data have shown that IDE and 
its closest marker lie on the same bacterial artificial chromosome (GenBank accession 
number AL356128). Overall these findings indicate an AD susceptibility gene on the 
long arm of chromosome 10, although it may not be IDE (Bian et al. 2004; Boussaha 
et a l  2002).
1,3 Familial Alzheimer’s disease
Population studies have shown that 25-62% of AD patients have at least one other 
affected first degree relative, the higher values being obtained in younger patients 
(Campion et al. 1999; van Duijn et a l  1994). In elucidating the genetic aetiology of 
AD it became clear that because of variations in AAO and transmission patterns in 
different families that there was clinical and genetic heterogeneity (Farrer et a l  1990). 
Farrer et al (1990) analysed AAO in 70 familial AD kindreds and concluded that two 
or more mechanisms were involved in the expression of the illness. There was 
evidence for two distinct groups of families based on bimodality of AAO, with a 
cutoff age of 58 years. As a result two distinct categories of AD can be distinguished: 
pre-senile or early onset AD (EOAD) and senile or late onset AD (LOAD). 
Furthermore, in EOAD families the pattern of transmission is consistent with an 
autosomal dominant inheritance model. In some LOAD families the disease also 
segregates as an autosomal dominant trait, but the pattern in the majority of LOAD 
families is less clear suggesting that other genetic or shared environmental factors 
contribute. In view of EOAD families being clearly autosomal dominant the term 
familial AD (FAD) in this thesis refers to these families only unless further specified.
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To determine the prevalence of FAD we first need to review the epidemiological 
literature of EOAD.
1.3.1 Epidemiology
Most of the epidemiological studies on AD have measured prevalence of the disease 
in elderly populations. Of these only three studies include estimates of the prevalence 
of EOAD (Kokmen et al 1989; Schoenberg, Anderson, & Haerer 1985; Sulkava et al. 
1985). A further four studies were specifically designed to determine the prevalence 
of early onset dementia (Harvey, Skelton-Robinson, & Rossor 2003; McGonigal et al. 
1993; Newens et al. 1993; Ratnavalli et al. 2002), whereas only one study has looked 
specifically at the prevalence of FAD (Campion et al. 1999); these data are 
summarised in Table 1.1.
These population based studies varied in their design and diagnostic criteria. 
Schoenberg et al (1985) used the diagnosis “severe dementia” of unspecified 
aetiology whereas Sulkava et al (1985) used the diagnosis “primary degenerative 
dementia”. The more recent studies have used standard diagnostic criteria. In the 
Framingham study, Kokmen et a l (1989) used NINCDS-ADRDA criteria. In the UK 
Northern Health Region Study Newens et a l (1993) used DSM-III-R criteria 
(American Psychiatric Association 1987). The NINCDS-ADRDA criteria were used 
in the Scotland Study (McGonigal et al (1993)), the London Study (Harvey et a l 
(2003)) and the Cambridge Study (Ratnavalli et al. (2002)).
The only epidemiological study to determine the relative prevalence of EOAD 
and FAD performed to date is a population based study from the French city of Rouen 
(population 426,710) (Campion et al 1999). In this study all known patients with a 
diagnosis of dementia with an AAO of less than 61 years were referred to a single 
neurology clinic by local general practitioners, neurologists, and psychiatrists. 
Nursing/residential home or psychiatric hospital in-patients were excluded if they had 
not been resident in Rouen prior to their institutionalisation. Only Probable AD 
(NINCDS-ADRDA) patients were included. To determine family history a structured 
questionnaire was used to obtain a detailed three generational family history from the 
next of kin and confirmed by at least a second informant. A mutational analysis of the 
three causative AD genes (see section 1.3.2) was performed in all familial patients. 
They identified 39 patients with EOAD; 15 were sporadic cases and 24 had a positive 
family history. Of those with a family history five (13%) were autosomal dominant
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early onset AD (FAD) defined as having patients with early onset AD in each of three 
generations. Two further patients had a family history of both early and late onset 
within three generations (termed AD AD in their study) and 17 patients did not have a 
family history that corresponded with either FAD or ADAD. The calculated global 
prevalence per 100,000 inhabitants at risk, defined in this study as those aged 41-60 
years, was 41.2 for early onset AD and 5.3 for FAD.
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Table 1.1: Prevalence of early onset AD
Study Age range Individuals Cases Prevalence
(first author) (years) at risk found (per 100,000)
Schoenberg 1985 40-59 4,422 2 45.2
Sulkava 1985 30-59 5,466 1 18.2
Kokmen 1989 45-59 7,422 2 26.9
Newens 1993 46-64 655,800 227 34.6
McGonigal 1993 40-64 1,402,655 317 22.6
Campion 1999 41-60 94,593 39 41.2
Ratnavalli 2002 45-64 72,815 11 15.1
Harvey 2003 30-64 193,493 42 21.7
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1.3.2 Causative genes and pathogenic mutations
Three causative genes for FAD have been identified: the (3 amyloid precursor protein 
(APP; OMIM 104760) gene on chromosome 21 (Goate et al. 1991), the presenilin 1 
(PSEN1; OMIM 104311) gene on chromosome 14 (Sherrington et al. 1995m) and the 
presenilin 2 (PSEN2; OMIM 600759) gene on chromosome 1 (Levy Lahad et al. 
1995b; Rogaev et al. 1995).
1.3.2.1 p-Amyloid Precursor Protein gene
The modem molecular era of AD research begins with Glenner and Wong’s 
identification of the (3-amyloid (Ap) sequence in meningovascular deposits from AD 
and Down’s syndrome brains (Glenner & Wong 1984b; Glenner & Wong 1984a). 
With the realisation that Ap peptide was the subunit of the amyloid filaments in senile 
plaque cores (Masters et al. 1985) and the cloning of the p-amyloid precursor protein 
{APP) gene (Goldgaber et al. 1987; Kang et al. 1987; Robakis et al. 1987; Tanzi et al. 
1987a) it would seem that it was only a matter of time before FAD mutations in APP 
were found. However, though initial linkage studies co-localised the AD gene to the 
same chromosomal region as APP (St George Hyslop et al. 1987; Tanzi et al. 1987a), 
the assumption that there would be a single AD gene led to the incorrect conclusion 
that this AD gene and APP were genetically separate (Tanzi et al. 1987b; Van 
Broeckhoven et al. 1987). The subsequent discovery of a missense mutation in APP 
in families with hereditary cerebral haemorrhage with amyloidosis of the Dutch type 
(HCHWA-D), a rare Dutch stroke disorder (Levy et al. 1990), showed that mutations 
in APP could lead to amyloid deposition albeit not in the brain parenchyma. This and 
the realisation that AD was genetically heterogeneous, led Goate et al (1989) to 
concentrate on studies of single pedigrees. Dementia Research Group Family 23, 
which had previously been linked to chromosome 21, was an obvious candidate. 
Direct sequencing of exons 16 and 17 of APP (which encode the AP domain) revealed 
a point mutation at codon 717, just beyond the carboxy-terminus of the p-amyloid 
sequence (Goate et al. 1991). The mutation resulted in the substitution of valine for 
isoleucine (V717I) in the APP amino acid sequence which co-segregated with the 
affected individuals. This V717I mutation subsequently became known as the London 
mutation, it is the most common of the 16 APP mutations and has been found in 23 
FAD families from the UK, France, Germany, Italy, Japan, and Thailand (see Online
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Alzheimer Disease and Frontotemporal Dementia Database). The next two mutations 
to be identified: V717F (Murrell et al. 1991) and V717G (Chartier-Harlin et al. 1991) 
were both at the same residue. Residue 717 is close to the y-secretase site and it was 
proposed that the effects on APP metabolism were the key to their pathogenicity. The 
discovery of the KM670/671NL (Swedish) mutation (Mullan et al. 1992a) adjacent to 
the p-secretase site and the A692G (Flemish) mutation (Hendriks et al. 1992) adjacent 
to the a-secretase site provided additional support for this theory. The APP mutations 
described to date are shown in Figure 1.1.
Mutations in APP have been shown to account for 15% of FAD families 
(Campion et al. 1999). The mechanism of action of APP mutations is discussed later 
in this thesis.
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Figure 1.1 The APP m olecule
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1.3.2.2 Presenilin 1 gene
Many of the families in which EOAD had been linked to chromosome 21 did not 
segregate with a mutation in exons 16 and 17 of APP. A genome wide search was 
undertaken and almost simultaneously several groups reported linkage to 
chromosome 14 (George-Hyslop et al. 1992; Mullan et al. 1992b; Schellenberg et al. 
1992; Van Broeckhoven et al. 1992). Subsequently PSEN1 was identified, a gene of 
unknown function that had five missense mutations in eight FAD families 
(Sherrington et a l 1995m). PSEN1 encodes a protein of 467 residues in length that is 
predicted to be an integral membrane protein with six to eight transmembrane 
domains (Li & Greenwald 1998). Approximately 140 mutations in PSEN1 have been 
reported in nearly 200 families (see Online Alzheimer Disease and Frontotemporal 
Dementia Database). It is not surprising therefore that mutations in PSEN1 are the 
major cause of FAD accounting for 18-55% of families (Campion et al. 1999; Cruts et 
al. 1998). Pathogenic mutations occur throughout PSEN1, but there is a predilection 
for the exon 8 region (Perez-Tur J. et al. 1996) and for transmembrane domain 2, 
which between them account for nearly 50% of known mutations (Cruts & Van 
Broeckhoven 1998). The effects of the mutations on the structure of PSENl are 
difficult to assess, but transmembrane domains are believed to adopt an a-helical 
conformation, particularly transmembrane domain 2 (Clark et al. 1995e). Recently 
Hardy and Crook (2001) have mapped the known mutations onto the most widely 
accepted model of PSENl (Li & Greenwald 1998) and have shown that many of the 
mutations involve the disruption of transmembrane helical faces, particularly in 
transmembrane domains 2, 3, 4 and 6 and possibly transmembrane domain 1. They 
propose that mutations cause disruption of the helical faces resulting in impaired 
presenilin function. The mechanism of action of PSENl mutations is discussed later 
in this thesis.
1.3.2.3 Presenilin 2 gene
The report that demonstrated linkage to chromosome 1 in the Volga German families 
was “in press” at the time the article reporting the cloning of PSENl was published 
(Levy Lahad et al. 1995c). As a result both groups searched for genes homologous to 
PSENl and a second gene, which mapped into the Volga German region was 
identified (Levy Lahad et al. 1995b; Rogaev et al. 1995). Because of the high
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homology the new gene was called PSEN2. The overall homology between PSENl 
and PSEN2 is 67%, with higher homology in the transmembrane domains. Mutations 
in PSEN2 are a much rarer cause of FAD, having been described in only ten families 
including the Volga-German kindred, initially thought to be nine families until the 
demonstration of a founder effect (Cruts et al. 1998; Finckh et al. 2000; Lao et al. 
1998; Levy Lahad et al. 1995b; Rogaev et al. 1995). The mechanism of action of 
PSEN2 mutations is discussed later in this thesis.
1.3.3 Risk genes
1.3.3.1 The Apolipoprotein E polymorphism
For FAD due to APP the APOE s4 allele has long been recognised as a determinant of 
AAO and possibly amyloid load (Alzheimer's Disease Collaborative Group 1993; 
Sorbi et al. 1995a). After initial negative reports (Levy Lahad et al. 1995a; Van 
Broeckhoven et al. 1994b) there have now been several studies that have shown a 
similar effect in PSENl and PSEN2 (Janssen et al. 2000; Pastor et al. 2003; Wijsman 
et al. 2005).
1.3.3.1 Other risk genes
Variation in AAO has also been reported both between families with the same 
mutation, e.g. PSENl Ml39V (Fox et al. 1997) and PSENl H163R (Poorkaj et al. 
1998b), but also within families e.g. PSENl H163Y (Axelman, Basun, & Lannfelt 
1998). These data suggest that there are further as yet unidentified genetic factors.
A promising candidate gene is Nicastrin (NCSTN; OMIM 605254), a recently 
identified component of the presenilin containing y-secretase complex (see later in 
this thesis) that is involved in the cleaving of APP and Notch in their transmembrane 
domains (Chen et al. 2001; Yu et al. 2000). The effect of NCSTN has been 
investigated in two population based samples of AD patients (Dermaut et al. 2002). 
These two populations were an EOAD cohort of 116 patients, of whom 78 were 
familial (i.e. at least one relative with dementia) with a subset of ten FAD patients 
(five with PSENl mutations, two with PSEN2 mutations and three without a 
recognised causative mutation) and 240 LOAD patients drawn from the Rotterdam 
study. Fourteen NCSTN single-nucleotide polymorphisms (SNPs) were found: 10 
intronic SNPs, 3 silent mutations, and 1 non pathogenic missense mutation (N417Y).
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A SNP haplotype estimation in patients with EOAD (n=116) and LOAD (n=240) 
indicated that the frequency of one SNP haplotype (HapB) was higher in the group 
with familial EOAD (7%), compared with the LOAD group (3%) and control group 
(3%). In patients with familial EOAD without the APOE-e4 allele, the HapB 
frequency further increased, to 14%, resulting in a fourfold increased risk (odds ratio 
= 4.1; 95% confidence interval 1.2-13.3; P=0.01). None of the seven FAD patients 
with presenilin mutations carried the HapB haplotype and it is therefore not clear 
whether this may be a modulator of the FAD phenotype in a different population.
1.4 Pathology o f Alzheimer’s disease
On macroscopic examination, an AD brain can vary in appearance from normal to 
severely atrophic. Typically, there is widening of the sulci and ventricular 
enlargement which is most marked in the lateral ventricles. There is generalised 
atrophy of the cerebral cortex but in addition a greater degree of atrophy of temporal 
lobe structures including amygdala, hippocampus and parahippocampal gyrus (Braak 
& Braak 1991; Gomez-Isla et al. 1996a). This predilection for medial temporal lobe 
structures can also be seen in vivo using neuroimaging, which will be discussed in 
detail later in this thesis. In addition to neuronal loss the definite diagnosis of AD 
relies on the demonstration of the histological features that were first described by 
Alzheimer: amyloid plaques and neurofibrillary tangles. The relative significance of 
these hallmark lesions is reflected in the various published criteria for the pathological 
diagnosis of AD, which are based on an evaluation of the frequency neuritic plaques 
(Mirra et al. 1991) or the quantitative assessment of both plaques and tangles 
(Khachaturian 1985). The recent consensus recommendations from the National 
Institute on Aging and Reagan Institute emphasized the numbers of tangles and 
neuropil threads in the cerebral cortex (Hyman & Trojanowski 1997).
Another major neuropathological feature of AD is cerebral amyloid 
angiopathy (CAA) which is characterised by amyloid deposition within the walls of 
arteries and arterioles within the subarachnoid space and in the cerebral and cerebellar 
cortex. Although CAA occurs independently, particularly in elderly individuals 
(Greenberg et al. 1993), it is present to some degree in virtually all cases of AD. 
Capillaries and veins may also be involved, but blood vessels in the white matter are 
generally spared. The amyloid tends to be associated with the vascular smooth-muscle 
cells or pericytes, and periarterial Ap deposition contributes to CAA (Weller et al.
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2000). The effect of CAA on the blood-brain barrier in AD remains controversial and 
is beyond the scope of this thesis, but in cases of extensive amyloid deposition within 
cortical blood vessels, i.e. dyshoric angiopathy, perivascular plaques maybe seen in 
close proximity to blood vessel walls; for a review see Kalaria (1999).
1.4.1 Pathology of Sporadic Alzheimer’s disease
1.4.1.1 Amyloid plaques
Amyloid plaques are extracellular and are best visualised using Bielschowsky or 
Bodian silver stains or immunohistochemical techniques using an antibody to Ap. 
Amyloid plaques are divided into two main types: diffuse (“pre-amyloid”) plaques 
and neuritic plaques. Diffuse plaques are composed of homogeneous deposits of 
fibrillary material but contain only scant numbers of amyloid fibrils and do not stain 
with Congo red. Amyloid fibrils are made up of fine (7-10 nm) filaments comprised 
of an insoluble form of the 4 kDa Ap peptide (Glenner & Wong 1984a; Glenner & 
Wong 1984b; Masters et al. 1985), which is derived from the larger amyloid 
precursor protein (APP). Neuritic plaques are more heterogeneous in composition, 
with a central dense core of amyloid fibrils. Dystrophic neurites occur both within this 
amyloid deposit and immediately surrounding it. These neurites are often dilated and 
tortuous and are marked by ultrastructural abnormalities including paired helical 
filaments, virtually indistinguishable from those that comprise neurofibrillary tangles 
(see below). Such plaques are also intimately associated with microglia and they are 
surrounded by reactive astrocytes. Neuritic plaques stain with Congo red. The key 
difference between the two types of plaque is that neuritic plaque Ap occurs in the 
form of insoluble, and possibly neurotoxic, P-pleated sheets. Amyloid plaques are 
mainly observed in the neocortex, with only small numbers seen in the hippocampal 
formation during the early stages of AD. Plaque density in the cortex increases with 
disease severity. The time it takes for a neuritic plaque to develop is unknown, but 
these lesions probably develop over a period of many months to years.
1.4.1.2 Neurofibrillary tangles
Neurofibrillary tangles (NFTs) are intracellular structures often occupying the cell 
body and apical dendrite of the neuron. Neurofibrillary tangles are not specific for AD 
as they are found in the brains of normal aged individuals as well as in a variety of
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other conditions: including progressive supranuclear palsy, dementia pugilistica, 
subacute slerosing panencephalitis, Niemann-Pick's disease type C, parkinsonism- 
dementia complex of Guam, postencephalitic parkinsonism, myotonic dystrophy, 
Hallervorden-Spatz disease, and Gerstmann-Straussler-Scheinker syndrome 
(Wisniewski et al. 1979). Yet, despite the fact that NFTs occur in many other 
conditions they remain a key diagnostic feature of AD. Although some NFTs may be 
apparent on haematoxolin and eosin stained sections, where they have a 
slightly basophilic appearance, other stains are required for optimal detection. These 
include a variety of silver impregnation methods, e.g. modified Bielschowsky, 
Galiyas, Sevier Munger and Bodian preparations. In addition, tangles are effectively 
demonstrated by immuno-histochemistry using antibodies directed against tau 
epitopes or paired helical filaments (PHFs). A monoclonal antibody, Alz50, 
recognizes a 68-kDa polypeptide called A68 (Wolozin et al. 1986). This antibody 
labels neurons with neurofibrillary tangles as well as many neurons that are especially 
vulnerable to developing tangles. This A68 protein was subsequently shown to be a 
major subunit of PHF, representing a phosphorylated form of tau. The general contour 
of neurofibrillary tangles varies with the nature of the neurons in which they reside. 
Tangles in the pyramidal cells of Ammon's horn in the hippocampus, for example, are 
usually flame shaped, whereas those in the rounder neurons of the nucleus basalis of 
Meynert or locus coeruleus usually have a more globose contour. Tangles in the 
hippocampus, particularly in CA1 and the entorhinal cortex, may survive after the 
neurons that harbour them have died and lost their cell membranes. These “ghost” or 
“extracellular” tangles, the tombstones of once viable neurons, are best detected using 
silver and other routine stains. Tangles in the cerebral cortex have a varied 
morphology depending upon the conformation of the neurons involved. Composed 
of two filaments measuring around 20 nm in diameter, PHFs exhibit a regular periodic 
constriction to about 10 nm occurring every 80 nm. Kidd's (1963) finding that this 
change consisted of two filaments wound in a double helix was soon 
confirmed (Terry 1963; Terry, Gonatas, & Weiss 1964; Wisniewski, Narang, & Terry 
1976). These PHFs have since been shown to be composed primarily of 
hyperphosphorylated microtubule associated protein, tau (Goedert et al. 1992).
Braak and Braak (1991) described a hierarchical staging system for the 
neuropathological changes in AD, based on the distribution of NFTs in the cerebral 
cortex. The first neurons to exhibit NFTs and neuropil threads are the pre-a projection
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neurons in the transentorhinal cortex, a transition zone between the entorhinal cortex 
(EC) and the adjacent isocortex. Other areas with early development of NFTs are the 
entorhinal cortex and field CA1 of the hippocampus. In Stages I-Il (the 
"transentorhinal stages") these minor pathological changes are restricted to the EC 
and hippocampus. Stages III-IV (the "limbic stages") are characterised by moderate 
numbers of NFTs and neuropil threads in the transentorhinal cortex, EC and CA1, 
with additional scant numbers of NFTs in CA4, the subiculum and the parasubiculum. 
Small numbers of NFTs and neuropil threads are also found in association cortices. In 
stages V-VI (the "isocortical stages") all hippocampal subfields and isocortical 
association areas are severely affected. Primary sensory cortex is affected in stage VI.
1.4.1.3 Medial temporal lobe pathology
The vulnerability of the medial temporal lobe and specifically the EC early in the 
disease process is based on the observation of extensive loss of layer II neurons and 
widespread infiltration of stellate cells by NFTs in very mild AD (Gomez-Isla et al. 
1996a). Tangle formation is also prominent in the pyramidal cells of layer IV, 
whereas layers III, V and VI are relatively free of AD pathology (Hyman, Van 
Hoesen, & Damasio 1990). Of the hippocampal subfields, NFT and amyloid plaque 
density is greatest in CA1 and the subiculum. The dentate gyrus, CA3 and CA4 
contain significantly fewer NFTs and amyloid plaques, with hardly any at all in 
the presubiculum. There are conflicting data on the severity of neuronal loss affecting 
the hippocampus proper. West et al (1994) reported that the most marked neuronal 
loss was observed in CA1, followed by CA4. The dentate granule cells and neurons in 
CA3 and CA2 were relatively spared. By contrast, Simic et al. (1997) found that there 
was no significant difference in neuronal loss in CA1 in AD and normal ageing, and 
that the greatest differences in neuronal numbers were observed in the granule cell 
layer and the subiculum. Neuronal numbers in CA1, CA4 and the subiculum have 
been found to correlate with the duration and severity of AD (Bobinski et al. 1998).
1.4.1.4 The pathology of normal ageing
Amyloid plaques and NFTs are also observed in the brains of nondemented aged 
individuals (Arriagada et al. 1992; Delaere et al. 1990). Diffuse plaques are found 
throughout the cerebral cortex, with additional plaques in the amygdala, EC and CA1. 
Smaller numbers of neuritic plaques are also found throughout the cortex, but with
40
relatively larger quantities in the medial temporal lobe structures (Schmitt et al. 
2000). Neurofibrillary tangles are universally present in nondemented elderly brains 
(Price & Morris 1999) and are most prominent in the hippocampus and 
parahippocampal regions, with NFT numbers in CA1 correlating with age (Schmitt et 
al. 2000). These AD-like changes have led to the suggestion that some “normal” 
elderly subjects may in fact have covert, or preclinical, AD (Hulette et al. 1998; Price 
& Morris 1999). However, others argue that the different patterns of neuronal loss 
within the hippocampus observed in AD and normal ageing suggest that they 
represent separate processes (Simic et al. 1997; West et al. 1994).
1.4.2 Pathology of Familial Alzheimer’s disease
It is generally agreed that FAD and sporadic AD share the same cytoskeletal 
pathology and are essentially indistinguishable (Lantos et al. 1992). More recent 
investigations have however, revealed that P-amyloid deposition is more severe in FAD 
brains. In cases due to APP mutations, the P-amyloid plaques are predominantly 
composed of AP1 4 2 0 ) with relatively little Api-40 present. The total amount of APm2(3) is 
considerably greater than in sporadic AD (Mann et al. 1996b). Similarly, in brains with 
FAD due to PSENl mutations, ApM2(3) was the main component of plaques (Mann et al. 
1996a). Moreover, the total amount of ApM2(3) and APmo was more than twice the 
amount deposited in cases of sporadic AD of similar duration, although the ratio 
between the extent of the deposition of the two amyloid species was the same compared 
with sporadic Alzheimer’s disease. In a larger neuropathological series of AD brains 
from individuals with one of ten PSENl or PSEN2 mutations, enhanced deposition of 
total P-amyloid and APm2(3), although not of Ap^o, in the superior temporal gyrus was 
noted when compared with sporadic cases (Gomez-Isla et al. 1999). Moreover some of 
the PSENl mutations (Ml39V, I143F, G209V, R269H and E280A) were also associated 
with faster rates of neurofibrillary tangle formation and an accelerated neuronal loss 
when compared with sporadic cases of similar duration.
Some interesting neuropathological phenotypes have been reported for FAD. 
In the Finland A pedigree the Ml46V PSENl mutation has been associated with mild 
cortical vacuolar changes (Clark et al. 1995e; Haltia et al. 1994). More prominent 
vacuolation and gliosis is seen in patients with the E280A PSENl mutation (Lopera et 
al. 1997). Spongiform encephalopathy with “microspongiosis bubbles identical to 
those seen in CJD” associated with strongly positive PrP immunostaining has been
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described in co-existence with characteristic AD pathology in two probands from a 
French family carrying the H163R PSENl mutation (El Hachimi et al. 1996).
Pick body-like inclusions in the dentate gyrus have been reported in the 
AM/JPN1 pedigree which has FAD due to the A260V PSENl mutation (Ikeda et al. 
1996). In the AM/JPN1 pedigree there is a variable age at onset of 27-46 years and 
disease duration of 8-19 years. In addition to the neuropathological hallmarks of AD 
two family members who have undergone neuropathological examination had Pick­
like neuronal inclusions in the dentate gyrus (silver and ubiquitin positive). This 
report by Ikeda et a l (1996) predates the recent advances in tau 
immunohistochemistry so it is uncertain whether these are genuine Pick bodies. This 
finding has not been reported in other FAD mutations and may be pathognomonic for 
this mutation.
Recently an atypical, yet very characteristic, clinical and neuropathological 
phenotype was described in a Finnish pedigree with the PSENl A9 mutation (Crook 
et al. 1998). The affected individuals manifested progressive dementia, often 
preceded by spastic paraparesis. The primary and association cortices and 
hippocampus showed a profusion of eosinophilic, roundish structures with distinct 
borders termed "cotton wool" plaques (CWPs) (Brooks et al. 2003; Steiner et al. 
2001; Verkkoniemi et al. 2000; Verkkoniemi et al. 2001). The CWPs were 
immunoreactive for Api.4 2 0 ) but weakly or not at all for AP40. They were devoid of a 
congophilic core, and fibrillar amyloid could not be identified within them by electron 
microscopy. Confocal microscopy showed reduced density of axons within individual 
CWPs and only few CWP related PHF tau-positive dystrophic neurites. CWPs were 
particularly numerous in the medial motor cortex, representing the lower extremities, 
and degeneration of the lateral corticospinal tracts was observed at the level of the 
medulla oblongata and the spinal cord. In addition to the predominant CWPs, variable 
numbers of diffuse and cored plaques were found in the cerebral cortex. Diffuse and 
non-neuritic cored amyloid plaques but no CWPs occurred in the cerebellum. Despite 
the significant deposition of AP42, no neuritic pathology was observed in association 
with these unusual lesions. This together with data from cell models overexpressing 
the mutation suggests that amyloid plaque formation may not be a pre-requisite for 
dementia and neurodegeneration. This AD phenotype with spastic paraparesis 
associated with CWPs has now been described with several different PSENl 
mutations and is associated with the highest Ap concentrations described to date
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(Houlden et al. 2000). Careful neuropathological studies of sporadic LOAD patients, 
has revealed a patient with numerous neocortical CWPs as well as severe CAA and 
marked leukoencephalopathy (Le et al. 2001). In their study Le et al. (2001) 
additionally studied 16 patients with LOAD with similar degrees of CAA and 
leukoencephalopathy. They found that CWPs were well-circumscribed amyloid 
deposits infiltrated by ramified microglia and surrounded by dystrophic neurites that 
were immunopositive for APP, but only weakly for neurofilament and PHF-tau. Apj. 
12 was diffuse throughout the CWP, while A(337.42 was peripherally located and AP20-40 
more centrally located. Two of the 16 LOAD patients in the comparative group also 
had CWPs, but they were also admixed with diffuse plaques and plaques with dense 
amyloid cores. Pyramidal tract degeneration was neither a consistent finding nor a 
prominent feature in any case. Their results suggest that CWPs are not specific for 
FAD with spastic paraparesis.
Considerable variation in the degree of CAA occurs in association with the 
presenilin mutations. In a Volga German family with N141I PSEN2 mutation 
neuropathological examination revealed the presence of severe or moderately severe 
CAA in five family members with clinical dementia (Nochlin et al. 1998). The index 
case with the PSEN2 mutation had late-onset dementia at age 73 years, died of an 
acute intracerebral haemorrhage, and pathologically showed severe amyloid 
angiopathy but only rare neuritic senile plaques and neurofibrillary tangles. In two 
Japanese families with disparate PSENl mutations, a patient with the E184D mutation 
exhibited severe CAA whereas another individual with a N405S mutation showed 
only limited CAA, yet profound cortical amyloid deposition (Yasuda et al. 2000a). 
Mann et al. (2001) correlated amyloid angiopathy and variability in AP deposition in 
presenilin-1-linked AD to the position of the presenilin mutation. They reported a 
correlation between CAA and the location of mutation in FAD associated with PSENl 
mutations. The amount of AP42P). but not AP40, deposited in the frontal cortex of the 
brain was increased in 54 cases of PSENl FAD, encompassing 25 different mutations, 
compared to sporadic AD. The amount of Ap4o in PSENl FAD varied according to 
the APOE e4 dose. Although the amounts of Ap4o and Ap42(3) deposited did not 
correlate with the genetic location of the mutation in a strict linear sense, the 
histological profile did. Patients with mutations between codon 1 and 200 showed, in 
frontal cortex, many diffuse plaques, few cored plaques, and mild or moderate 
amyloid angiopathy. Cases with mutations occurring after codon 200 also showed
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many diffuse plaques, but the number and size of cored plaques were increased (even 
in the absence of APOE e4) and these were often clustered around blood vessels 
severely affected by CAA.
Although the co-existence of Lewy body and Alzheimer lesions is recognized 
in sporadic AD it appears to be more common in FAD. In a series of 74 FAD cases, 
22% were complicated by Lewy bodies demonstrated by a-synuclein immunostaining 
(Lippa et a l 1998). It is possible that these Lewy bodies arise from defective amyloid 
processing. Some cases have sufficient Lewy body pathology to consider a secondary 
diagnosis of dementia with Lewy bodies when applying the original Newcastle 
consensus criteria (McKeith et al. 1996). Usually however, the Lewy body pathology 
is minimal when compared with the overwhelming Alzheimer type lesions and there 
is no clinical evidence of Lewy body symptomatology to support the diagnosis.
1.5 Pathophysiology o f Alzheimer9s disease
1.5.1 Amyloid precursor protein structure and function
The APP gene encodes an alternatively spliced transcript that, in its longest isoform, 
codes for a single membrane spanning polypeptide of 770 amino acids (Goldgaber et 
al 1987; Kang et al. 1987; Robakis et al. 1987; Tanzi et al 1987a). Alternative 
splicing of exons 7 and 8  results in polypeptides of either 695 amino acids, APP695 
expressed predominantly in brain, or of 751 amino acids (APP751). The APP protein 
products are integral membrane proteins that contain an N-terminal signal peptide, a 
large ectodomain with sites for N-glycosylation, a single membrane-spanning helix 
and a short cytoplasmic domain (Kang et al 1987).
The physiological function of APP is unknown. Knockout of the mouse APP 
gene results in fairly subtle phenotypes, including minor weight loss, decreased 
locomotor activity, abnormal forelimb motor activity and minor nonspecific reactive 
gliosis in the cortex (Zheng et a l 1996). This lack of a vital consequence may be 
explained by the fact that mammals have other genes homologous to APP, the 
amyloid precursor-like protein genes (APLPs) (Slunt et a l  1994). Cell culture studies 
have shown that secreted APP can function as an autocrine factor to stimulate cell 
proliferation and cell adhesion, and can support nerve growth factor induced neurite 
outgrowth (Milward et al. 1992; Saitoh et al. 1989). Other studies have indicated that 
APP might be able to associate with heterotrimeric GTP binding proteins to contribute
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to signal transduction (Nishimoto et al. 1993). More recent evidence suggests two 
other possible roles for APP. First, it might serve as a receptor for kinesin 1 during the 
fast axoplasmic transport of vesicles that contain (3-site APP-cleaving enzyme 
(BACE, see below) and presenilins; the cleavage of APP releases kinesin from the 
vesicular membrane which is thought to modulate the transport (Kamal et al. 2001). 
Second, the proteolytic cleavage of APP generates a labile C-terminal stub in addition 
to generating A(3. This C-terminal stub is transported to the nucleus where it might 
function as a signal transduction molecule (Cao & Sudhof 2001), in a similar fashion 
to the Notch intracellular domain (Sastre et al. 2001).
1.5.2 Amyloid precursor protein processing
1.5.2.1 a-secretase mediated cleavage
The APP holoprotein undergoes a series of endoproteolytic events, referred to as a-, 
p- and y-secretase cleavage (see Figures 1.1 and 1.2). The first of these, termed a- 
secretase, results from a membrane associated protease activity which cleaves APP695 
within the Ap domain between residues Lys687 and Leu688 (residues 16 and 17 of AP) 
resulting in two products (Weidemann, Konig, & Bunke 1989). First, a large soluble 
fragment the extracellular amino-terminal ectodomain of APP (APPsa) which is 
released into the culture medium (in vitro) or the cerebrospinal fluid (in vivo) (Palmert 
et al. 1989). Second, a membrane retained C-terminal fragment (CTF) of 83 amino 
acids, that is sometimes referred to as the 10-kd CTF (Esch, Keim, & Beattie 1990; 
Selkoe et al. 1988; Weidemann, Konig, & Bunke 1989). This pathway is non- 
amyloidogenic, because a-secretase mediated cleavage precludes the formation of Ap. 
Interestingly a-secretase does not require a strict amino acid sequence to recognise the 
cleavage site. Its only requirement is an a-helical domain proximal to the cleavage 
site, but it cleaves substrates at a well-defined distance (-16 residues) from the plasma 
membrane (Sahasrabudhe et al. 1993). It is likely that a-secretase activity is a 
property of several enzymes at the cell surface, including tumour necrosis factor-a 
(TNF-a)-converting enzyme (TACE) and ADAM 17, members of the disintegrin 
metalloproteinase family (Buxbaum et al. 1998; Lammich et al. 1999; Parvathy et al. 
1998).
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1.5.2.2 p-secretase mediated cleavage
The formation of Ap from APP involves two sequential cleavages, by p- and y- 
secretase enzyme activities. P-secretase cleaves the extracellular domain of APP, 
either between Met671 and Asp672 (the +1 site), or between residues 682 and 683 
(the +11 site). P-secretase cleavage results in a 99-amino-acid, membrane bound 
fragment (the p-stub), which is carried out by BACE1 within endocytic compartments 
(Sinha et a l  1999; Vassar et a l 1999; Yan et a l  1999). Since the homologous protein 
BACE2 is expressed at much lower levels in the brain it is thought to have a smaller 
role in APP processing in the central nervous system. The cloning of BACE and its 
characterisation as a standard, membrane bound aspartyl protease has resolved the 
identity of the molecular p-site cleavage event that generates the N-terminus of Ap. 
Cleavage mediated by y-secretase is rather more complex and is described below.
1.5.1.2 y-secretase mediated cleavage
The p-stub is cleaved by y-secretase leading to the formation and release of Ap. This 
cleavage process involves an unusual form of proteolysis in which the P-stub is 
cleaved within the transmembrane domain at residue +40 or +42 generating AP40 or 
Ap42. The Ap peptide, particularly AP40 is a normal product of cells (Haass et a l 
1992). It is now clear that around 90% of secreted Ap peptides are AP40, a soluble 
form of the peptide. The remaining secreted Ap peptides are Ap42 and AP43 two 
species that are highly fibrillogenic, and are deposited selectively and early on in 
amyloid plaques in individuals with AD and Down’s syndrome (Saido et a l 1995). 
Furthermore it is these fibrillogenic Ap species that are secreted in vivo by FAD 
mutations in APP, PSENl and PSEN2 (Scheuner et a l 1996), providing direct 
evidence for the “amyloid cascade hypothesis” of Hardy and Higgins (1992). An 
overview of the amyloid cascade hypothesis is shown in Figure 1.2.
The nature of y-secretase is increasingly understood and recent work on the 
presenilins and their associated proteins, particularly nicastrin, has resulted in the 
proposal that presenilin and nicastrin are essential components of a complex that 
confers y-secretase activity (Yu et al. 2000). The details of this form of 
intramembranous proteolysis are emerging only now, but it also seems to be used for 
the processing of several other type 1 transmembrane proteins, including Notch (Chen 
et al 2001; De Strooper et a l  1999); a transmembrane receptor involved in
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intercellular signal transduction in embryogenesis and postnatal maturation of cells, 
cell proliferation and differentiation. Like APP, PSENl and PSEN2 FAD mutations 
(Scheuner et al. 1996), artificial mutations in NCSTN also increase AP4 2 0 ) production 
(Yu et al 2000). Conversely cells deficient in PSENl show markedly reduced 
production of Ap accompanied by the intracellular accumulation of a- and P-stubs of 
APP (De Strooper et al. 1998), whereas cells deficient in both PSENl and PSEN2 
show no secretion of Ap peptides into the culture medium at all (Herreman et al. 
2000; Zhang et al. 2000). The exact roles of the presenilins and nicastrin in the y- 
secretase complex are unclear. Nicastrin itself is unlikely to be a protease and it has 
been proposed that the presenilins themselves have y-secretase catalytic activity or 
alternatively that the two highly conserved aspartate residues at positions 257 and 385 
might be important for the assembly of the functional y-secretase complex (Wolfe et 
al. 1999). However, overexpression of both PSEN and NCSTN is not sufficient to 
generate more y-secretase activity (Kimberly et al. 2002), suggesting that other 
factors are important. Two additional proteins APH-1 and PEN-2 have recently been 
shown to be physical members of the y-secretase complex and that the combination of 
them with PSENl and NCSTN augments y-secretase activity in mammalian cells 
(Kimberly et al. 2003). The exact mechanism of action of y-secretase remains to be 
elucidated but, the contribution of APH-1 and PEN-2 to the y-secretase complex has 
recently been confirmed by further studies (Prokop et al. 2004; Shirotani et al. 2004).
1.5.3 Amyloid deposition as primum movens in AD?
Although the influence of FAD mutations on the formation of both amyloid plaques 
and neurofibrillary tangles is clear, the same cannot be said for late onset AD. Though 
transgenic mouse models bearing FAD mutations show an increase in AP4 2 0 ) levels 
and subsequent plaque pathology most of these models, including bigenics {APP and 
PSENl double mutants), do not show neuronal loss, tau phosphorylation or NFT 
formation as predicted by the amyloid cascade hypothesis (Citron et al. 1997; Duff et 
al. 1996; Games et al. 1995; Holcomb et al. 1998). Furthermore, in man there are 
areas such as the cerebellum, where there is considerable Ap immunoreactivity, but 
no demonstrable neuronal loss or NFT deposition, a situation that is known to exist 
even in severe PSENl FAD (Singleton et a l  2000).
This evidence gives credence to an alternative to the amyloid cascade 
hypothesis; this is less clearly formulated but essentially consists of a collection of
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related ideas that maintain the primacy of NFT formation. This theory is further 
supported by the fact that tangles occur within neurons and accumulate to occupy 
much of the neuron and appear to result in neuronal death as signified by the “ghost 
tangle”. Additional supportive evidence was that the progression of Ap deposition 
was not thought to follow a clear hierarchical pattern nor to correlate with cognitive 
decline (Arriagada et al. 1992; Bierer et al. 1995; Braak & Braak 1991; Nagy et al. 
1995). Recently, however, Naslund et al. (2000) reported findings from a cross- 
sectional post-mortem study of 79 elderly nursing home residents with clinical 
dementia rating scale (CDR) (Hughes et al. 1982) scores of 0.0 to 5.0 who died 
between 1986 and 1997. They compared the levels of Apx-4o and Apx^ 2  in the cortices 
of patients with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n =11]), 
mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR 
score, 4.0 or 5.0 [n = 15]) dementia. The CDR scores were based on cognitive and 
functional status during the last six months of life. They found that levels of both Apx_ 
40 and Apx-42 were elevated even in cases classified as having questionable dementia 
(CDR score = 0.5), and increases of Ap correlated with progression of dementia. 
Levels of the more fibril-prone Apx_42 were higher than those of Apx-4o in 
nondemented cases and remained higher throughout progression of disease in all 
regions examined. Furthermore they found that increases in Apx^ o and Apx_42 
preceded significant tau pathology in the frontal cortex, an area chosen for 
examination because of the absence of neuritic changes in the absence of disease. 
Additional evidence comes from the recent finding that a chromosome 10 locus 
associated with late onset AD, a risk factor for AD independent of APOE genotype 
(Myers et al 2000), is also associated with increased Ap generation (Ertekin-Taner et 
al. 2 0 0 0 ).
1.5.4 Tau (MAPT) gene mutations and dementia
Paradoxically the amyloid cascade hypothesis was strengthened significantly by the 
discovery that mutations in tau (Microtubule associated protein tau - MAPT; OMIM 
157140) caused a neurodegenerative dementia per se in the absence of amyloid 
deposition: frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17) (Hutton et al. 1998; Poorkaj et al. 1998a; Spillantini et al. 1998b). 
Frontotemporal dementia has a similar prevalence to AD in the presenium (Harvey, 
Skelton-Robinson, & Rossor 2003; Ratnavalli et al. 2002). It comprises a group of
48
disorders characterized by focal lobar atrophy, which determines the clinical features 
of behavioural changes and language deficits. Three prototypical clinical syndromes 
have been described: frontotemporal dementia - frontal variant (FTD), progressive 
nonfluent aphasia (PA) and semantic dementia (SD) (McKhann et al. 2001; Neary et 
al. 1998). The dominant features of FTD are early personality change and disordered 
social conduct; PA is a disorder of expressive language and SD is characterised by an 
impairment of semantic memory (impaired understanding of word meaning and/or 
object identity). In all three syndromes, perceptual and spatial functions, praxis, and 
memory are generally intact or relatively well preserved until the disease is advanced. 
Although most cases of FTD are sporadic, up to 40% of patients have a family 
history, a subset of whom show an autosomal dominant pattern of inheritance (Foster 
et al. 1997; McKhann et al. 2001; Stevens et al. 1998). The majority of these families 
have tau-positive neuronal and glial inclusions at histology, which are usually 
associated with mutations in tau. These tau-positive inclusions consist of four repeat 
tau. Tau is alternatively spliced in adult human brain to produce six different tau 
isoforms which differ in the presence or absence of exons 2, 3 and 10. Inclusion of the 
alternatively spliced exon 1 0  generates tau protein with four imperfectly repeated 
micro tubule-binding domains (four repeat tau) (Spillantini, van Swieten, & Goedert
2000). Mutations in tau lead to an overproduction of four repeat tau isoforms or to a 
reduced ability of tau to interact with microtubules. These mutations fall into three 
groups: exon 1 0  coding mutations, non-exon 1 0  coding mutations, and mutations that 
affect the alternative splicing of codon 1 0 .
Over 20 tau mutations have been reported (see Appendix 1 for phenotypic 
details) and the commonest clinical phenotype is FTD. One of the more common tau 
mutations is located at the +16 position of the intron after exon 10 (OMIM 
157140.0006 [MAPT, IVS10, C-U, +16]). The 10+ l6  mutation accounts for 17 
families in the UK (Janssen et al. 2002; Pickering-Brown et al. 2002) out of 25 
families world wide (Hutton et al. 1998; Poorkaj et al. 2001). These families have 
subsequently been shown to have a single common founder (Pickering-Brown et al. 
2004). In nine DRG families with the 10+16 mutation the commonest presenting 
symptom in 23 patients was disinhibition (Janssen et al. 2002). A minority of family 
members presented with frontal dysexecutive symptoms, apathy, impairment of 
episodic memory or depression. All these patients subsequently developed personality 
and behavioural change. Memory impairment, language deficits, ritualistic behavior,
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hyperphagia and hyperorality were frequent symptoms. Parkinsonism, neuroleptic 
sensitivity and/or primitive reflexes were present in half the patients where these data 
were available. Neuropathological examination of 12 patients demonstrated the 
hallmark tau positive neuronal and glial inclusions (Lantos et al. 2002) quite different 
from AD, though one patient fulfilled additional criteria for a definite AD diagnosis. 
The latter was thought to be due to an interaction of an APOE s4 genotype. The 10+ l6  
mutation destabilises a proposed stem-loop structure involved in regulating the 
alternative splicing of exon 10. Studies on both post mortem brain tissue and in vitro 
exon trapping experiments support the modulation of tau exon 1 0  splicing by the 
exon 10+ l6  mutation, the overproduction of exon 10 containing tau RNA isoforms and 
the predominant deposition of four repeat tau protein (Goedert et al. 1999; Hutton et 
al. 1998; Poorkaj et al. 2001). Ultrastructural analysis of brain tissue from patients 
with exon 1 0  splice site mutations indicates that these tau filaments appear as wide 
twisted ribbons, different from the paired helical filaments seen in Alzheimer's 
disease (Spillantini et al. 1997; Spillantini et al. 1998a).
The fact that tau mutations give rise to tau inclusions but not plaques and yet 
APP, PSEN1 and PSEN2 mutations give rise to both plaques and tangles suggests that 
amyloid pathology occurs upstream of tau pathology in AD. Additional evidence to 
support this comes from development of in vivo models of tau pathology subsequent 
to the discovery of tau mutations. Perhaps not surprisingly a double transgenic mouse 
model expressing both APP and tau mutants has both plaques and tangles (Lewis et 
al. 2001). Interestingly this bigenic mouse model has many more tangles in the limbic 
system and olfactory cortex than transgenic animals expressing only mutant tau. This 
suggests either that APP or its product Ap influences the formation of tau tangles. 
Taking a different approach, Gotz et al. (2001) directly injected Ap42 into the 
hippocampus of tau mutant mice and observed a dramatic increase in tangles in the 
amygdala, one of the regions affected in AD, allowing the same conclusion to be 
drawn.
1.5.5 Immunotherapy for Alzheimer’s disease
The ultimate test of the amyloid cascade theory will be whether Ap vaccination, 
which both prevents and removes AP deposits in PDAPP mice (Schenk et al. 1999) 
and prevents their cognitive decline (Janus et al. 2000; Morgan et al. 2000), works in 
man. The initial excitement over these animal data has been rather tempered by the
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early discontinuation of human trials after the develepmont of subacute 
meningoencephalitis (SAME) in a subset of patients immunized with AP42 (Orgogozo 
et al. 2003). The neuropathological findings of a patient who developed SAME 
following vaccination with AN 1792 in the Phase I study and subsequently died in 
February 2002 has been reported (Nicoll et al. 2003). In addition to diagnostic AD 
signature lesions there were several unusual features: (i) extensive areas of neocortex 
with very few Ap plaques; (ii) those areas of cortex that were devoid of Ap plaques 
contained densities of tangles, neuropil threads and cerebral amyloid angiopathy 
(CAA) similar to unimmunized AD, but lacked plaque-associated dystrophic neurites 
and astrocyte clusters; (iii) in some regions devoid of plaques, Ap-immunoreactivity 
was associated with microglia; (iv) T-lymphocyte meningoencephalitis was present; 
and (v) cerebral white matter showed infiltration by macrophages (Nicoll et al. 2003). 
A second patient who came to autopsy following SAME showed very similar changes 
(Ferrer et al. 2004). Taken together these results suggest that an effective immune 
response was generated that resulted in clearance of Ap from these patients. 
Moreover, it has been shown that patients who generate an antibody response exhibit 
slower rates of cognitive decline, an effect present even in those patients who 
experienced transient SAME (Hock et al. 2003).
It remains to be seen whether Ap immunotherapy given early in life could 
prevent accumulation of Ap and, if so, whether tau pathology might also be 
prevented. Studies of Ap immunotherapy are likely to provide a crucial test of the the 
putative causal role of Ap in the pathogenesis of AD.
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1.6 Neuroimaging in Alzheimer’s disease
Computed tomography (CT) and magnetic resonance imaging (MRI) are the two 
structural neuroimaging modalities. Structural imaging in dementia may be used to 
exclude structural lesions such as tumours, identify ischaemic changes and patterns of 
atrophy. By contrast, functional imaging can identify patterns of hypometabolism 
which implicate a particular disease in the setting of neurodegeneration. Functional 
imaging changes may exist in the absence of structural changes and may be 
complementary to them. The main functional imaging modalities are Positron 
Emission Tomography (PET), Single Photon Emission Computed Tomography 
(SPECT) and functional MRI (fMRI). Both PET and fMRI are largely research tools 
and remain confined to a small but growing number of centres. This section will only 
consider the relevance of structural imaging to the understanding of AD as a 
background to the structural imaging studies performed as part of this thesis.
1.6.1 X-ray computed tomography
CT scans are widely available, cheap and relatively rapid. A major disadvantage of 
CT is the radiation dose necessary for acquisition of images, but CT also has 
limitations in terms of image quality (DeCarli et al. 1990). Tissue contrast and 
resolution are inferior to MRI; within plane resolution is 4-5 mm when regions differ 
by less than five Hounsfield units in density and 1 mm when contrast between tissues 
is maximal. Beam hardening artefacts limit visualisation of cortical structures 
adjacent to bone and partial volume effects are considerable. Beam hardening effects 
are due to the increased absorption of lower energy X-rays by the skull which means 
that the medial temporal lobe is poorly visualised with conventional CT scanning. 
Temporal-lobe-oriented CT scanning improves visualisation and measurement of this 
region (Jobst et al. 1992). Partial volume effects refer to the mixing of signal from 
neighbouring tissues (e.g. CSF and brain) which results in pixels on the boundary 
having a value which is an average of the two adjacent tissue values. The 
development of spiral CT has reduced scan times and allows three dimensional 
reconstruction, but as yet image quality remains inferior to MRI (Bahner et al. 1998).
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1.6.2 Magnetic resonance imaging
Structural MRI utilises the fact that hydrogen nuclei, in a magnetic field, emit a radio 
signal following excitation by a radiofrequency (RF) pulse at their resonant 
frequency. Since every cell in the brain contains water, and therefore protons, the MR 
dataset can give a display of the density of hydrogen nuclei (commonly referred to as 
proton density), slice by slice through the brain. Protons within an external magnetic 
field have different energy states depending on the alignment of their spin axis: 
parallel or anti-parallel with respect to the external field. Protons precess around 
magnetic field lines, the higher the field strength the higher the frequency of 
precession as determined by the Larmor equation (precession frequency is equal to the 
product of the gyro-magnetic ratio and field strength). The precession or resonance 
frequency is also referred to as the Larmor frequency. An RF pulse at the precession 
frequency of the protons has two effects on the protons: it lifts some protons to a 
higher level of energy (decreasing the longitudinal magnetisation) and it causes the 
protons to precess in phase (establishing transversal magnetisation). If after the RF 
pulse the longitudinal magnetisation has disappeared - resulting in only transversal 
magnetisation - this is termed a “90-degree” pulse. When the RF pulse is switched off 
the system returns (decays) to its original or natural state. The increase in longitudinal 
magnetisation gives rise to the T1-curve, the time constant T1 is the longitudinal or 
spin-lattice relaxation time. The loss of phase coherence or transversal magnetisation 
gives rise to the T2-curve, the time constant T2 is the transversal or spin-spin 
relaxation time and is much shorter than the T1 time constant.
Proton density images show little contrast between soft tissues but relatively 
good contrast between soft tissue and cerebrospinal fluid (CSF). Soft tissue contrast in 
MR is produced primarily by differences in the spin-relaxation times for protons in 
different types of tissue. The signal is influenced by how constrained the protons are 
within the particular tissue. Each type of tissue thereby produces a relatively 
characteristic signal with different T1 and T2 values, longitudinal spin-lattice and 
transversal spin-spin relaxation times, respectively. However the considerable overlap 
between tissues means that tissues cannot be classified solely on their proton-density, 
T1 and T2 parameters. The pulse sequences employed as well as the characteristics of 
the tissue determine the signal intensity. Images can be T1-weighted, T2-weighted, or 
proton-density-weighted. The degree of weighting depends on the pulse sequence,
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repetition time and echo time. A short repetition time leads to T1-weighting, a long 
echo time leads to T2-weighting. Tissues with a large amount of freely mobile water 
appear dark in T1-weighted images but bright in proton density and T2-weighted 
images.
Variations in MR signal allow relatively sensitive differentiation of tissue 
types such as grey and white matter and the detection of pathological tissue or 
inhomogeneities within tissues. High spatial resolution (better than 1 mm within- 
plane) and the absence of artefact due to bone, contribute to improved tissue contrast 
and have allowed more accurate quantification of smaller cerebral structures. Data 
may also be acquired in different imaging planes and in three dimensions. There is an 
increasing range of different MRI procedures for acquiring images offering improved 
sensitivity to tissue characteristics (physical or chemical), thinner slices, or increased 
speed of imaging, in particular echo planar imaging (EPI) (Reiser & Faber 1997). 
MRI avoids X-ray irradiation, but MRI scanners are more expensive than CT and due 
to their physical characteristics more likely to produce claustrophobia. Longer 
scanning times mean MR images are sensitive to patient movement artefact which 
may be a particular problem in dementia where patients may forget instructions and 
have difficulty keeping still. Moreover, because of the powerful magnetic fields 
employed in MRI it is not possible to scan patients with pacemakers or ferro-magnetic 
clips or implants.
1.6.3 Excluding structural causes of cognitive impairment
The revised American Academy of Neurology practice parameter for the diagnosis of 
dementia (Knopman et al. 2001) recognises the inherent uncertainty of an in vivo 
clinical diagnosis of AD and recommends neuroimaging at the time of initial clinical 
assessment to complement the clinical assessment and to help exclude alternative 
pathologies which may present with a similar clinical presentation. The most 
important of these alternative pathologies are cerebral tumours, hydrocephalus and 
subdural haematomata. These are all relatively rare (Alexander et al. 1995), but are 
nevertheless the most common surgically treatable lesions that may present as 
dementia. Most of these pathologies will be detected by routine unenhanced CT or 
MR scanning. Both modalities will identify space-occupying lesions such as a frontal 
meningioma which may mimic frontotemporal dementia. Subdural haematomata, 
which can cause problems in the elderly, may also occur in the setting of degenerative
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dementia. Normal pressure hydrocephalus, with its typical imaging appearances of 
enlarged ventricles with prominent periventricular white matter changes without 
corresponding sulcal widening, may produce AD-like symptoms. Normal pressure 
hydrocephalus can, however, be treated with ventriculo-peritoneal shunting. An 
unexpected scan result, for example extensive white matter changes, better seen on 
T2-weighted MRI, may also suggest the need for further investigation. On rare 
occasions this may include cerebral biopsy, to exclude a treatable condition such as 
cerebral vasculitis. Infectious causes of cognitive decline, particularly in the 
immunocompromised, may mimic a degenerative dementia and MRI and then CSF 
examination are essential to avoid overlooking a treatable condition.
1.6.4 Diagnostic neuroimaging in AD
The ideal diagnostic test for AD should reflect its pathophysiology, be validated 
neuropathologically, be able to detect early AD and differentiate it from other 
dementias; it should also be reliable, non-invasive and affordable (Black 1999). The 
NINCDS-ADRDA criteria in moderate to severely affected patients predict a 
neuropathological diagnosis of AD in 60-90% of patients (Davis et al. 1995; Risse et 
al. 1990; Tierney et al. 1988). It has therefore been suggested that any new diagnostic 
measurement must be judged by its ability to improve the certainty of a diagnosis of 
AD at an earlier stage of the disease (de Leon et al. 1993a). However, the distinction 
between normal ageing and mild AD using imaging is often problematic as there is 
overlap between these two groups due to the wide variation seen in normal controls. 
In order to be clinically useful any method needs to distinguish mild AD from normal 
ageing and ideally from other causes of cognitive impairment. Validation of a 
diagnostic test for AD requires comparison of an AD group with age- and sex- 
matched controls, where histological confirmation is available for both. Ideally the 
patients should be matched for pre-morbid intelligence as significant correlations 
between intelligence and intracranial, cerebral, temporal lobe, hippocampal and 
cerebellar volumes have been reported (Andreasen et a l 1993), although this 
relationship is by no means clear cut (Jenkins et al. 2000).
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1.6.4.1 Atrophy as a diagnostic marker
Concomitant to the microscopic changes which typify the neuropathological 
hallmarks of AD there are macroscopic changes, such as cerebral atrophy particularly 
involving the temporal cortex and enlargement of CSF spaces which can be assessed 
with neuroimaging. Pathological studies have shown cortical atrophy, reduced brain 
weight and ventricular enlargement all to be more prominent in AD patients (Hyman 
& Trojanowski 1997; Mirra, Hart, & Terry 1993).
Whilst cortical atrophy is more prominent in AD patients there is considerable 
overlap with age-matched controls with a reduction in brain volume and increases in 
ventricular and sulcal volumes. These features are not linearly related to age, but 
become more important sometime after the fifth decade, although there appear to be 
significant variations (Coffey et al. 1992; Dekaban 1978; Ho et al. 1980). Even with 
correction for head size to control for variations in individual brain size there is a 
wide range in measures of atrophy, particularly in very elderly patients; e.g. Nagata et 
al. (1987) found a four fold range in the ratio of CSF to cranial volume in 80 year 
olds. Brain volume and cortical thickness gradually decline and rates of loss increase 
with age (Jemigan, Press, & Hesselink 1990; Pfefferbaum et al. 1994; Scahill et al. 
2003).
A cross-sectional study of 194 healthy subjects ranging in age from 16 to 65 
years found significant age-related increases in CSF spaces and a reduction in total 
brain volume of approximately 2ml per year in the 40 to 60 year age range (Blatter et 
al. 1995c). A smaller but more recent study examined 39 subjects between the ages of 
31 and 84 years and found that total brain volume declined by 0.32% per year with a 
concomitant increase in ventricular CSF volume of 0.65mls per year (Scahill et al. 
2003). With ageing white matter volumes appear to be relatively constant, but 
increasing amounts of altered signal are observed (Coffey et al. 1992; Erkinjuntti et 
al. 1994; Jemigan, Press, & Hesselink 1990). Inevitably there are methodological 
difficulties in deducing white matter and grey matter volumes using signal intensities 
which are themselves changing with age. Grey matter losses and ventricular 
enlargement increased notably after the age of 50 years (between 0.5 and 1.0 ml per 
year in the following decade). By contrast Jemigan et al. (1990) suggested there was a 
linear decrease with age across the whole age range, 8 to 79 years, in their measure of 
brain volume which they defined as “non-CSF cerebral pixels”. Coffey et al. (1992)
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studied 76 healthy adults with MRI and found a gradual decrease in overall 
hemispheric volume of 0.23% per year and a slightly faster decline in the volume of 
the frontal lobe of 0.55% per year. Temporal lobe and amygdala-hippocampal 
complex volumes declined at a rate that was only slightly greater than the total 
hemispheric rate of loss: 0.28% and 0.30% per year respectively. These age-related 
reductions in the hippocampus, fusiform gyrus, and parahippocampus are present 
even after controlling for global brain atrophy (Convit et al. 1995).
Studies of normal ageing are compounded by the various co-morbid 
pathologies that become more common with advancing age, including hypertension, 
atherosclerosis, diabetes and dementia. The studies described above are cross- 
sectional and thus open to the criticism that pre-clinical pathologies may have been 
present in one group, but not in another. In a longitudinal study Jack et al. (1998) 
showed hippocampal volume losses of 1.6% per year in apparently healthy elderly 
individuals (with a mean age of 80 years) scanned annually. There is a paucity of data 
on those over 85 years of age. In a longitudinal study of 46 healthy elderly 
individuals, including 20 subjects aged 85 years, Mueller et al (1998) found rates of 
atrophy did not continue to accelerate with advancing age over the age of 65 years. 
These results are at variance with cross-sectional studies and need to be confirmed by 
larger studies. Confirmation of these findings would have important implications for 
the potential of imaging markers to differentiate AD from healthy ageing in the very 
elderly.
1.6.4.2 Patterns of atrophy in AD: neuropathological evidence
The histopathological changes of AD can involve nearly all cerebral areas but 
particularly affect the medial temporal lobe and limbic system. Braak and Braak’s 
(1991) hierarchical staging system, based on the distribution of NFTs in the cerebral 
cortex, shows early NFT accumulation in the entorhinal cortex and hippocampus. 
These findings are in accord with the clinical observation that memory impairment is 
one of the earliest manifestations of AD (Hodges & Patterson 1995; Newman et al. 
1994). The causal links and time course of this process are not established, but these 
neuropathological changes are known to be associated with atrophy. This atrophy can 
be quantified with imaging and provides an indirect method of in vivo assessment of 
the underlying disease process. Imaging studies have tended to assess global cerebral
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atrophy or have focused on region specific atrophy, particularly hippocampal and 
amygdala atrophy.
1.6.5 Qualitative assessments of atrophy
Present clinical practice in a case of probable AD, consists of excluding causes such 
as space occupying lesions and then making a judgement of the amount of cerebral 
atrophy and the extent of white matter change. Qualitative ratings of global atrophy, 
when formalised, use a scoring system for the size of specific structures or of 
ventricles and/or sulci as markers of atrophy.
The sensitivity of qualitative assessments of generalised cerebral atrophy on 
CT are limited to no better than 60%, with a specificity of 90%. In a comprehensive 
review DeCarli et al. (1990) concluded that the sensitivity of this method was limited 
to slightly more than a chance level of 50%. Qualitative assessments of temporal lobe 
atrophy (temporal horn enlargement, reductions in the size of the hippocampus, 
medial and lateral temporal cortex) result in improved sensitivity and specificity, 
although 20% or more of normal controls or AD patients are still incorrectly classified 
(George et al. 1990; Kido et al. 1989; LeMay et al. 1986).
To address these shortcomings of CT, The Consortium to Establish a Registry 
for Alzheimer’s Disease (CERAD) assessed the reliability of standardised (axial T2- 
weighted spin echo and T1-weighted coronal sequences) qualitative MRI evaluation 
for AD. This multi-centre study found that inter-rater agreement of the MRI scans was 
unsatisfactory and concluded that “eyeball” interpretation of MRI scans was highly 
subjective and that more objective techniques were required (Davis et al. 1992).
Since then several qualitative rating scales have been developed to assess 
temporal lobe atrophy on MRI. Studies have continued to show an overlap between 
the patient and control groups, particularly when mildly affected subjects were 
studied. For a specificity of 90% the sensitivity of ratings of atrophy have varied from 
40% to 95%, the latter using entorhinal cortex (Davis et al. 1992; de Leon et al. 1997; 
Erkinjuntti et al. 1993; Horn et al. 1996; Scheltens et al. 1992b). Visual assessment 
of dilatation of the perihippocampal fissures has been shown to be predictive of 
cognitive decline in minimally impaired individuals with a sensitivity of 91% and a 
specificity of 89% (Convit et al. 1993; de Leon et al. 1993b). The same group found 
hippocampal atrophy in 96% of severely affected AD patients but also in 48% of 
subjects aged 76-90 years of age (de Leon et al. 1997). Scheltens et al. (1997) have
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extensively investigated the use of visual assessment of cerebral and medial temporal 
lobe atrophy in the assessment of AD. When atrophy ratings on a 0-3 scale of 13 
regions were performed independently by four raters relatively poor inter-rater 
agreement was found. They concluded that this assessment of cerebral atrophy on 
MRI in an elderly population had poor reproducibility among raters. However, it 
provided regional atrophy measures and the authors felt the method was quite reliable 
when performed by a single rater. Assessment of medial temporal lobe atrophy 
appears more sensitive than assessment of generalised atrophy. However, while the 
presence of atrophy on visual inspection makes the diagnosis of AD more likely, the 
absence of atrophy does not exclude the diagnosis.
1.6.6 Quantitative measures of atrophy
In order to achieve greater objectivity several quantitative measurements of atrophy 
have been developed. These measurements may be linear, of cross-sectional area or of 
volume. To correct for pre-morbid normal variation in brain size these measurements 
should be normalised (Bergin et al. 1994; Free et al. 1995; Jack et al. 1997; 
Pfefferbaum et al. 1994). The most commonly used denominators are total 
intracranial width, area or volume. Some studies have compared volumes of a region 
of interest with that of another structure deemed to be relatively unaffected by the 
disease, such as the lenticular nucleus (Seab et al. 1988).
1.6.6.1 Linear measurements
Linear measurements are generally simple and quickly performed as they consist of 
the measurement of the distance between two recognisable anatomical landmarks. 
Using this method the widths of the lateral ventricles and the third ventricle in several 
CT studies have been shown to be significantly different between AD and normal 
controls, although the sensitivity was no better than 70% (DeCarli et al 1990). Using 
a single linear measurement of the minimum width of the medial temporal lobe on 
temporal-lobe-oriented CT, Jobst et al. (1992) were able to reliably differentiate AD 
patients (severely affected with a mean MMSE of 9/30) from normal controls. Using 
this technique the same group went on to demonstrate a greater rate of reduction in 
the minimum width of the medial temporal lobe in patients with AD compared with 
controls when these were followed longitudinally (Jobst et al. 1994). Linear measures 
of ventricular size on MRI have been shown to correlate with dementia severity
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(Schmidt 1992). Although the maximal transverse width of the temporal horns on 
MRI differs significantly between mild AD and controls there is considerable overlap 
(Erkinjuntti et a l 1993).
1.6.6.2 Area measurements
Ventricular size has been estimated by measuring the cross-sectional area of the 
ventricles divided by total brain area at a single defined level on CT or MRI. This 
measurement, termed ventricular brain ratio (VBR), has been shown to increase with 
age in normal controls. Patients with AD have significantly increased areas of the 
third ventricle, lateral ventricles and interhemispheric fissure when compared with 
normal controls. These measures have been used with CT to distinguish AD patients 
from controls, and though more sensitive than linear measures they have not been 
shown to be clinically useful in early AD or in the differential diagnosis of dementia 
(DeCarli et al 1990).
Using MRI, Seab et al. (1988) measured hippocampal cross-sectional area at 
the level of the lateral geniculate body and found a 40% reduction in mean 
normalised hippocampal area in the AD patients compared with controls. This was a 
small study with only ten patients and seven controls but importantly there was no 
overlap between patients and controls. Interestingly there was no correlation between 
the hippocampal measurements and disease severity. Similar changes were shown by 
Ikeda et al. (1994) using single normalised area measurements of the hippocampal 
formation, the parahippocampal gyrus and the temporal lobe in patients with possible 
(n=6) and probable AD (n=8) (MMSE 21-27/30) and in controls (n=8). Both the 
normalised hippocampal formation and parahippocampal gyrus areas were 
significantly smaller in the AD groups than in the controls but with some overlap. 
Although the temporal lobe measurements were only smaller in the probable AD 
group they failed to differentiate between patients with possible and probable AD. 
They concluded that hippocampal and parahippocampal atrophy occurs early in AD, 
and is more useful than neocortical atrophy for early diagnosis. Conversely Cuenod et 
al (1993) demonstrated that the hippocampus measured from a single slice did not 
differ significantly between mild AD and normal controls.
Although area measurements may provide a better estimate of atrophy than 
linear measures they may not accurately estimate volume change. This is because a 
single slice has to be chosen for measurement and the volume change may not be
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uniform along the length of the cerebral structure being measured (Cook et al. 1992). 
Furthermore because of normal anatomical variation between subjects it is difficult to 
ensure that the equivalent section of a structure is being measured.
1.6.6.3 Volumetric measurements
Cerebral structure volumes are estimated from image slices using Cavalieri’s 
principle: a region or area of interest is defined on a number of slices and then the 
area measurements are summed and multiplied by the distance between the cross- 
sections measured (Free et al. 1995). This is identical to voxel counting methods 
based on slice-by slice region delineation. The smaller the distance between slices 
measured the greater the accuracy of the estimate, until the distance becomes of the 
same order as the within-plane resolution. The methods used to define the structure 
seen on the slice vary from manual outlining using anatomical landmarks to an 
automated segmentation. Automated methods use thresholds, either Hounsfield units 
(CT) or grey scale level (MRI), to distinguish CSF, grey and white matter on the basis 
of signal intensity. Though MR imaging produces greater distinction between tissue 
types, calculated volumes are influenced by the intensity level that is set for each 
image (Harris et al. 1994). Partial volume averaging, i.e. the mixing of signal from 
adjacent regions, limits accuracy but may be partly compensated for when two or 
more MR sequences are combined (Jack 1991; Rusinek et al. 1991).
In the largest study to have compared area and volume measurements Laakso 
et al. (1998) showed hippocampal volumetry to have significantly better 
discriminative power than area measurements. They compared these measures in 160 
subjects and found the discrimination based on volumetry resulted in an overall 
correct classification of 92% of AD patients versus non-demented elderly subjects, 
whereas discrimination based on hippocampal area was less accurate, producing a 
correct classification in 80% of the subjects.
1.6.6.4 CSF volumes
Early CT derived measurements showed that mean CSF volume increased with 
severity of AD with significant differences in CSF volume between AD patients and 
normal controls (sensitivity and specificity approaching 90%) (DeCarli et al. 1990; 
Ichimiya et al. 1986). The sylvian fissure and temporal horn CSF volumes appear to
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have the greatest discriminatory value (Sandor et al. 1992; Sullivan et al. 1993). 
Longitudinal studies suggest that cognitive performance correlates with rates of 
change in ventricular CSF volumes (Luxenberg et al. 1987). Sulcal or extraventricular 
CSF volumes are difficult to estimate using CT due to beam hardening artefact from 
adjacent bone.
MRI allows improved separation of all CSF spaces and validation studies 
suggest reasonably high accuracy and low interobserver variability (Jack 1991). MRI 
with its higher definition of extraventricular CSF has shown the increase in CSF 
spaces to include, to a lesser extent, sulcal CSF (Tanna et al. 1991). When comparable 
CSF regions in the same subjects are assessed, MRI is better than CT at separating 
AD from controls (Sandor et al 1992).
1.6.6.5 Grey and white matter volumes
Concomitant with increasing ventricular and sulcal spaces, total MRI brain volume 
measurements are reduced in AD compared with controls. Tanna et al (1991) used 
T2-weighted MRI to show that mild to moderately affected AD patients have 7% less 
total brain volume than controls. Pantel et al. (1997) found that in moderately affected 
patients (mean MMSE =17) brain volumes were reduced by 12% relative to controls, 
when corrected for intracranial volume. However, their AD patient group was almost 
ten years older than the controls and so some of this difference may be age-related.
Rusinek et al (1991) used two MR inversion recovery sequences to 
compensate for partial signal averaging and assign voxels to either grey or white 
matter compartments or CSF and found that the percentage of brain tissue identified 
as grey matter in AD patients was significantly lower than in control subjects, 45% as 
opposed to 50%. Loss of grey matter is strongly associated with increases in CSF in 
each cortical lobe. Automated tissue segmentation techniques have given consistent 
results regarding the contribution of white matter losses to cerebral atrophy. Tanabe et 
al (1997) suggested that in mildly affected individuals white matter volumes were 
unchanged. However, such conclusions must be treated cautiously because automated 
tissue segmentation routines require the signal characteristics of brain tissues to be 
relatively unaffected by the disease. It is likely that both grey and white matter losses 
contribute to reduced brain volume even in early disease (de la Monte 1989; 
Matsumae et al. 1996; Rusinek et al 1991).
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Overall lower brain volumes correlate with gross measures of severity of 
cognitive impairment. However, as might be expected, the uncorrected brain volume 
measurement has little diagnostic value due to the wide range in normal brain size 
(Murphy et al. 1993). The brain normally occupies 85% to 92% of the intracranial 
volume and consequently relatively small decrements in brain size lead to large 
increments in ventricular and/or extraventricular volumes (Matsumae et al 1996). 
This might imply that the CSF measures would be sensitive markers of disease, 
however, in addition to large normal variations in CSF volumes the coefficient of 
variation in CSF measurements has previously been unsatisfactory. Very considerable 
overlap is present when mildly or even moderately affected patients are studied. 
Tanabe et al. (1997) concluded from their MRI study of mild AD that “tissue 
segmentation may increase our understanding of dementia but as yet, when used 
alone, it does not play a role in the premorbid diagnosis”.
1.6.7 Regional volumetric measures
The prominent neuropathological involvement of the medial temporal lobes and the 
hippocampal formation in AD has resulted in the atrophy of these structures being 
extensively studied and there is now a considerable imaging literature which is 
reviewed briefly in this section.
1.6.7.1 Medial temporal lobe atrophy
Several studies have shown that temporal lobe volume reductions in AD are 
proportionately greater than whole brain volume losses (Jemigan et a l  1991; Rusinek 
et al. 1991). DeCarli et al. (1995) measured the volumes of several brain structures 
and CSF spaces in 19 men with AD (mean MMSE of 16) and 18 age-matched 
controls. The AD group had significantly smaller mean cerebral and temporal lobe 
volumes, and significantly larger mean ventricular and temporal lobe peripheral CSF 
volumes than did controls. Mean volume of temporal lobe brain matter was found to 
have decreased significantly more than whole brain volume. Thirteen studies 
involving over 400 patients with mildmoderate AD were recently reviewed: 
hippocampal and medial temporal structure volumes detect dementia from normal 
ageing with an average sensitivity of 85% and specificity 88% (Bosscher & Scheltens 
2002).
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1.6.7.2 Hippocampal atrophy
Of the temporal lobe structures the hippocampus is relatively easy to separate from 
surrounding tissue by manual outlining and has consistently been shown to have 
volume loss in severe AD. In an early study Kesslak et al. (1991) reported a 40% 
reduction in the hippocampus and the parahippocampal gyrus using only five coronal 
slices to estimate volumes. Jack et al. (1992) with a larger sample (20 patients and 22 
controls) showed that normalised volumes of anterior temporal lobe and hippocampal 
formation were both significantly smaller in the AD patients. However there was 
some overlap between patients and controls; the hippocampal formation was the best 
discriminator with 85% (17/20) of patients falling outside the range for the controls. 
Pearlson et al. (1992) measured the amygdala as well as the hippocampus by area 
measurements on only two MRI slices. Using this method they compared 15 
moderately severe AD patients with 16 normal controls and found that their AD 
patients had a 30% reduction in each of these structures. A similar volume reduction 
(33%) in the amygdala of AD patients compared with controls was found by Cuenod 
et al. (1993), though they showed a less pronounced and non-significant reduction in 
hippocampal volume.
Studies of patients described as mildly affected (MMSE >21) have shown that 
on average the hippocampal formation has already lost 25% or more of its volume 
when compared with normal controls (Killiany et al. 1993; Krasuski et al. 1998; 
Laakso et al. 1995; Lehericy et al. 1994). In a large and carefully conducted study 
Jack et al. (1997) used MR-based volumetry to measure the hippocampus, 
parahippocampal gyrus, and amygdala in 94 individuals with probable AD and 126 
controls. Volumes of each structure declined with increasing age in control subjects. 
The volume of each medial temporal lobe structure was significantly smaller in AD 
patients than control subjects. The hippocampal measurements were best at 
discriminating control subjects from AD patients. Hippocampal volumes declined 
with disease severity.
Hippocampal volumetry using MRI has been used in an attempt to distinguish 
patients with MCI from normal ageing. Cross-sectional studies have suggested that 
measures of hippocampus or entorhinal cortex may be useful predictors as to which 
patients will proceed to develop AD from either MCI or normal ageing (De Santi et 
al. 2001; Dickerson et al. 2001; Du et al. 2001; Krasuski et al. 1998; Rusinek et al.
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2003). Furthermore studies of patients destined to get AD on the basis of a mutation 
in PSEN1 or APP have been shown to have reduction of medial temporal lobe 
volumes prior to the onset of symptoms (Fox et al. 1996; Schott et al. 2003).
1.6.7.3 Entorhinal cortex
Braak and Braak’s (1991) neuropathological staging studies have resulted in several 
groups looking at MR volumes of the entorhinal cortex (EC). Juottonen et al. (1998) 
measured EC in 30 AD subjects (mean MMSE = 21) and 32 controls and found that 
normalised volumes were reduced by almost 40%. In a later study using the same 
subjects they showed that both EC and hippocampal volumes classified control 
subjects and Alzheimer's disease patients with a high degree of accuracy 
(approximately 90%) with hippocampus performing marginally better (Juottonen et 
al. 1999). De Leon et al (2001) outlined what they termed the entorhinal landmark 
surface area on thin slice T1-weighted MRI and then corrected for intracranial 
volume. This area measurement was 27% lower in eight patients with very mild AD 
than in eight matched control subjects while in the same patients the hippocampal 
volume was only reduced by 12%. Killiany et a l (2002) compared MRI volumes of 
the entorhinal cortex and the hippocampus in normal controls (n=28), MCI patients 
who did not progress (n=73), MCI patients who progressed to AD (n=21), and 
patients with mild AD at baseline (n=16). They found that measures of both the EC 
and the hippocampus were different for each of the pairwise comparisons between the 
groups. However, the volume of the EC differentiated the subjects from those 
destined to develop dementia with considerable accuracy (84%), whereas the measure 
of the hippocampus did not. The findings in MCI and early AD that the atrophy rate 
in the EC is higher than in the hippocampus is consistent with the view that AD 
pathology begins in the entorhinal cortex. These studies suggest that entorhinal cortex 
measurements would be powerful aids to the early diagnosis of AD.
1.6.8 Longitudinal studies
Cross-sectional studies have the disadvantage that small changes in brain structure 
tend to be masked by the large variation within normal individuals. Hence scans of 
affected patients may be reported as normal as they lie within the normal range for the 
population as a whole. Longitudinal studies have the advantage of being able to use 
each individual as their own control but necessitate serial scans. Longitudinal studies
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also allow the assessment of early change and the correlation of symptom onset with 
structural change. Even with longitudinal studies, detection of small, diffuse change 
remains difficult. Manual volumetric measurement involves outlining particular 
regions of interest and there is a critical dependence on the reproducibility of 
identifying anatomical structures and on a priori decisions about which areas to 
measure. Furthermore, variations in scan acquisition can make significant differences 
to the rates of change measured; In addition there are inevitable changes in the MRI 
magnetic field that occur over time due to scanner gradient changes. These changes 
can result in fluctuation in voxel size, further complicating comparison (Gunter et al. 
2003; Whitwell et a l  2001).
Many of these criticisms are addressed by using the method of rigid body 
serial registration of MRI scans, in which patients act as their own controls (For 
review see Ashbumer (2003)). Several automated techniques have been designed to 
allow accurate scan matching (Freeborough, Woods, & Fox 1996; Woods et al. 1998). 
These algorithms compare signal intensities from all voxels within the brain. The aim 
is to superimpose voxels of a similar signal intensity (i.e. grey voxels to grey voxels; 
white voxels to white voxels), thereby using all the information within the scan to 
perform the matching process. Freeborough et al. (1996) described such a voxel 
intensity based method of registration, employing an optimisation procedure based on 
minimising the standard deviation of voxel intensity ratios. The basic registration 
involves: (1) segmenting (scalping) the scan to remove non-brain tissues (e.g. skull 
and scalp); (2) determining and applying a series of rotations and translations to 
match a repeat scan to the baseline. Three translations are applied in each direction 
within the x, y, and z axis and three rotations around these axes produce a so-called 
six degrees o f freedomregistration -  6dof. The process can be extended to allow 
voxels to stretch to a small extent in each of the three planes (nine degrees o f freedom 
registration -  9dof). This theoretically allows for correction of inconsistencies in 
voxel size that may occur between the two scans. Once registered, a difference image 
can be created, so that change between scans can be visualized (see Figure 1.3). This 
validated technique permits accurate study of changes over time and the 
quantification of such changes using the brain boundary shift integral (BBSI) (Fox, 
Freeborough, & Rossor 1996). In essence the BBSI calculates the shift at the 
brain/C SF boundary at every point across the three dimensional registered scan-pair, 
the sum of which approximates closely to the brain volume lost; being a direct
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measure this leads to a reduction in the error associated with indirectly comparing two 
scans (Freeborough and Fox, 1997). This process is shown diagrammatically in 
Figure 1.4.
Non-linear registration allows for a more accurate matching of gyral anatomy 
by allowing scans not merely to match through movement as a rigid body, but 
additionally through a warping procedure. One such approach is fluid registration 
(Christensen et al. 1996; Freeborough and Fox, 1998), which models the 
transformation from one scan to another based on the physical properties of a viscous 
compressible fluid. Following a 9dof rigid body registration the model aims to find an 
exact match between source and target scan; in so doing a displacement vector is 
generated for each voxel within the image, with the degree of stretch or contraction 
demonstrating atrophy or expansion over the period; this can be demonstrated as an 
overlay image (voxel compression map - VCM), providing an unbiased means of 
demonstrating the pattern of regional atrophy occurring between two scans without 
the need for a priori decisions as to which structures should be assessed. This 
technique allows an individual’s pattern of progressive atrophy to be visualized. Fluid 
registration has also been shown in pilot studies to be useful in propagating outlined 
hippocampal volumes forward from a baseline scan to a registered repeat, thus 
potentially increasing accuracy and reducing time in making hippocampal 
measurements (Crum et al. 2001); however at present fluid registration is generally 
used to demonstrate qualitative rather than quantitative patterns of atrophy. Other 
computational methods for determining atrophy patterns in an unbiased fashion have 
also been developed and are summarized by Ashbumer et al. (2003).
1.6.8.1 Global brain atrophy
Global brain volume loss can be assessed using manual measures of whole brain or 
CSF spaces or automated techniques (e.g. the BBSI). Ventricular expansion is an 
inevitable consequence of atrophy of brain tissue, and can be reliably and accurately 
measured from serial scans. Studies suggest that ventricular expansion occurs at 
approximately 5-8ml/yr (DeCarli et al. 1992; Luxenberg et al. 1987; Shear et al. 
1995; Silbert et al. 2003; Wang et al. 2002), far higher than the 0.7-lml per year seen 
in healthy controls (Scahill et al. 2003; Schott et al. 2003; Wang et al. 2002). 
Measures assessing whole brain change using several methods including the direct 
automated BBSI technique have determined rates of whole brain atrophy in AD to be
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approximately 2-2.4%/yr far in excess of those reported in normal ageing (Bradley et 
a l  2002; Fox et a l  1999; Fox et a l  2000; O'Brien et a l 2001; Wang et a l 2002). 
Furthermore brain volume loss correlates well with dementia severity (Fox et al. 
1999). Brain volume loss and ventricular enlargement are highly correlated, but this 
relationship may theoretically be altered by treatments or by pathology (e.g. 
obstructive hydrocephalus).
1.6.8.2 Atrophy of temporal lobe structures
Rates of hippocampal and medial temporal lobe atrophy have all been shown to be 
significantly greater in AD than in normal controls when subjects are rescanned after 
an interval of a year or more both in CT (de Leon et a l  1989; Jobst et al 1994) and 
MRI studies (Jack et a l  1998; Jack et a l 2000; Jack, Jr. et a l 2003; Kaye et a l  1997; 
Laakso et a l 2000). Some of these studies are summarised in Table 1.2. There is 
excess atrophy compared to controls in all studies. For hippocampal atrophy there is 
large variability between studies, and in some cases there is also significant within- 
study variation (reflected by a large standard deviation). The former is likely to be due 
to a combination of measurement error and differences in measurement protocols; the 
latter to be due to inter- and intra-rater variability in measuring the hippocampus, as 
well as the possibility that the hippocampus might undergo different rates of atrophy 
at different disease stages. Studies in FAD have demonstrated that excess 
hippocampal and entorhinal cortex atrophy is probably occurring years prior to the 
clinical manifestation of the disease (Fox et al 1996; Schott et a l 2003), and excess 
medial temporal lobe atrophy can predict which patients will proceed from a 
diagnosis of MCI to AD (Jack et al 2000). Conversely it may be that the rate of 
medial temporal atrophy decreases later in the disease process (Scahill et a l  2002; 
Silbert et al 2003), perhaps when the hippocampus has little volume left to lose.
Although entorhinal cortex atrophy has been reported to undergo both earlier 
and higher rates of atrophy than the hippocampus, most authors conclude that 
hippocampal measures (which are less prone to measurement error) are likely to be 
overall a more practical marker of disease progression (Jack, Jr. et a l 2004; Schott et 
al 2003; Xu et a l  2000).
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1.6.8.3 Conclusions
Early medial temporal lobe atrophy, accompanied by increased rates of whole brain 
atrophy occurs in AD. The rate of MTL atrophy is likely to be higher than that of 
whole brain atrophy particularly in early AD, but is likely to show more variability 
due to measurement errors associated with manual outlining, and possibly variability 
in rate over the course of the disease. Rates of either medial temporal lobe or whole 
brain atrophy are increased in AD compared to age-matched controls.
1.6.9 Detection of early change
By definition retrospective studies of AD patients cannot detect presymptomatic 
changes in AD. In order to fulfil criteria for a diagnosis of probable AD progressive 
multiple cognitive deficits must be present. In order to detect the very earliest changes 
of AD asymptomatic subjects need to be studied prospectively. The incidence of AD 
for unselected healthy individuals from the general population is actually quite low, 
and a prospective imaging study would require a very large number of subjects to be 
studied in order for the sample to include sufficient numbers of subjects who will 
become affected during the study. Enriching the study population by selecting 
subjects at high(er) risk of AD would make a prospective imaging study more 
feasible. The most robust risk factors for AD include: age, family history, and APOE 
e4 homozygosity. Suitable alternatives would be the recruitment of the very elderly 
(85 years of age and over), those with cognitive impairment but not (yet) fulfilling 
criteria for AD e.g. those with MCI or asymptomatic individuals from FAD pedigrees 
entering the age range of highest risk for symptom onset. The FAD group avoids the 
problems associated with co-morbid pathologies (e.g. vascular disease) and reduces 
the risk of censuring of the cohort by unrelated pathologies. Furthermore in the FAD 
group the development of cognitive decline can almost certainly be ascribed to AD 
even without neuropathological confirmation.
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Table 1.2 Rates o f  Change in Alzheimer's Disease
Author
CT/MRI
Structure AD
Mean (±SD) 
loss per year
Control 
Mean (±SD) 
loss per year
Luxenberg (1987) 
CT
Lateral ventricles -13 (8)cc -0.5 (1.2)cc
Bums (1991) 
CT
Vent-brain ratio 
Third ventricle 
Total cortex
9.3(12.6)% 
-16.6 (33.3)% 
6.8(13.6)%
-/-
DeCarli (1992) 
CT
Lateral ventricles -7.3 (9)cc -0.6 (2)cc
Jobst (1994) 
CT
Minimum thickness of 
medial temporal lobe
15.1 (11.6)% 1.5 (4.5)%
Shear (1995) 
CT
Ventricular system -5.28 (5.89)cc -0.61 (2.55)cc
Kaye (1997) 
MRI
Hippocampus 
Parahippocampus 
Temporal lobe
2.3 (2.0) % 
2.9 (2.3) % 
1.24(1.41)%
2.1 (3.5)%
2.2 (2.4) % 
0.01 (1.67)%
Fox (1997) 
MRI
Brain 2.78 (0.92)% 0.24 (0.32)%
Jack (1998) 
MRI
Hippocampus 
Temporal horn
3.98(1.92)%
-14.16(8.47)%
1.55 (1.38)% 
-6.15(7.69)%
Jack (2000) 
MRI
Hippocampus 3.5 (1.8)% 1.7 (0.9)%
Fox(2000) 
MRI
Brain 2.37(1.11)% 0.41 (0.47)%
Laakso (2000) 
MRI
Right hippocampus 
Left hippocampus
6.9(18.2)% 
7.2 (20.1)%
1.6(15.1)%
3.6(15.1)%
O’Brien (2001) 
MRI
Brain 2.0 (0.9)% 0.5 (0.7)%
Wang (2002) 
MRI
Ventricles
Brain
-8.2ml
2.14(1.2)%
-0.8ml 
0.4 (0.5)%
Jack(2003) 
MRI
Hippocampus 4.9 (2.1)% -/-
Silbert (2003) 
MRI
Ventricles
Brain
-5.5 (3.2)ml 
17.9 (18.0)ml
-3.3 (3.5)ml 
1.8 (9.6)ml
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Figure 1.3 Registered coronal Tl-weighted images of an individual with AD.
(A) Baseline image; (B) repeat scan registered to baseline; and (C) difference image 
(i.e. scan A subtracted from scan B) following rigid body registration
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Figure 1.4 Outline of the steps required to quantify whole brain atrophy.
After acquisition of two serial volumetric MRI scans, both must be segmented 
(scalped) - stage 1. The two segmented scans are then digitally matched using a rigid- 
body registration - stage 2. Quantification is performed using the brain boundary shift 
integral which sums voxel shift between scans 2 and 1 at every brain:CSF boundary - 
stage 3.
73
2. Methods
2.1 Patient selection and inclusion criteria
2.1.1 Familial AD pedigrees
Pedigrees with a strong family history of Alzheimer's disease were identified from the 
records of the Dementia Research Group (DRG), St Mary’s Hospital, and the National 
Hospital for Neurology and Neurosurgery, London, UK. The initial referral source of 
the families varied, some were collected following clinical or research referral of 
patients with a family history of dementia to Professor Martin Rossor, whilst other 
affected and unaffected individuals with a strong family history had contacted the 
DRG directly to enrol in research projects. Families were identified where the mode 
of inheritance appeared to be autosomal dominant and where the diagnosis of FAD in 
the pedigree was not in doubt (e.g. due to pathological confirmation in a previous 
generation). The mean age at onset (AAO) in each family was <61 years. In fourteen 
families mutations in the amyloid precursor protein (APP) or presenilin-1 (PSEN1) 
gene had been identified prior to commencement of the study. During the study 
further pathological mutations were identified in several other families.
Recruitment for clinical, neuropsychological, biochemical and MRI studies is 
described below by subject categories.
2.1.2 At risk subjects
Asymptomatic at-risk members of FAD pedigrees were asked to participate in the 
longitudinal study if they were within five years of the historical age at onset for their 
family. At recruitment a careful history for the presence of symptoms was obtained 
independently from the subject and their spouse or other close family member. 
Subjects were excluded from the at risk cohort if they already fulfilled NINCDS- 
ADRDA criteria for possible or probable AD. Subjects were only included if both 
they and other informants felt they had no symptoms of cognitive decline. Inclusion 
also required a close informant (usually a family member) who could provide a 
reliable independent history. At risk subjects were also recruited for plasma amyloid (3 
(Ap) peptide studies as described in Chapter 5.
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2.1.3 Control subjects
The normal control subjects for the longitudinal study consisted of neurologically 
healthy individuals without a family history of early onset AD or other dementia. The 
control subjects were largely recruited from the spouses of affected or at risk study 
members. Control subjects were also considered for Ap studies as described in 
Chapter 5.
2.1.4 Sporadic and familial AD subjects
Patients who already fulfilled NINCDS-ADRDA criteria for probable AD were also 
studied. These patients were recruited from the specialist cognitive disorders clinic at 
the National Hospital for Neurology and Neurosurgery. Both individuals with FAD 
and those without a strong family history of AD, sporadic AD (SAD), were included. 
All individuals had been fully investigated prior to recruitment. The investigations 
included screening blood tests for the reversible causes of dementia, brain MRI, EEG, 
Neuropsychology and CSF examination. The FAD subjects were also considered for 
genetic studies as detailed in Chapter 3. Both FAD and SAD subjects were also 
considered for Ap studies as described in Chapter 5.
2.2 Consent and ethical considerations
The studies described in this thesis were approved by the local research ethics 
committees at The National Hospital for Neurology and Neurosurgery, Queen Square 
and St Mary’s Hospital, Praed Street, London, UK. Informed written consent for each 
individual study was obtained from all study subjects or their appropriate legal 
representative. In addition written consent was obtained for each MRI scan. 
Individuals were not scanned if they had a contraindication to MRI such as a cardiac 
pacemaker. Although travelling expenses were reimbursed study subjects received no 
other payments or inducements. All subjects were informed that participation was 
entirely voluntary. They were also informed that they could at any time withdraw 
from the study and that withdrawal would not in any way influence any subsequent 
clinical care. Additionally for the longitudinal study a missed assessment would not 
preclude them from rejoining the study at a later date.
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All individuals, and in particular the “at risk” cases, were made aware that the 
data collected as a part of the study were confidential and of a research nature. As part 
of the process of informed consent it was emphasised that the study would not provide 
any specific results on an individual basis. The one exception to this rule was if an 
MR scan revealed an unrelated but clinically important structural lesion such as a 
cerebral neoplasm in which case they and their general practitioner would be 
informed of the scan results. It was stressed that because of the experimental nature of 
the MRI analysis technique it would not be possible to provide information as to 
whether or not there was a suggestion of the onset of a degenerative process. It was 
however, made clear that if individuals or their relatives were concerned that they 
might be becoming symptomatic they could be referred to the National Hospital for 
evaluation in a clinical setting and further investigation as appropriate. All such 
referrals were accompanied by counselling. During the course of the study several 
subjects chose to be referred for these purposes.
For the genetic study described in Chapter 3 consent for research screening 
was obtained on the basis that there would be no individual results available. The 
consent obtained allowed family members to be informed of positive mutation 
findings for each specific family. These results were mailed using a standard letter to 
registered family members and their general practitioners without making individual 
results available to that family. It was made clear that these research findings would 
have to be confirmed in a clinical setting. This practice led to a small number of 
asymptomatic at risk individuals of FAD requesting genetic testing. In these cases 
referral for genetic counselling for consideration of predictive genetic testing was 
suggested via their general practitioner to either their local Clinical Genetics Service 
or to Professor Nick Wood, consultant neurogeneticist at The National Hospital for 
Neurology and Neurosurgery. In either case any information to assist in the genetic 
counselling process was made available to the clinician on request. In addition an 
offer to perform the actual genetic test under confidential clinical conditions by 
Professor John Collinge, Director of the MRC Prion Unit was always made as FAD 
mutation screening is not generally available in the UK. The finding of pathogenic 
mutations also allowed diagnostic genetic testing in patients who fulfilled NINCDS- 
ADRDA criteria.
In view of the stresses and anxieties which at risk individuals and their 
spouses experience and the fact that research assessments may exacerbate those
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stresses, every effort was made to provide time for subjects in addition to that 
necessary for the research assessments. This allowed discussion of their concerns and 
provision of general information on AD and research being carried out. Members of 
families were also offered access to CANDID (counselling and diagnosis in dementia) 
a national telemedicine service supporting the care of younger patients with dementia 
run from the National Hospital for Neurology and Neurosurgery (Harvey et al. 
1998b). Many of the subjects stated that they did not expect their participation in a 
research project to benefit them personally but hoped that they might help future 
generations.
2.3 Clinical and neuropsychological assessment
2.3.1 Assessment schedule
Subjects who fulfilled the inclusion criteria for the longitudinal study and who agreed 
to participate were asked to attend assessments accompanied by their spouse or a 
close family member. Study visits were scheduled to take place at intervals of 
approximately one year. However, if an individual was unable to make an assessment 
this did not exclude them from further study. Each assessment for the longitudinal 
study consisted of an interview, neurological examination, neuropsychological 
assessment and brain MRI. In addition blood samples for plasma Ap studies were 
taken. The accompanying relative was interviewed separately to corroborate the 
history and to discuss their concerns about the disease. Many individuals travelled 
considerable distances to take part in the study and therefore the total assessment time 
was designed to allow travel and the assessment to be completed within the day.
2.3.2 History and examination
The Medical Research Council (UK) guidelines for assessment of AD research 
patients provided the basis for the clinical interview (Medical Research Council 
1986). Specific questions covered activities of daily living, occupational history, and 
whether there had been any recent difficulties in coping with the demands of the job 
or home. Memory functions that were specifically enquired about included difficulties 
in remembering names, appointments, routes, telephone messages, errands or lists of 
items such as shopping. The subject and informant were independently asked by me 
whether there had been any change in memory functions and how the subject’s
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memory compared to that of other individuals of a similar age. Enquiries were also 
made about any changes in other cognitive functions or in behaviour. In addition to 
basic demographic data about the subject a full general medical and psychiatric 
history was obtained including alcohol, drug and tobacco consumption. Details of the 
family history were corroborated and the estimated age at onset of symptoms in 
affected family members verified. A standardised (modified) Mini Mental State 
Examination (see Appendix 2), and the Clinical Dementia Rating (CDR) (Hughes et 
a i 1982) were recorded for each visit for all subjects. A general neurological 
examination was performed on all subjects which included assessments of tone, 
tendon and primitive reflexes, myoclonus and praxis.
2.3.3 Neuropsychology
A comprehensive assessment was carried out by a neuropsychology assistant under 
the supervision of Dr Lisa Cipolotti, Head of the department of Neuropsychology, 
National Hospital for Neurology and Neurosurgery. The following areas of cognition 
were investigated: General intellectual functions (Shortened version of the WAIS-R) 
(Wechsler 1981), Advanced Progressive Matrices (Raven 1965), Verbal recognition 
and recall memory (Verbal version of the Recognition Memory Test (Warrington 
1984), Paired Associate Learning Test (Warrington 1996), Visual Memory (Visual 
version of the Recognition Memory Test (Warrington 1984), Topographical memory 
test (Warrington 1996), Nominal function (Graded-difficulty naming test (McKenna 
& Warrington 1980)), Word comprehension (Synonyms test (Warrington, McKenna, 
& Orpwood 1998)), Literacy and calculation using the National Adult Reading Test 
(NART) (Nelson & Willison 1991), Graded-Difficulty Spelling Test (Baxter & 
Warrington 1994), Graded-difficulty Arithmetic Test (Jackson & Warrington 1986), 
Visual perceptual and visuospatial functions (Silhouettes and Cubes from the Visual 
Object and Space Perception Battery (Warrington & James 1991), Frontal ‘executive’ 
functions (Modified Card Sorting Test, (Nelson 1976), Cognitive Estimates test, 
(Shallice & Evans 1978), Trail Making test (Reitan 1958), Hayling sentence 
completion test (Burgess & Shallice 1996), Weigl colour form sorting test (Weigl 
1948), Speed and attention (Digit copying and Cancelling 0’s (Willison & Warrington 
1992).
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The assessment schedule was designed as a compromise between being as 
short as possible and yet being comprehensive. This test battery takes between 90 and 
120 minutes to administer. Tests were chosen that were of graded difficulty and on 
which normal subjects rarely score at ceiling. So as to allow measurement of change 
the NART (or Schonell in severely affected individuals) was used to provide a 
measure of optimum level of pre-morbid intellectual function (Nelson & Willison 
1991).
2.3.4 Blood sampling
For genetic studies three plastic 10 ml EDTA tubes were drawn using a standard 
aseptic Vacutainer® technique and either taken directly to the laboratory for DNA 
extraction or frozen at -70°C for subsequent DNA extraction. For the plasma Ap 
studies two EDTA tubes were drawn and immediately centrifuged at 4000 rpm for 
three minutes. As soon as the centrifuge had stopped the supernatant was pipetted into 
1 ml plastic aliquots without disturbing the buffy coat. These aliquots were 
immediately “fast” frozen using dry ice and transferred to a -70°C laboratory freezer 
for later analysis.
2.4 Magnetic resonance imaging
2.4.1 Acquisition
MR imaging was performed on a General Electric 1.5 Tesla Signa Advantage Unit 
(GE, Milwaukee, USA) at one of three sites: St. Mary’s Hospital, Paddington, the 
NMR Research Unit at the Institute of Neurology or Queen Square Imaging Centre at 
the National Hospital for Neurology. All scans included a routine sagittal (Tl- 
weighted) localizer sequence and an axial dual-echo sequence (T2- and proton 
density-weighted). In addition volumetric imaging was performed in the coronal 
plane, using a spoiled gradient echo technique (SPGR) with a 24 x 24 x 19.2 cm field 
of view yielding 124 contiguous 1.5 mm thick slices through the head on a 256*128 
image matrix. The acquisition parameters were as follows: time to echo, 5 ms; time to 
repeat 35 ms; flip angle 35° (35/5/1/35 - TR/TE/NEX/FLIP).
Subjects were reminded to remain as still as possible during the scanning and 
were given earplugs to wear. They were positioned supine on the scanner table and 
head movement restricted by foam wedges either side o f the head and a Velcro® band
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across the forehead. Despite these restraints head movement remains possible and 
their function is mainly to support the head and to remind subjects to keep still. For 
comfort a foam wedge was placed under the knees to keep them partly flexed. For 
anxious at risk or affected subjects I remained in the scanner suite within the visual 
field of the head coil mirror for reassurance and to remind them to keep still. Sedation 
was not used. The duration of acquisition for the volumetric SPGR sequence was nine 
and a half minutes.
2.4.2 Image analysis tools
Digitised MR images were transferred to a Sun work station (Sun Microsystems Inc., 
Mountain View, CA) and analysis performed using the DRG in-house MIDAS image 
analysis programme (Freeborough, Fox, & Kitney 1997). The programme allows the 
3-D data to be visualised in two windows simultaneously showing different 
orthogonal views (i.e. any two of axial, coronal, or sagittal planes). A 2-D cut of the 
data is displayed in the main window and the region of interest is defined upon it, 
using a mouse driven cursor to draw around an area and deposit a seed within it. The 
outlined region follows pixel boundaries. The outlining may be performed at a range 
of magnifications, and the level of magnification may be changed at any stage without 
any loss of data. Thresholding based upon grey level (signal intensity) may also be 
used to facilitate segmentation. The region of interest appears as it is defined, in real 
time, on orthogonal 2-D cuts displayed in the adjacent MIDAS window. In this way 
the relationship between the outlined region and neuroanatomical landmarks used to 
guide the outlining can be viewed in different planes simultaneously. This improves 
reproducibility of anatomical definition. The outlining may be edited in any other 
plane and corrected if  it does not coincide with anatomical landmarks. Measurements 
may be outputted as slice-by-slice cross-sectional area measurements or as a volume. 
All regions can be saved and corrected at a later date.
2.4.3 Registration of serial MRI
Automated image subtraction allows all areas of the brain to be examined 
simultaneously without laborious manual measurements and a priori decisions of 
predetermined structures. However accurate positional matching must be achieved in
80
order for subtraction of serial studies to be meaningful. Careful standardised head 
alignment within the scanner (Bergstrom et al. 1981; Hajnal et al. 1995; Strother et al. 
1994) is not sufficient because of the changing position of the atrophying brain 
relative to the skull interior. This has resulted in the development of post-acquisition 
positional matching or registration algorithms to align regions of interests on the 
baseline and follow-up studies. In this thesis registration was achieved using signal 
intensities from all voxels within the brain so that voxels representing the same 
underlying anatomical structures are superimposed. The DRG semi-automated 
morphological approach was used to define the brain region (Freeborough, Fox, & 
Kitney 1997; Freeborough, Woods, & Fox 1996). This interactive method uses 
conditional morphology in a way that minimises the distortion of structure and results 
in consistent placing of boundaries on different scans, features that are particularly 
important when dealing with the atrophied brain. The method is tailored for Tj 
weighted MRI scans (Freeborough, Fox, & Kitney 1997; Freeborough, Woods, & Fox 
1996). The primary tissue types, in such scans, of white matter (WM), grey matter 
(GM) and cerebro-spinal fluid (CSF) have high, intermediate and low voxel 
intensities respectively. The steps (see Appendix 3 for description and illustrations) 
involve selecting: 1) a range of intensities for brain tissue and a level at which to cut 
the spinal cord from the brain, 2) a number of conditional erosions and an intensity 
threshold for each, which prevents erosion of voxels with higher intensity (note: after 
each erosion voxels which are not part of the largest connected set are discarded), 3) a 
number of dilations conditional on voxel intensities being within 60%-160% 
(arbitrary) of the mean intensity over the set and 4) a sampling factor, r, used to 
define an ‘interior’ of the brain over which the 60%-160% criteria is reapplied. 
Manual editing can be added where necessary.
Registration using this method appears most robust when only brain regions are 
registered (excluding non-brain voxels which may move relative to brain) and a multi­
resolution approach is adopted. Scaling changes (voxel size inconsistencies) have 
consistently been an important source of error on the three scanners used. Registration 
was improved when these were compensated for. These methods achieve consistency 
of registration to subvoxel level both in controls and patients with neurodegenerative 
disorders (Freeborough, Fox, & Kitney 1997; Freeborough, Woods, & Fox 1996).
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2.4.4 Quantification of volume change from registered MRI
Once the scans are accurately registered points in the scans may be compared directly. 
This may be done by simple subtraction or alternatively areas of change may be 
highlighted on the scans using a difference overlay image (DOI); as illustrated in 
Figure 8.1. A DOI gives a magnified view of one scan on which pixels of significant 
change are coloured using alternate pixels to add colour without losing structural 
detail (Fox, Freeborough, & Rossor 1996). An increase in pixel intensity is 
represented by green and a decrease by red. Qualitatively the amount of change 
between scans may best be appreciated visually by toggling between scans or by 
displaying the red and green overlay to identify voxels of significant intensity change. 
Objective quantification of change was achieved using the Brain Boundary Shift 
Integral (BBSI), which automatically determines the total volume through which the 
whole boundary of a 3-D structure shifts from the voxel intensities of accurately 
registered serially acquired scans (Fox, Freeborough, & Rossor 1996).
2.4.5 Ventricular segmentation
The protocol that I used for ventricular segmentation is described in detail in 
Appendix 4, but in essence involves the semi-automated labelling of the region of 
interest using a set of “rules”. Once labelled on one scan it can be “copied and pasted” 
onto the next of a pair of registered scans and edited. This minimizes changes in the 
application of the “rules” within individual patients.
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3. A study of the genetics of familial Alzheimer’s disease
3.1 Family review
Against a background of only fourteen DRG FAD families having an identified 
causative mutation (see Table 3.1) at the start of this project I reviewed the collection 
of families to identify potential probands for genetic screening using the following 
criteria:
1. Probable or definite AD using NINCDS-ADRDA criteria
2. Mean age of onset 60 years or less
3. Family history:
> autosomal dominant inheritance defined using recognised criteria as 
having at least three affected members in two or more generations
> affected relative(s), but not fulfilling recognised criteria for autosomal 
dominant inheritance
4. Availability of stored blood, stored DNA, frozen brain tissue or living affected
family member involved in research project/ clinical follow up from whom a
sample could be drawn with appropriate consent
5. Not known to be related to a DRG family with a known mutation
The majority of probands identified belonged to families that had previously been 
screened and no mutation found (e.g. F53, F I05, F I34, F I60, and F I75 who were 
reported as not having APP mutations by Fidani et al. in 1992). As shown in Figure 
3.1, two thirds of DRG FAD families did not have an identified mutation raising the 
possibility that there might be a fourth AD locus.
In order to determine the proportion of DRG FAD families accounted for by 
mutations in known genes a systematic genetic evaluation was carried out by 
sequencing APP, PSEN1 and PSEN2.
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segregation between the mutation and the disease. In many families, however, this 
analysis was not possible, since there were no other living affected relatives/or stored 
DNA available. In addition 100 normal Caucasian controls were genotyped to 
determine the prevalence of a novel finding in the normal population. A standard one 
stage PCR technique was used to determine APOE genotype for probands in whom a 
causative mutation was not identified (Wenham, Price, & Blandell 1991).
3.3 Results
Seventeen patients with probable and 14 patients with definite AD (NINCDS- 
ADRDA criteria) were recruited. The mean AAO was 46.9 years (median: 45 years; 
range: 33-60 years). The majority of patients (23/31) belonged to families with three 
or more affected family members in at least two generations and thus had a family 
history fulfilling recognized criteria for autosomal dominant inheritance. The 
remaining eight patients had a single affected first degree relative; for six patients this 
was a parent and for two patients a sibling.
As shown in Table 3.4 sixteen PSEN1 mutations were identified in 17 (55%) 
probands including eight recognised PSEN1 mutations: Y115C, M l461, LI53V, 
L171P, G184D, A260V, R269H and the intron4 or A4 mutation (Thr 113/114 ins), a 
novel three base pair deletion (A167) and seven novel missense point changes: 
Y154C, I229F, F237L, L235V, C263F, R377M and G378V. The A167 deletion was 
characterized by the deletion of the third base pair of codon 167 and the first and 
second base pair of codon 168.
As shown in Table 3.3 three APP mutations were identified in four (13%) 
probands, including the recognised V717I (London) mutation in two probands and 
two novel missense point mutations: V715A and H677R.
All novel mutations identified were absent from 100 healthy unrelated white 
control patients. In three families DNA was available from affected relatives. In these 
three families co-segregation of the mutation and the disease could be tested. In 
families 134 (PSEN1 G378V) and 267 (PSEN1 L235V) the presence of the sequence 
variant was demonstrated in all affected patients for whom DNA was available. In 
familiy 134 the G378V mutation was present in three patients, and in family 267 the 
L235V mutation was present in two patients. However, in family 209 the APP H677R
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mutation was absent from the affected sibling; both siblings were APOE s3 
homozygotes. Thus in this series 21/31 (6 8 %) probands were associated with a 
mutation in APP  or PSEN1. For the subset of patients with definite AD who also fulfil 
criteria for autosomal dominant inheritance 9/11 (82%) probands were associated with 
a mutation in APP  or PSENJ (five recognized mutations, two mutations that co- 
segregate with disease and two novel mutations only demonstrated in a single 
proband). Similarly 10/13 (77%) probands with probable AD (NINCDS-ADRDA), 
who also fulfilled criteria for autosomal dominant inheritance, were associated with a 
mutation in APP  or PSEN1 (seven recognized mutations and three novel mutations 
only demonstrated in a single proband).
The mean age of probands with mutations was 44.7 years, whereas those 
without mutations were significantly older at 55.4 years (P = 0.001). The mean age of 
probands with PSEN1 mutations was not significantly younger than those with APP  
mutations (43.7 years v. 50.3 years; NS).
In 10 probands a mutation was not identified in PSEN1 or the examined exons 
of APP  and PSEN2; three probands were homozygous and five patients were 
heterozygous for APOE  e4 (see Table 3.5). The frequency of the APOE  e4 allele was 
0.80 in these probands without mutations.
3.4 Discussion
Mutational analysis showed that 21/31 probands in this UK cohort had PSENJ or APP 
mutations. In addition PSENJ E318G, a non-causative rare polymorphism (Dermaut 
et al. 1999), was identified in family 181.
Evidence for the co-segregation of FAD and the novel mutations was only 
available in two families and so the fact that some of the novel mutations are non- 
pathogenic cannot be excluded. However, the pathogenicity of PSENJ and APP 
mutations is well recognised. Mutations in APP  are located close to the major APP 
processing sites, either adjacent to the Ap domain (the P and y secretase cleavage 
sites) or within the AP domain itself (the a secretase cleavage site). The 
pathophysiological mechanisms of these mutations vary. The only known mutation 
near to the p secretase cleavage site is the 670/671 (Swedish) double mutation which 
consists of the substitution KM —► NL. This mutation results in increased total Ap, by 
increasing both AP40 and, to a lesser extent, Ap42 (Scheuner et al. 1996). Those near 
the y secretase cleavage site generally increase production of the more amyloidogenic
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AP42 (Scheuner et al. 1996). However, the V715M (French) mutation results in a 
reduction of Ap4o without affecting Ap42 production suggesting that it is the increase 
in the ratio of Ap42 to Ap4o which is important rather than the absolute amount of 
Ap42 (Ancolio et al. 1999). The V715A APP mutation described in this thesis is also 
at this residue. The neuropathology of the proband is typical of AD, but due to the 
lack of DNA specimens from further affected relatives co-segregation with disease 
could not be demonstrated. A more recent study of six mutations near the y secretase 
cleavage site not only confirmed the findings of Ancolio et al. (1999), but also 
confirmed this for the V715A mutation (demonstrated in a German pedigree without 
neuropathology), and further demonstrated an inverse correlation between these ratios 
and AAO (De Jonghe et al. 2001).
Pathogenic intra-Ap mutations (see Figure 1.1) are generally associated with 
amyloid accumulation in cerebral blood vessels in addition to amyloid plaque 
formation. Carriers of the E693Q (Dutch) mutation have intracerebral haemorrhages 
(Levy et al. 1990), whereas patients with the A692G (Flemish) mutation, frequently 
have intracerebral haemorrhage but may survive to develop a progressive AD-like 
dementia (Hendriks et al. 1992). The E693G (Arctic) mutation is associated with a 
more typical early onset AD phenotype without evidence of intracerebral hemorrhage. 
The three known mutations at codon 693 (see Figure 1.1) result in reduced AP42 levels 
in conditioned media, which contrasts with increased levels of both Ap4o and AP42 in 
media for the A692G (Flemish) mutation (Nilsberth et al. 2001). For the E693G 
(Arctic) mutation this reduction in Ap was observed even in pre-symptomatic 
mutation carriers 20-30 years before the expected onset of the disease. This together 
with the finding that Arctic Ap formed protofibrils at a much higher rate and in larger 
quantities than wild type Ap is the basis of a proposed alternative pathogenic 
mechanism for this kindred where protofibrils result in the accelerated buildup of 
insoluble Ap (Nilsberth et al. 2001). The pathogenicity of APP H677R, the novel 
intra-Ap sequence variant which was present in one of two siblings of family 209, is 
not certain. The diagnosis in both siblings is secure since they both underwent 
neuropathological examination which confirmed the signature lesions of AD. Neither 
sibling had an APOE e4 allele, a mutation in PSEN1 or the sequenced exons of 
PSEN2 to account for their disease. Nothing is known about the previous generation 
in this family so it remains a possibility that the mutation is an autosomal dominant 
pathogenic mutation accounting for the disease in one of the siblings with the other
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sibling being a phenocopy i.e. having sporadic AD. Alternatively it is a rare non- 
pathogenic polymorphism, absent from 100 normal Caucasian controls, and both 
siblings have sporadic AD. Further structural modelling and Ap metabolism studies 
for this novel sequence variant are awaited.
Of the seven novel PSEN1 missense mutations in this study two occur at 
residues where mutations have previously been reported: C263F and G378V 
(Besancon et al. 1998; Wasco et al. 1995). In keeping with previous reports the 
remaining five missense mutations occur in transmembrane domains (TM). The 
Y154C mutation further extends the previously discussed mutation cluster in TM 2 in 
exon 5 (see Table 4.6). The I229F and F237L mutations are in TM 5 in exon 7 
(Aldudo, Bullido, & Valdivieso 1999; Campion et al. 1995a; Campion et al. 1995b; 
Campion et al. 1999; Cruts et al. 1998; Kwok et al. 1997). The L235V mutation lies 
in a small cluster in TM 6 in exons 6/7 (Forsell et al. 1997; Hutton et al. 1996; 
Rogaev et al. 1995; Sherrington et al. 1995m). The R377M mutation is in the TM7 
cluster in exon 11 (Besancon et al. 1998; Campion et al. 1995b; Campion et al. 1999; 
Cruts et al. 1995; Tedde et al. 2000).
The pathogenicity of PSEN1 deletion mutations is also well recognised (Crook 
et al. 1998; Kwok et al. 1997; Steiner et al. 2001), and though critically dependant on 
what is actually deleted, the novel PSEN1 A167 mutation is probably also pathogenic.
Mutations of APP  and PSEN1 show almost complete penetrance by the age of 
60 years with the exception of four PSEN1 missense mutations: A79V (Cruts et al. 
1998), I143F (Rossor et al. 1996), H163Y (Axelman, Basun, & Lannfelt 1998), and 
H163R (Poorkaj et al. 1998b). The level of penetrance and mechanism of 
pathogenicity remain to be determined for the novel mutations described here. No 
mutations were identified in exons 4, 5, and 7 of PSEN2 which may reflect the 
selection of families with an early and relatively constant AAO.
The proportion of PSEN1 and APP mutations described in the present study is 
much higher than the 18% reported by Cruts et al. (1998) who used the same criteria 
to define autosomal dominant inheritance. The findings from this study are in accord 
with a French FAD study in which 24/34 (71%) families fulfilling stricter three 
generational criteria to define autosomal dominant inheritance were found to have 
mutations in APP  or PSEN1 (Campion et al. 1999).
Ten probands did not have a mutation in APP, PSEN1 or PSEN2. Despite 
there being two very early onset probands (families 278 and 373) in this group it is of
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interest to note that the mean age of these probands was ten years older than those 
with mutations (P = 0.001) and that, three (30%) of these probands were homozygous 
and five (50%) were heterozygous for APOE e4. Thus the observed frequency of the 
APOE s4 allele of 0.80 was higher than the 0.15 observed in the general Caucasian 
population (Campion et al. 1999; Weiner et al. 1999). In view of their older AAO it is 
plausible that some of these patients may in fact have early onset AD due to the 
presence of one or two e4 alleles. The proband from family 278, with a three 
generational family history, did not have an e4 allele, and the absence of an APP, 
PSEN1 or PSEN2 mutation in this neuropathologically confirmed family, could be 
explained by a mutation located outside the regions that were analysed, or by the 
involvement of other causative and risk genes for FAD. Although the proband from 
family 373 was homozygous for c4, it seems unlikely that this is APOE driven AD 
and again a mutation outside the regions analysed or the involvement of another 
genetic factor seems more likely.
Familial AD is a rare disease with an estimated prevalence of 5.3 persons per 
100,000 at risk (Campion et al. 1999). The data from this study are therefore from a 
highly selected population of patients who have been carefully characterised and fulfil 
either ante-mortem NINCDS-ADRDA criteria for a diagnosis of probable AD or have 
neuropathologically verified AD. Eighty-one percent of FAD patients (9/11) with 
neuropathologically confirmed definite AD had an associated mutation in either APP 
or PSEN1. Six of these mutations have been previously reported, two were novel 
changes for which co-segregation was demonstrated, and one was a novel change 
demonstrated in the proband only. Seventy seven percent of probable FAD probands 
(10/13) had associated mutations in APP or PSEN1. Seven of these mutations were 
recognised pathogenic mutations and three were novel mutations demonstrated in a 
single proband only. It is these novel mutations only demonstrated in a single proband 
that cause the greatest difficulties in clinical practice, particularly for PSEN1 
mutations as many are private, i.e. they are only found in a particular individual or 
family (Blacker & Tanzi 1998; Cruts et al. 1998). It is therefore difficult to interpret 
the causative effects of the novel mutations described and this will require extending 
the families where possible, looking at the pathophysiology of the mutations with 
regards their effect on APP processing and waiting for further reports.
Because a molecular genetic diagnosis of an inherited disorder affects not only 
the patient, but also the entire family, genetic counselling must be an essential
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component of the diagnosis of inherited disorders (Gasser et al. 2001). In the case of 
predictive testing this will invariably involve trained clinical geneticists using a 
(modified) Huntington’s disease protocol. The observed mutation frequency of 78% 
in 23 FAD probands in this study suggests that a molecular diagnosis is well worth 
pursuing in a patient with early onset probable AD. On the whole these data and the 
literature (Campion et a l 1999; Cruts et al. 1998; Finckh et al. 2000) would suggest 
that this should be confined to those with a clearly positive family history of 
autosomal dominant inheritance and an early A AO in all family members. Mutational 
screening of affected individuals without such an autosomal dominant family history 
is rarely indicated unless there is a very characteristic phenotype and inadequate 
family history (Gasser et al. 2001). This would certainly apply to the two EOAD 
patients with an AAO in the fourth decade of life with PSEN1 mutations and possibly 
the sib-pair of F209, although both non-paternity and the remote possibility of a de 
novo mutation should also be considered. Routine counselling prior to diagnostic 
testing would include making the patient and the family aware that a mutation may 
not be found and that a novel finding may be difficult to interpret.
In a clinical setting, however, the emphasis must remain on making an 
accurate clinical diagnosis and excluding the many reversible conditions that can 
masquerade as AD. In addition it should not be forgotten that families who do not 
have a proven pathogenic mutation or who do not wish to undergo diagnostic genetic 
screening should not be denied the benefits of genetic counselling based on the 
autosomal dominant risk model. Even for those with a known pathogenic mutation the 
uptake of predictive testing may be low, similar to Huntington’s disease (Binedell, 
Soldan, & Harper 1998), in the absence of a disease modifying treatment.
Following the completion of this study, and the finding of the intron 4/A4 
mutation in F105/160 and F I75 (De Jonghe et al. 1999b) the combined post-study 
DRG FAD mutation prevalence is 88% (as illustrated in Figure 3.2). Though the 
likelihood of a fourth FAD locus existing would appear to be much diminished 
several large kindreds e.g. F278 and F373 are yet to be accounted for in this series and 
we are sequencing the remaining exons of PSEN2 and reviewing the pathology of 
these non-mutation FAD families, prior to embarking on further studies.
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Table 3.1 DRG FAD families with known mutations in 1998
Family Gene Mutation First Author
19 APP V717G Chartier-Harlin, 1991
23 APP V717I Goate, 1991
74 PSEN1 A9 S290C Perez-Tur, 1996
102 PSEN1 E280G Clark, 1995
121 PSEN1 E120K Hutton, 1996
148 PSEN1 Ml 39 V Clark, 1995
156 PSENJ I143F Palmer, 1999
168 PSENJ E280G Clark, 1995
172 APP V717I Fidani, 1992
183 PSENJ E280G Clark, 1995
184 PSENJ L250S Hutton, 1996
196 PSENJ P267S Clark, 1995
206 PSENJ M139V Clark, 1995
223 PSENJ P436S Palmer, 1999
APP = amyloid precursor protein gene mutation 
PSEN1 = presenilin 1 gene mutation
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Table 3.2: Mutations demonstrated and method of confirmation
Family Gene Mutation Controls Confirmation
Assay
ASOH probe 
Wild type/mutant
36 APP V717I - ASOH AGTGATCG/ATCATCAC
37 PSENJ F237L 100 ASOH CCTGGTGT/CTTATCAA
53 PSENJ A167 100 ASOH GCTT ATT AT AT CAT C/ 
TGGCTTATATCATCT
134 PSENJ G378V 100 ASOH TT AGGGGG/T AGT A A A A
177 PSENJ L153V 100 ASOH GGT GGTT C/GT GT AT AA
181 PSENJ E318G - ASOH A AT GC AG AA AGT AGG/ 
AATGCAGGAAGTAGG
209 APP H677R 100 N laH I -
226 PSENJ R269H - Nde I -
250 APP V715A 100 Pvu I -
266 PSENJ L171P - ASOH TCATCTCT/CATTGTTG
267 PSENJ L235V 100 ASOH CAT GGCCC/GT GGT GTT
283 PSENJ R377M 100 Bsl I -
286 PSENJ I229F 100 ASOH CATTATGA/TTTAGTGC
301 PSENJ C263F 100 ASOH GTTTT GT G/TTCCG A A A
325 PSENJ Ml 461 - ASOH TTGTCATG/AACTATCC
342 PSENJ lntron4 - Pvu II -
344 PSENJ Intron4 - Pvu II -
349 APP V717I - ASOH AGTGATCG/ATCATCAC
353 PSENJ A260V - ASOH TT AGT GGC/TT GTTTT G
364 PSENJ E184D - Afl in -
369 PSENJ Y154C 100 ASOH GTTCTGTA/GTAAATAC
372 PSENJ Y115C - ASOH AGAATCTA/GTACCCCA
ASOH = Allele specific oligonucleotide hybridisation
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Table 3.3 Pro bands with APP mutations
Family Affected Generations AAO, 
Patients (n) Mean 
(n) (range) 
years
Exon Mutation Amino Acid 
Change
PM
36 5 2 52, 50 
(49-52)
17 V717I Val717Ile AD
209 2 1 55, 55 
(55-56)
16 H677R His677Arg* AD
250 3 2 42, NK 
(NK)
17 V715A Val715Ala* AD
349 5 3 54, NK 
(NK)
17 V717I Val717Ile -
* Novel mutation
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Table 3.4 Probands with PSEN1 mutations
Family Affected 
Patients 
(n)
Generations
(n)
AAO,
Mean
(range)
years
Exon Mutation Amino Acid 
Change
PM
37 3 2 46, 51 
(46-57)
7 F237L Phe237Leu* -
53 5 2 45, 52 
(45-60)
6 A167 A167* AD
134 13 3 43, 45 
(41-49)
11 G378V Gly378Val** AD
177 3 2 35, 35 
(35-36)
5 L153V Leul53Val AD
181 2 2 52, 61 
(52-70)
9 E318G Glu318Gly*** “
226 4 3 53, 53 
(50-56)
8 R269H Arg269His AD
266 3 3 38, 38 
(38-38)
6 L171P Leul71Pro “
267 6 3 44, 47 
(44-50)
7 L235V Leu235Val** AD
283 2 2 38, 39 
(38-41)
11 R377M Arg377Met* AD
286 2 2 33, 33 
(33-33)
7 I229F Ile229Phe* AD
301 3 2 58, 58 
(58-60)
8 C263F Cys263Phe*
325 3 2 49, 49 
(49-50)
5 Ml 461 Metl46Ile
342 3 3 34, NK 
(NK)
IVS4 Intron4/
A4
Thr 113/114 ins “
344 3 2 37, NK 
(NK)
IVS4 Intron4/
A4
Thr 113/114 ins AD
353 6 2 40, 41 
(40-42)
8 A260V Ala260Val -
364 5 3 42, 42 
(40-44)
7 E184D Glul84Asp -
369 6 3 41, NK 
(NK)
5 Y154C Tyrl54Cys* -
372 5 3 36, 48 
(36-54)
5 Y115C Tyrl 15Cys -
* Novel mutation, ** Co-segregation demonstrated, *** Non causative polymorphism
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Table 3.5 Probands without causative FAD mutations
Family Affected
subjects
Generations AAO, Mean 
(range) years
APOE
Genotype*
PM
112 2 2 55, 62 (55-69) 3,4 -
150 4 2 60, 61 (60-63) 4,4 -
157 4 2 58, 59 (58-60) 4,4 -
165 2 2 53, 56 (53-60) 3,4 AD
167 2 2 58, 58 (57-58) 3,4 AD
181 2 2 52, 61 (52-70) 3,4 -
278 13 3 47, 45 (42-48) 3,3 AD
287 5 3 60, 59 (58-60) 3,4 -
296 2 2 60, 60 (60-60) 3,3 -
373 5 3 36, 34 (32-36) 4,4 AD
AAO = age at onset,
PM = post mortem diagnosis 
* Of the index patient
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Figure 3.1 Mutation frequency in DRG FAD families in 1998
Autosomal dominant FAD 
(n = 41 families)
NK, 27,
APP, 3, 7%
PSEN1, 11,
27%
Figure 3.2 M utation frequency in DRG FAD fam ilies in 2001
Autosomal dominant FAD 
(n = 41 families)
NK, 5, 12% APP, 6, 15%
PSEN1, 30,
73%
APP = amyloid precursor protein gene mutations 
PSEN1 = presenilin 1 gene mutations 
NK = not known
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4. A study of the clinical phenotype of three presenilin 1 
mutations
4.1 Methods
4.1.1 Background
Family 105/160 (PSEN1 intron4), Family 177 (PSEN1 LI53V) and Family 102 
(PSEN1 E280G) are three kindreds from the British Isles. Their family trees are 
shown in the relevant subsections. Whenever possible, the history was verified by an 
independent interview with the primary carer.
4.1.2 Neuropsychology
In family 105/160 three patients (V.16, V.17 and VI.08) underwent neuro­
psychological assessment as described previously. A further patient (IV. 15) had only 
been assessed on the Wechsler Adult Intelligence Scale (Wechsler 1955). In family 
177 three members are enrolled in the longitudinal “at risk” study, but of the affected 
patients only III.3 had undergone a limited neuropsychology assessment. Similarly for 
family 102 only limited data are available for the affected family members.
4.1.3 Molecular Genetics
All available DNA specimens from each of the families were screened by restriction 
digest and sequencing of all PSEN1 coding exons as previously described in Chapter
3. Normal controls (n >100) were screened by restriction digest for the then novel 
mutations PSEN1 intron 4 and LI53V. At least one normal control was also screened 
by sequencing all coding exons. A one stage PCR technique was used to determine 
APOE genotype using DNA from the same affected cases as previously described 
(Wenham, Price, & Blandell 1991).
4.1.4 Neuropathology
Neuropathological examinations were carried out in each of the three families. These 
were carried out by Professor Peter Lantos of the MRC Neurodegenerative Diseases 
Brain Bank at King’s College Hospital on the following affected family members 
105/160.V. 10, 105/160.VI.08, and 177.III.3. Details of a further two necropsies
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performed previously on patients 105/160.IV.11 and 105/160.IV. 15 were also 
obtained. A brain biopsy had previously been performed on patient 102.III.2 and this 
was re-evaluated in detail by Professor Michael Farrell, Department of 
Neuropathology, Beaumont Hospital, Dublin.
Blocks of tissue from the brains of cases 105/160.V. 10, 105/160.VI.08, and 
177.III.3 were taken from the frontal, temporal (with the hippocampus and the 
amygdala), parietal and occipital lobes, the basal ganglia (to include the caudate 
nucleus, the lentiform nucleus, the claustrum and the nucleus basalis of Meynert), the 
thalamus with the subthalamic nucleus, midbrain, pons, medulla oblongata and from 
the cerebellar hemisphere and vermis. The sections were stained with haematoxylin 
and eosin, impregnated with silver according to the modified Bielschowsky method and 
luxol fast blue and cresyl violet (on selected sections). Antibodies were used to 
immunostain p-amyloid, glial fibrillary acidic protein (GFAP), tau protein (all from 
DAKO) and a-synuclein (kindly provided by Professor B H Anderton, Institute of 
Psychiatry, London).
4.2 Results
4.2.1 PSEN1 intron 4 mutation (Thr 113/114 ins)
PSEN1 intron 4, the only intronic PSEN1 mutation, was first reported in two 
individuals from a series of 40 cases of autopsy-confirmed early-onset AD that were 
all unselected for family history (Tysoe et al. 1998). It was subsequently 
demonstrated in four additional early onset FAD pedigrees including family 105/160 
(De Jonghe et al. 1999b). The detailed clinical and neuropathological features of 21 
affected individuals from family 105/160 are reported here. Figure 4.1 shows the 
family tree of family 105/160.
4.2.1.1 Family overview
Table 4.1 summarises the clinical features of family members. The mean age at onset 
was 37.4 years (95% Cl: 36.7-38.2 years). The mean age at death was 44.7 years (95% 
CI:43.1-46.3 years). Disease duration was 7.3 years (95% Cl: 5.9-8.7 years). 
Individuals 1.1, II. 1 and II.3 are known to have died at home following a dementing 
illness, no medical records survive. Cases III. 1 to IV.08, V.07 and V.09 are all known 
to have died in the same local psychiatric hospital and to have had dementia. Their
98
clinical records were destroyed in a hospital fire. Ages at death were obtained from 
death certificates.
4.2.1.2 Case reports
IV  09. Age at onset 37 years; age at death 45 years. His first symptom was memory 
loss. He was eventually dismissed from his job, for continually wandering, one year 
before death. He had become increasingly childish, and was looked after by his 
family at home. He had frequent jerky movements and occasional generalised 
seizures. He became acutely confused one week prior to death having become violent 
and aggressive at home. He was admitted to the local psychiatric hospital. On 
examination he was disoriented in time and place. His speech was slurred. He was in 
poor physical condition. General examination was normal. His gait was reported to be 
ataxic and jerky movements, which were termed purposeless, were noted. He had 
symmetrical hyper-reflexia. Baseline blood tests and CSF examination were normal. 
The day following his lumbar puncture he developed acute dyspnoea, and died of 
bronchopneumonia. Postmortem examination confirmed bilateral pneumonia. The 
working diagnosis had been Huntington’s disease, but the death certificate merely 
stated pre-senile dementia as the underlying cause of death. From the incomplete 
pathology notes the diagnosis of Alzheimer’s disease had been considered. No formal 
histopathology data survive, other than the documented fresh brain weight of 1293 g.
IV. 10. Age at onset 38 years; age at death 48 years. From the General 
Practitioner’s records his first symptom was increasing forgetfulness, both at work 
and at home, and as a result he was given a less responsible job. He had considerable 
insight into his condition at the outset. He did not have chorea. Two months prior to 
death he was admitted to his local psychiatric hospital. Unfortunately the hospital 
records have been destroyed. His death certificate listed the following: la status 
epilepticus, duration two and a half hours. Ib cerebral degeneration, and II pre-senile 
dementia.
IV. 11. Age at onset, 36 years; age at death 41 years. Only limited clinical 
details survive. This lady presented with symptoms of depression. Two years before 
death an EEG was mildly abnormal, but non-specific, with an 8 Hz dominant rhythm 
and some theta activity. She was pyrexial when admitted to hospital, and died of 
autopsy confirmed bilateral bronchopneumonia. Macroscopically the brain was
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atrophied, most marked anteriorly, and “internal hydrocephalus” was noted. Sections 
for histology were taken from the left hemisphere, cerebellum and medulla oblongata. 
Routine staining with haematoxylin and eosin revealed changes consistent with AD. 
Plaques were most numerous in the frontal fragments. There was complete loss of 
cortical cyto-architecture, and significant neuronal degeneration, with the remaining 
neurones showing chronic degenerative changes, including a few cells with 
granulovacuolar degeneration.
I V 15. Age at onset 38 years; age at death 45 years. This lady presented to her 
local neurological hospital with at least a nine month history of progressive memory 
impairment. She had difficulty remembering names of familiar people and mild word 
finding difficulties were noted. She had considerable insight into her forgetfulness, 
and found it distressing. For one month prior to admission she had been having 
“sudden jerks” of the limbs. Lumbar air encephalogram showed evidence of cortical 
atrophy, with dilatation of the third ventricle and rounding of the lateral ventricles. 
Routine blood and CSF examination were normal. An EEG was abnormal, with 
reduced alpha activity in the posterior-central regions and theta activity in all regions. 
Non focal multiple spike and wave complexes were also seen. As she deteriorated she 
developed frequent generalised seizures and was admitted to a psychiatric hospital for 
full nursing care. She was treated with chlorpromazine, phenobarbitone and 
phenytoin. Two years later she died of pneumonia. Pathological examination (1969): 
revealed a brain weight of 964 gm with generalised cerebral atrophy but, relative 
sparing of the cerebellum and brainstem. Histology showed the characteristic features 
of AD. Recently performed ubiquitin immunostaining demonstrated many 
neurofibrillary tangles and neuritic plaques.
V.08. Age at onset, 40 years; age at death 44 years. This man presented at the 
age of 42 with a two year history of cognitive decline at work. He had worked as a 
trained instrument mechanic, but had had his responsibilities reduced because of 
memory and concentration problems. At the time of assessment he was working as an 
odd job man. On examination he was disorientated in time, and his digit span was 
three. It was noted that he showed a “peculiar type of motor restlessness”, which was 
not clearly choreiform. At times he tried to disguise the movements by converting 
them into gesticulation. His wife had noted that the jerky movements were worse 
when he was dropping off to sleep. An EEG was abnormal and was thought to 
provide evidence of an organic dementia. A clinical diagnosis of Huntington’s disease
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was made because of the jerky movements and a strong family history of a mental 
disorder resulting in death at an early age. He died of pneumonia having been an in­
patient in his local psychiatric hospital for a year.
V.10. Age at onset 39 years; age at death 54 years. This university graduate 
presented when he was made redundant from his teaching job for being unable to 
maintain discipline and forgetting staff meetings. At presentation there was a three 
year history of memory loss; he was fully aware of his family history and had 
preserved insight at the outset. General and neurological examinations were 
unremarkable; baseline dementia screening blood tests were normal or negative. Brain 
CT scan showed minimal cerebral atrophy. His EEG was abnormal with a low 
amplitude record with a symmetrical, regular and responsive alpha rhythm at 9-11 Hz. 
In addition there was a large amount of theta activity, which was maximal anteriorly. 
He deteriorated gradually, and his wife noted a personality change, with him 
becoming distrustful, and occasionally violent. There were times when he would not 
recognise her and thought that she was stealing their car. He became increasingly 
childlike, and began to wander. He neglected personal hygiene and was noted to have 
developed purposeless choreiform movements, particularly affecting the hands and 
arms, 7 and 8 years respectively into the disease. He became an inpatient 3 years later 
requiring full nursing care. Over the next eighteen months he continued to deteriorate, 
he became mute, and had his first generalised seizure, following which he was started 
on carbamazepine. Five years later he died of bronchopneumonia, neuropathological 
examination confirmed the diagnosis of Alzheimer’s disease with amyloid angiopathy 
(see neuropathology section below).
V I 2. Age at onset 40 years; age at death 45 years. The onset of this lady’s 
symptoms coincided with a deterioration in the glycaemic control of her diabetes. A 
sudden deterioration in her memory and a change in her personality occurred after a 
severe hypoglycaemic episode accompanied by a generalised seizure two years prior 
to death. This resulted in a period of unconsciousness lasting for 11 hours. Since that 
time she had a clearly progressive dementing illness, and was noted to have 
myoclonus of the fingers and arms particularly, but also the legs and trunk. She had 
no further generalised seizures. She died in hospital of autopsy confirmed 
bronchopneumonia.
V16. Age at onset 33 years. This right handed woman presented with a two 
year history of impairment in episodic memory and a change in personality; she had
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become more introverted. She experienced word finding difficulty but otherwise 
continued to look after her family without significant problems. She had initially been 
treated for post-natal depression, but had failed to improve on tricyclic anti-depressant 
medication. There was no other past medical history, she did not smoke. Clinical 
examination revealed cognitive impairment which was confirmed on formal testing 
(see neuropsychology section and table 4.2), she scored 21/30 on the Mini Mental 
State Examination (MMSE) (Folstein, Folstein, & McHughs 1975). General physical 
examination was normal. Neurological examination revealed finger myoclonus. A 
pout and glabellar tap reflex were elicited. Baseline blood and CSF examination were 
normal or negative. Brain CT scan showed slight sulcal widening. An EEG revealed 
sporadic, symmetrical 8-9 Hz alpha rhythm over posterior regions and widespread 5-6 
Hz irregular theta activity. Brain MRI, one year later, showed diffuse cortical atrophy 
with bilaterally small hippocampi. Examination now revealed Gegenhalten and mild 
dyspraxia. MMSE was 18/30. Two years later her myoclonus had become more 
marked and her MMSE had declined to 13/30. She made body part substitution errors 
during an assessment of praxis and had difficulty copying gestures with the left hand 
but not the right. She had suffered a single generalised seizure and had been started on 
sodium valproate. Four years after presentation there was evidence of further 
cognitive decline with speech and comprehension difficulties. The following year she 
had become increasingly dependent and required full time nursing care.
V.17. Age at onset 38 years. This right handed woman was referred to the 
Specialist Cognitive Disorders Clinic with a two year history of memory impairment. 
Her family commented that initially her conversation had become repetitive and she 
had increasing difficulties with remembering errands and telephone messages. 
Subsequently her culinary skills and the standard of her housekeeping had declined 
and she had started using lists to help organise her day’s chores. Her MMSE was 
27/30 (see neuropsychology section and Table 4.2 for cognitive profile). There was no 
past medical history of note. She was a non-smoker. Physical and neurological 
examinations were normal. Volumetric MRI brain scan was reported as normal 
(Figure 4.2A). A diagnosis of Alzheimer's disease was made. Repeat MRI brain scan 
13 months later (Figure 4.2B) remained normal. When she was re-assessed at 24 
months her MMSE had declined to 25/30. She had become more dependent in 
household activities. Volumetric MRI brain scan was repeated at 22 months (Figure
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4.2C) and was again regarded as being within normal limits, however comparison 
with earlier scans showed progressive ventricular enlargement.
VI. 08. Age at onset, 36 years; age at death 43 years. This left handed man, 
who had left school at the age of 16 years without formal qualifications, presented at 
the age of 38 years with at least an 18 month history of a progressive loss of mental 
agility. He had lost his job as a driver 30 months earlier, which was probably as a 
result of difficulties at work. There had been deterioration of his episodic memory and 
in particular with remembering the content of messages. More recently he had great 
difficulty with several practical skills. His family denied problems with route finding, 
faces or names. He was said to be independent in his activities of daily living. He had 
lost interest in reading, and spontaneous conversation was noted to be minimal. On 
examination his MMSE was 9/30, he was disorientated in time and place (see 
neuropsychology section and Table 4.2 for details). General physical and neurological 
examination was normal. Baseline blood investigations were normal or negative. MRI 
brain scan showed diffuse cerebral atrophy. EEG was abnormal with marked 
generalised slow (2-3 Hz) and theta (4-6 Hz) activity. There was modest attenuation 
of the slower components with eye opening. Over the next year he deteriorated further 
with evidence of visual disorientation, and finger myoclonus; he also developed 
generalised seizures, which were controlled with carbamazepine. He became 
increasingly aggressive. He was found wandering by the police, and admitted to his 
local psychiatric hospital where he remained an inpatient until his death 18 months 
later. An autopsy was arranged for brain donation (see neuropathology section).
4.2.1.3 Molecular Genetics
The PSEN1 intron 4 mutation (Tysoe et al. 1998) was demonstrated in the four 
affected individuals for whom DNA was available (cases V.10, V.16, V.17 and
VI.08). It was absent from one unaffected member of FI 05/160 who was screened by 
restriction digest and sequencing of all coding exons. In addition two unaffected 
members and three non-consanguineous spouses were screened by restriction digest 
alone. Normal controls (n = 111) were screened by restriction digest, and one of these 
was also screened by sequencing all coding exons. The mutation was therefore.found 
to co-segregate with the disease. Linkage studies gave a LOD score of 3.72 and the 
mutation is thought to be fully penetrant.
103
The same four affected patients were APOE genotyped and these data are 
listed in Table 4.1. In one further deceased individual (case IV. 15) it was possible to 
infer the APOE genotype from the APOE status of first degree relatives as her two 
affected children were respectively homozygous s3/e3 and e4/s4.
4.2.1.4 Neuropsychology
The neuropsychological assessments of four affected patients (IV. 15, V.16, V.17 and
VI.08) are summarised in Table 4.2.
General Intellectual Function
To obtain a measure of current intellectual functioning a shortened version of the 
Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler 1981) was 
administered to all patients, except Case IV. 15, who had been assessed on a shortened 
version of the WAIS. The WAIS IQ scores were converted into WAIS-R scores for 
comparison. The patients’ premorbid optimum levels were estimated with the National 
Adult Reading Test (NART) (Nelson & Willison 1991). The discrepancy between the 
NART and the WAIS-R IQ scores provides a measure of the severity of intellectual 
deterioration.
At the time of their first assessment both IV. 15 and V.16 presented with 
intellectual deterioration, affecting non-verbal IQ to a greater extent than verbal IQ. 
On subsequent assessments both patients showed increasing deterioration, affecting 
non-verbal functions to a greater extent. However, patient IV. 15 presented a severe 
generalised decline on her third assessment. Patient V.17 showed mild intellectual 
decline on both measures, verbal scores being lower than performance scores. Patient
VI.08 presented with global intellectual decline. Inspection of the cohort's age-scaled 
scores reveals that, in the verbal domain, the arithmetic and digit span subtests 
showed the greatest impairment in all cases, except V.17. In summary all patients had 
Verbal IQs that were higher than Performance IQs. In the verbal domain the 
arithmetic and digit span subtests were more affected than the vocabulary and 
similarities subtests.
Memory Skills
At the time of her first assessment patient IV. 15 already had a severe and global 
memory impairment, which prevented formal assessment. Verbal and visual memory
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functions were assessed with the Recognition Memory Test (RMT) (Warrington 
1984) and the easy recognition memory test (Clegg & Warrington 1994) in patients 
V.16 and V.17, and with the shortened version of the Recognition Memory Test 
(CSRMT) (Warrington 1996) in patient VI.08.
At first assessment both patients V.16 and V.17 presented with selective 
verbal memory impairment. Subsequently patient V.16’s memory functions became 
globally and severely impaired. In contrast case V.17 continued to present a selective 
verbal memory impairment. Case VI.08 presented with a severe and global memory 
impairment.
Naming Skills
Naming skills were assessed with the Graded Naming Test (GNT) (McKenna & 
Warrington 1983). Throughout assessments they remained well preserved in patients
V.16 and V.17. Patient VI.08 obtained a poor score on the GNT, however, on the 
easier Oldfield Picture Naming Test (Oldfield & Wingfield 1965) he obtained a 
creditable score (22/30) in the context of his modest premorbid verbal functioning. 
Thus naming skills were well preserved in all patients across the assessments.
Literacy skills
Reading skills were assessed on the NART, spelling skills were assessed with the 
graded difficulty spelling test (GDS) (Baxter & Warrington 1994), and calculation 
skills were assessed with the graded difficulty arithmetic test (GDA) (Jackson & 
Warrington 1986). All patients demonstrated intact reading skills, which remained 
remarkably stable across assessments. In patients V.16 and V.17 spelling skills were 
preserved and did not deteriorate across assessments. Patient VI.08 obtained a poor 
score in the GDS, which in the context of his modest reading skills and relatively 
poor education, cannot be taken to indicate unambiguously a spelling impairment. 
Calculation skills were found to be severely impaired in all patients with the 
exception of V.17. In summary, reading and spelling skills were remarkably well 
preserved in two patients (V.16 and V.17), and did not deteriorate as the disease 
progressed. By contrast, calculation skills were impaired in two patients (VI.08 and
V.16).
Perceptual and spatial skills
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Three subtests of the Visual Object and Space Perception Battery (VOSP) 
(Warrington & Janies 1991), were administered to obtain a measure of perceptual 
(fragmented letters and silhouettes) and spatial skills (cube analysis). 
At first assessment patients V.16 and V.17 presented with preserved perceptual and 
spatial skills. Perceptual skills were found to be gravely impaired in patient VI.08.
Frontal executive functions
Frontal ’executive' functions were assessed using the Weigl test (Weigl 1948), the 
Wisconsin Card Sorting Test (Nelson 1976) and Verbal Fluency tests (Spreen & 
Strauss 1998). Patients V.16 and VI.08 failed these tests. Patient V.17 completed the 
Wisconsin Card Sorting Test competently at her first assessment, but had become 
mildly impaired at her second assessment.
4.2.1.5 Neuropathology
The brain weight of case V.10 was 963g, and the weight of the brainstem and the 
cerebellum 174g. The leptomeninges were thickened and the large cerebral arteries 
showed a few atherosclerotic plaques with up to 50% narrowing of the lumina. In case
VI.08 the brain weighed 105 lg  and the cerebellum with the brainstem 162g. The 
leptomeninges were normal, but there were occasional small atherosclerotic plaques in 
the large cerebral vessels. The remaining neuropathology was identical for both cases 
and shall be described together. The cranial nerves were normal. There was severe 
diffuse tissue loss affecting all lobes, but more pronounced in the ffontotemporal region: 
the gyri here were considerably narrowed and the intervening sulci widened. The lateral 
ventricles were greatly enlarged with rounding of the angle. Both the substantia nigra 
and the locus coeruleus were paler than usual. The histological sections showed many 
neurofibrillary tangles, neuropil threads and neuritic plaques throughout the neocortex 
(see Figure 4.3). In places there was superficial status spongiosus accompanied by 
astrocytosis indicating neuronal loss. The hippocampus showed neuronal loss from the 
CA1 area, many neurofibrillary tangles, senile plaques, granulovacuoles and Hirano 
bodies (see Figure 4.4). The nucleus basalis of Meynert was depopulated and many of 
the surviving neurons contained neurofibrillary tangles (see Figure 4.5). A couple of 
neurofibrillary tangles were also seen in the caudate nucleus, in the lentiform nucleus, in
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the claustrum and in the subthalamic nucleus and several more were noted in the 
thalamus. The substantia nigra and the locus coeruleus showed neuronal loss, 
extraneuronal pigment and neurofibrillary tangles. These were also seen in the raphe 
nuclei and in the periaqueductal grey matter. There was slight focal Purkinje cells loss in 
the cerebellum with accompanying mild to moderate astrocytosis of Bergmann glia. The 
walls of the small and medium-sized cerebral and leptomeningeal blood vessels were 
thickened, and often appeared homogeneously eosinophilic with occasional double 
barrelling, particularly in case V.10. The enlarged perivascular space contained 
mononuclear cells including lymphocytes and pigment-bearing macrophages. 
Immunohistochemistry for p-amyloid showed extensive deposition in the grey matter 
(see Figure 4.6) as well as in the leptomeningeal and parenchymatous blood vessels. In 
the cerebellum the P-amyloid deposition was more severe in the blood vessels than in the 
parenchyma. Tau immunostaining confirmed all the cytoskeletal abnormalities, while 
reaction for a-synuclein was negative in VI.08, but revealed several Lewy bodies in the 
sustantia nigra, the locus coeruleus, the frontal and insular cortices, and in the 
parahippocampal gyrus of case V.10. GFAP highlighted astrocytosis in the cortex, 
subcortical white matter and, to a lesser extent, in the deep grey structures.
In conclusion both cases showed severe Alzheimer's disease fulfilling the 
CERAD as well as the more recent National Institute of Aging and Reagan Institute 
criteria for the diagnosis of definite Alzheimer's disease (Hyman & Trojanowski 1997) 
with extensive deposition of p-amyloid both in the grey matter and in the cerebral blood 
vessels.
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Figure 4.1 Family tree of family 105/160
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deceased members. For reasons of anonymity the current generation is represented by diamonds, and their "at risk" offspring are not shown.
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Figure 4.2 Brain MRI of subject 105/160.V.17
B
Images A, B and C are registered coronal Ti weighted MR brain images taken 
respectively at presentation, 13 and 22 months later. D = sagital Ti weighted MR 
brain image demonstrating the level at which coronal slices A-C have been taken.
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Figure 4.3 Neuropathology of 105/160.VI.08 (parietal cortex)
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Neuritic plaques, neurofibrillary tangles and neuropil threads against a background of 
status spongiosus in the superficial parietal cortex demonstrated using tau immuno- 
histochemistry (original magnification x 251).
F ig u re  4.4 N eu ro p a th o lo g y  o f 105/160.V I.08 (h ippocam pus)
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Neurofibrillary tangles and neuritic plaques in the hippocampus demonstrated with a 
modified Bielschowsky silver impregnation (original magnification x 251).
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F ig u re  4.5 N eu ro p a th o lo g y  o f 105/160.V I.08 (nucleus basalis)
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Neurofibrillary tangles in the nucleus basalis of Meynert demonstrated using tau 
immuno-histochemistry (original magnification x 465).
F ig u re  4.6 N eu ro p a th o lo g y  o f 105/160.V I.08 (c e reb ra l co rtex )
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Extensive deposition of p amyloid in the cerebral cortex demonstrated using pA4 
immunostaining (original magnification x 251).
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Table 4.1 Summary of the clinical features of family 105/160
Subject Age (yr) 
at onset
Age (yr) 
at Death
Illness 
Duration (yr)
Autopsy ApoE
genotype
NINCDS-
ADRDA
First
Symptom
Other
Symptoms
Neurological
Features
Seizures
11.1 46 No .
II.3 - - - No - - - - - -
111.1 37 40 3 No - - - - - -
III.2 37 42 5 No - - - - - -
III.7 39 47 8 No - - - - - -
III.8 38 44 6 No - - - - - -
IV. 04 38 47 9 No - - - - - -
IV.08 37 45 8 No - - - - - -
IV.09 37 45 8 Yes - Probable Memory Wandering Myoclonus Yes
IV. 10 38 48 10 No - Probable Memory - 0 Yes
IV. 11 36 41 5 Yes - Definite Depression - 0 No
IV. 15 38 45 7 Yes 34 Definite Memory - Myoclonus Yes
V.07 - 41 - - - - - - - -
V.08 40 44 4 No - Probable Memory - Myoclonus No
V.09 36 43 7 - - - - - - -
V.10 39 54 15 Yes 33 Definite Memory Personality Myoclonus Yes
V.12 40 45 5 No - Probable Memory Personality Myoclonus Yes
V.16 33 N/A 12 N/A 44 Probable Memory Personality Myoclonus Yes
V.17 36 N/A 5 N/A 33 Probable Repetitive Memory 0 No
VI.08 36 43 7 Yes 33 Definite Slowness Memory Myoclonus Yes
N/A = not applicable, 0 = a b s e n t , = unknown
112
Table 4.2 Neuropsychology data for family 105/160
Assessment
IV. 15 
1st 2nd 3rd
V.16
1st 2nd 3rd 4th
V.17
1st 2nd
VI.0*
1st
Time (months) 0 10 21 0 12 23 48 0 24 0
WAIS-R VIQ 70 66 <54 92 84 82 81 110 103 64
WAIS-R PIQ <56 <56 <56 76 73 65 57 116 86 59
Scaled Scores
Digit Span 1 4 0 10 7 8 4 14 12 2
Vocabulary 10 8 7 9 8 8 8 11 10 7
Arithmetic 5 5 2 8 8 5 4 10 9 4
Similarities 8 5 3 9 7 7 10 12 12 4
Picture Completion 6 3 2 6 8 5 4 15 9 5
Picture Arrangement NT NT NT 6 5 5 2 12 9 3
Block Design 0 0 0 6 4 3 2 9 7 0
Digit Symbol 0 0 0 NT NT NT NT NT NT NT
Object Assembly 2 2 0 NT NT NT NT NT NT NT
RMT words NT NT NT <5th <5th <5th NT <5th <5th <5th
RMT faces NT NT NT 25th 25th 10th <5th** 10th 25th <5th
GNT NT NT NT
75-
90th NT 90th
75-
90th 95th 95th <1st
NART NT NT NT >75th >75th >75th >75th >75th NT
10-
25th
GDST NT NT NT NT >75th >75th 50th >75th >75th <1 St
GDAT NT NT NT NT 5th <1st <1 St >75th 75th <1 St
VOSP
Silhouettes (%) NT NT NT NT 25th
10-
25th
5-
10th >75th >75th NT
Fragmented Letters*** NT NT NT Pass NT NT NT NT NT Fail
Cube Analysis*** NT NT NT Pass Pass Fail NT Pass Pass NT
NT = not tested
WAIS-R = Wechsler Adult Intelligence Scale Revised (Wechsler, 1981) 
VIQ = verbal IQ; PIQ = performance IQ;
RMT= Recognition Memory Test (Warrington 1986)
*/** = Shortened/Shortened and Easy version of the RMT 
GNT = Graded Naming Test (McKenna, 1986)
NART = National Adult Reading Test (Nelson, 1991)
GDST = Graded Difficulty Spelling Test (Baxter, 1994)
GDAT = Graded Difficulty Arithmetic Test (Jackson, 1986);
VOSP = Visual Perceptual and Space Perception Battery
(Warrington, 1991); *** 5% cutoff used to determine pass/fail
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4.2.2 PSEN1 L153V mutation
The PSEN1 LI53V mutation was first reported in a small French pedigree without 
neuropathological confirmation (Raux et al. 2000). This mutation is located in exon 5 
of PSEN1. The clinical and neuropathological features of family 177, that also carries 
the PSEN1 LI53V mutation, are reported here. Figure 4.7 shows the family tree of 
this small pedigree. Patients III.2 and III.3 were assessed clinically.
4.2.2.1 Family overview
The clinical findings are summarised in Table 4.3. Mean age at onset of symptoms 
was 35.3 years (95% Cl: 34.6-36.0 years), mean age at death was 44.0 years (95% 
Cl: 39.1-48.9 years) and mean duration of illness was 8.3 years (95% Cl: 4.7-11.9 
years). Patients III.2 and III.3 were assessed clinically.
4.2.2.2 Case reports and neuropsychology
II. 5 Age at onset 35 years; age at death 42 years; duration 7 years. This right-handed 
factory worker presented at the age of 40 years with a five year history of progressive 
memory problems. Neurological examination was normal. Baseline dementia 
screening blood tests were normal; the Wassermann reaction was negative. A 
ventriculogram showed good filling of the ventricular system without evidence of a 
space occupying lesion. A diagnosis of presenile dementia was established. At the 
age of 41 years he was admitted to a psychiatric hospital, he was moderately 
demented and required nursing care. He evaded answering direct questions. He 
appeared happy and cheerful but was totally disorientated. His memory was impaired 
and he had a digit span of three figures forwards. He was unable to perform simple 
calculations. He died of bronchopneumonia two years later. The death certificate 
recorded bronchopneumonia and presenile dementia as the causes of death. 
Neuropathological examination was not performed although Alzheimer's disease was 
felt to be the likely diagnosis.
I ll  2. Age at onset 35 years; age at death 41 years; duration six years. This 
man worked as a draughtsman. He was referred at the age of 38 years with a three 
year history of personality change, progressive memory impairment and difficulties at 
work. His past medical history was unremarkable. His wife noted a personality 
change in that he had become quieter and less outgoing. He subsequently had
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progressive memory failure and difficulty with his job. At the age of 37 years his 
employer referred him to their occupational health department because of poor work 
performance. He was aware of some of his cognitive difficulties, in particular with 
regards to memory. One year later he was referred to a neurologist who documented 
evidence of cognitive impairment. On formal testing (see Table 4.4) he obtained a 
full-scale IQ of 71 on the Revised Wechsler Adult Intelligence Scale (WAIS-R) 
(Wechsler 1981), which represented a moderate intellectual deterioration from his 
premorbid IQ estimate of 106 on the National Adult Reading Test (NART) (Nelson 
& Willison 1991). Deficits were also recorded in memory, spelling, writing, and 
reading. On neurological examination he was found to be mildly dysarthric, and to 
have asymmetric impairment of co-ordination in his right hand. He had a brisk pout 
and positive grasp reflex. Extensive investigations were normal including biochemical 
and haematological profiles, syphilis serology, serum vitamin B 12, red cell folate and 
thyroid function tests. A CT brain scan showed some minor degenerative changes and 
the EEG showed bilateral slowing of the background activity consistent with a 
diagnosis of Alzheimer's disease. Examination of his CSF was normal, as was an 
EMG. He progressively deteriorated and died without neuropathological examination.
III. 3. Age at onset 36 years; age at death 49 years; duration 13 years. This left- 
handed bookkeeper presented at the age of 37 years with a one year history of 
memory impairment and anxiety symptoms related to her family history of dementia. 
She complained of difficulty with mental arithmetic and impaired episodic memory. 
Her past medical histoiy was unremarkable. There was no history of head injury, 
epilepsy, or psychiatric illness. She did not drink alcohol and was a non-smoker. She 
underwent neuropsychometric assessment at this time (see Table 4.4) and obtained 
average Verbal and Performance IQ measures, which were in keeping with her 
optimal level of functioning as estimated using the NART. The recognition memory 
test (RMT) (Warrington 1984) revealed a mild global weakness in her memory 
functions. Nominal skills, as assessed using a naming by definition task, were 
preserved and in keeping with her expressive vocabulary. She performed flawlessly 
on the Unusual Views test (Warrington & James 1988) and on a subtest (Fragmented 
Letters) of the Visual Object and Space Perception Battery (VOSP) (Warrington & 
James 1991), which were used to obtain a measure of perceptual skills. An 
unenhanced brain CT was reported as being normal. There was felt to be insufficient 
evidence of significant cognitive impairment. Over the next 18 months she was
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downgraded at work, changed jobs and started work as a domestic cleaner and 
reported further deterioration of her memory. She also entered into a new marriage, 
but this was short-lived and her husband left her suddenly. She was having difficulties 
remembering lists, telephone numbers and appointments. A second CT brain scan 
showed cortical atrophy, but she was lost to follow up for three years. She was 
reassessed aged 41 years. By then she was having significant problems with episodic 
memory; in particular she could not remember the events of the previous day and the 
purpose of a visit outside the home. There were no difficulties with language or 
topographical memory. She no longer watched television or read books, as she could 
not retain what had gone before. She continued to be self caring, although she was not 
as fastidious as she had been. Her culinary skills had declined and she could no longer 
follow a recipe. She was very repetitive in conversation and often disorientated. Mini­
mental state examination was 12/30. General examination was normal. Neurological 
examination revealed normal gait. There was no amyotrophy, fasciculation or 
myoclonus. Tone was normal and there were no extrapyramidal signs. Tendon 
reflexes were symmetrical and plantars flexor. There was evidence of dyspraxia, with 
impaired copying of gestures and limb substitution. Cranial nerve examination 
showed a visual acuity of 6/6 bilaterally, with normal fundoscopy. There was a full 
range of ocular movements although pursuit movement was broken. The jaw jerk was 
slightly brisk. The remaining cranial nerves were normal. Neuropsychometry was 
repeated (see Table 4.4) and she obtained a borderline defective Verbal IQ and a 
defective Performance IQ. Her memory functions had gravely deteriorated; 
performance on the RMT for words was at chance and on the RMT for faces below 
the 1st percentile. Nominal skills were relatively well preserved on the Oldfield 
Picture Naming Test (Oldfield & Wingfield 1965). Visuoperceptual functions had 
deteriorated: she scored below the 5th percentile on the Silhouettes subtest of the 
VOSP. Frontal executive functions as assessed on the Weigl Sorting Test were normal 
(Weigl 1948). She performed poorly on a letter cancellation task. Dementia screening 
blood tests and CSF examination were normal. Brain MRI (see Figure 4.8) showed 
marked atrophy, particularly involving the parietal lobes bilaterally. The posterior 
parts of the frontal lobes were also affected, especially the region of the paracentral 
lobules on each side. The cerebellum appeared mildly atrophic. The temporal lobes 
were relatively spared, although careful visual inspection of the medial temporal 
structures suggested that the amygdalae might have been slightly atrophied. Little or
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no white matter disease beyond the immediate periventricular zone was seen. The 
ventricles were mildly enlarged particularly in the posterior parts of the bodies and 
trigones. The following year she entered long term nursing care and was noted to have 
developed myoclonus, which was treated with carbamazepine. She died of 
bronchopneumonia at the age of 49 years and underwent neuropathological 
examination.
4.2.2.3 Molecular Genetics
In this small pedigree DNA was only available for patient III.3. The LI53V mutation 
was demonstrated in patient III.3 and was absent from 100 unrelated normal controls 
from the same ethnic background.
4.2.2.4 Neuropathology
Only case III.3 was examined. The brain weighed 930g, the brainstem and cerebellum 
128g. The leptomeninges were thickened and the large cerebral blood vessels showed 
an occasional atherosclerotic plaque. There was severe generalised atrophy affecting 
all lobes of the brain. This was confirmed on coronal slicing: the lateral ventricles 
were greatly enlarged with rounding of the angle, the gyri were narrowed, and the 
intervening sulci widened.
Histological examination showed features of severe Alzheimer's disease: 
neurofibrillary tangles, neuritic plaques and neuropil threads were abundant in the 
hippocampus and the cerebral cortex (see Figure 4.9). In the hippocampus there was 
severe neuronal loss accompanied by astrocytosis. Superficial status spongiosus and 
astrocytosis were noted focally in the cerebral cortex, indicating severe neuronal loss. 
Neurofibrillary tangles occurred also in the deep grey matter, including the nucleus 
basalis of Meynert, the lentiform nucleus, substantia nigra, locus coeruleus, 
periaqueductal grey matter and the raphe nuclei.
Immunohistochemistry for a-synuclein revealed an occasional Lewy body in 
the transentorhinal, the cingulate, the insular and parietal cortices, as well as in the 
nucleus basalis of Meynert (see Figure 4.10). There was extensive deposition of p- 
amyloid both in the cerebral parenchyma and in the blood vessels (see Figure 4.11).
The neuropathological diagnosis was severe Alzheimer's disease with amyloid 
angiopathy with additional Lewy body pathology noted.
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Figure 4.7 Family tree of family 177
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To preserv e confidentiality this pedigree has been anonymised. 
Figure 4.8 M R I o f patient 177.III.3
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T2 weighted axial MRI showing biparietal atrophy
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Figure 4.9 N europathology of patient 177.III.3 (tem poral cortex)
Senile plaques, neurofibrillary tangles, and neuropil threads demonstrated using tau 
protein immunostaining (original magnification x 70).
Figure 4.10 N eu rop ath o logy  o f  patien t 177.III.3 (am ygdala)
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Lewy bodies using a-synuclein immunostaining (original magnification x 120).
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Figure 4.11 Neuropathology of patient 177.III.3 (cerebral cortex)
Immunostaining of p-amyloid in cerebral parenchyma, lepto meningeal and cerebral 
blood vessels (original magnification x 30).
Table 4.3 Summary of clinical features of family 177
Subject Age (y) 
at onset
Age (y) 
at death
Illness 
Duration (y)
First
Symptom
1.1 NA 65 NA Unaffected
1.2 NA 73 NA Unaffected
II.5 35 42 7 Memory
III.2 35 41 6 Memory
III.3 36 49 12 Memory
Cause of death Psychiatric Neurological
_______________ Features Features
Myocardial Infarction NA
Carcinomatosis NA
Bronchopneumonia
Bronchopneumonia Personality change
Bronchopneumonia ____________________Myoclonus
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Table 4.4 Neuropsychology results of patient 177.III.3.
Test Occasion 1 2
WAIS-R FIQ 98 72
WAIS-R VIQ 99 76
WAIS-R PIQ 97 65
NART 102 -
RMT Words 43/50 27/50
RMT Faces 41/50 33/50
Naming by definition 14/15 -
Oldfield Picture Naming - 22/30
Unusual Views 20/20 -
Fragmented Letters 20/20 -
Silhouettes - 15/30
signifies not tested, remaining abbreviations as in text
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4.2.3 PSEN1 E280G mutation
The E280G PSEN1 mutation was first demonstrated in two DRG families, F I68 and 
FI 83, which are both from Ireland (Clark et al. 1995e). The mutation is one of two at 
codon 280 and one of 23 in exon 8 of PSEN1. It has also been demonstrated in F I02 a 
large Irish family in which there have been nine affected members in three 
generations. The clinical care for this family has been with Professor Michael 
Hutchinson, consultant neurologist, St Vincent’s University Hospital, Dublin. Several 
“at risk” family members come to London annually to take part in the DRG 
longitudinal study. From the limited historical data that are available the typical 
phenotype has been one of dementia and myoclonus with onset early in the fifth 
decade. The clinical and neuropathological features of three affected individuals from 
family 102 with a rather different phenotype are reported here. Figure 4.12 shows the 
family tree of family 102.
4.2.3.1 Family overview
The clinical findings are summarised in Table 4.5. Mean age at onset of symptoms 
was 40.0 years (range 38.0-43.0 years), mean age at death was 50.0 years (range: 
48.0-52.0 years) and mean duration of illness was 11.0 years (range 10.0-12.0 years). 
Patients III.2 and III.3 were assessed clinically in Dublin, whereas patient III.9 was 
assessed clinically in Dublin and for research purposes in London.
4.2.3.2 Case reports and neuropsychology
IIP 9. Age at onset 43 years; current duration 5 years. This 48 year old man presented 
with a five-year history of stiffness and weakness in his legs. The onset of this 
symptom was insidious and the progression gradual. He had had to stop work as a 
municipal gardener because of his progressive gait difficulties. He also complained of 
urinary urgency and frequency. Against a background of marked anxiety, he had also 
noticed some minor memory problems. Although the family history is censored by 
FAD his only identifiable vascular risk factor was a 20 pack-year history of cigarette 
smoking. General examination revealed that he was normotensive. He scored 23/30 
on the MMSE. On the CAMCOG neuropsychological battery he obtained a score of 
71/107 (normal >80), indicating mild dementia (Roth et al. 1986). More detailed 
neuropsychological assessment was hampered by anxiety and limited schooling. He
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had particular difficulty with registration, recall and language expression. Apart from 
a brisk jaw-jerk, cranial nerve examination was normal. Tone and power were normal 
in his upper-limbs. There was evidence of mild finger-nose incoordination and upper 
limb reflexes were brisk. He had a spastic paraparesis with MRC grade 4 weakness 
bilaterally in a pyramidal distribution. He had bilateral ankle clonus and extensor 
plantar responses. He had no sensory impairment. He had a spastic-ataxic gait. 
Investigations included normal full blood count, erythrocyte sedimentation rate, 
electrolytes, liver enzymes and thyroid function tests. Vitamin B12 level was normal. 
Very long chain fatty acid levels were normal. Fasting lipid profile was normal. Chest 
X-ray and ECG were normal. Cranial MRI was abnormal (see Figure 4.13). There 
were minor changes of atrophy but no other abnormality on T1-weighted images. On 
T2-weighted and FLAIR images, there were extensive periventricular areas of high 
signal intensity. Foci of high signal intensity were also noted in the deep white matter 
bilaterally and in the pons and medulla. There were no abnormalities on whole spine 
MRI. Routine analysis of CSF was normal and oligoclonal bands were absent. Visual 
evoked potentials were normal. Antinuclear antibody (ANA) was mildly positive, but 
tests for antibodies to anti-double-stranded DNA and extractable nuclear antigens 
were negative. Antineutrophil cytoplasmic antibody (ANCA) was negative. Doppler 
ultrasound of carotid and vertebral arteries revealed no abnormalities.
III. 3. Age at onset 40 years; age at death 52 years; duration 12 years. This 
patient presented at the age of 43 years with moderate dementia. His initial complaint 
had been one of deteriorating memory. In addition to obvious abnormalities of higher 
mental function, neurological examination revealed prominent myoclonus. Spastic 
paraparesis was not reported. His cranial MRI had evidence of white matter 
abnormalities.
Ill:2. Age at onset 38 years; age at death 48 years; duration ten years. This 
patient presented at age 40 years with cognitive impairment and two years later 
developed gait difficulties. She also complained of diplopia. On examination she had 
evidence of an intemuclear ophthalmoplegia and a spastic-ataxic quadriparesis. A 
brain CT was normal, but unfortunately cranial MRI was not performed. Because of 
her somewhat unusual presentation at a time when the family diagnosis was 
unconfirmed a brain-biopsy was performed. She died within ten years of onset of 
cognitive impairment.
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4.2.3.3 Molecular Genetics
Patient III.9 underwent diagnostic genotyping. The complete open reading frame of 
exon 8 of the PSEN1 was sequenced and the E280G mutation demonstrated. Presence 
of the mutation was confirmed using allele specific oligonucleotide hybridisation.
4.2.3.4 Neuropathology
Patient III.2 had previously undergone brain biopsy. This was re-evaluated by 
Professor Michael Farrell, Department of Neuropathology, Beaumont Hospital, 
Dublin. It revealed numerous, large, non-cored, “cotton-wool” plaques (see Figure 
4.14). Cerebral amyloid angiopathy due to Ap deposition was widespread, affecting 
both cortical and meningeal vessels. Neurofibrillary tangles and neuropil threads were 
ubiquitous, although tau-positive neurites were sparse. Although significant 
deposition of Ap was observed, no neuritic pathology was associated with these 
lesions.
125
Table 4.5 Summary of clinical features of family 102
Subject Age (y) Age (y) Illness First Other Imaging Neuropathology
at onset at death Duration (y) Symptom Symptom Features
III.2 38 48 10 Memory SP, INO CT normal CWP on Biopsy
III.3 40 52 12 Memory Myoclonus, No SP MRI: WM abnormalities -
111.9 43 Alive 5+ SP Memory, Anxiety MRI: WM abnormalities -
SP = Spastic Paraparesis, INO = Intemuclear Ophthalmoplegia, CWP = “Cotton Wool” Plaques, WM = White Matter
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Figure 4.12 Family tree of family 102
mi III.2 III.3 III.8 111.11III.5 III.7 111.10III.6
Solid symbols are affected family members, open symbols are unaffected members, squares are males and circles are females. For reasons of 
anonymity the current generation is represented by diamonds, and their "at risk" offspring are not shown.
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Figure 4.13Cranial MRI o f patient 102.III.9
MRI (FLAIR sequence) shows areas of periventricular high signal intensity. There are 
additional discrete foci of high signal intensity in the deep white matter bilaterally. 
Foci of high signal intensity are also present within the brainstem.
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Figure 4.14 Neuropathology of patient 102.III.2
Section of temporal neocortex immunostained with (3A4 antibody (DAKO) to show 
cotton wool plaques together with immunopositivity of a parenchymal vessel (original 
magnification x 125)
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4.3 Discussion
4.3.1 Clinical features
The available clinical information for all three families suggests features broadly 
typical of AD. In common with many PSEN1 families myoclonus was a particularly 
marked feature in family 102 and family 105/160 (Frommelt et al. 1991; Haltia et al. 
1994; Kennedy et al. 1995b; Lampe et al. 1994). In family 177 only one individual 
had myoclonus. As with other PSEN1 mutation FAD pedigrees (Frommelt et al. 
1991; Haltia et al. 1994) the majority of the cases in family 105/160 experienced 
seizures (Frommelt et al. 1991; Haltia et al. 1994; Kennedy et al. 1995b; Lampe et al. 
1994). Indeed myoclonus and seizures were a feature common to all affected 
individuals in family 105/160 with the myoclonus starting approximately three years 
before the seizures. This phenomenon has previously been reported in two other DRG 
families (148 and 206) with PSEN1 Ml39V mutations (Fox et al. 1997). Although 
seizures are a well recognised feature of FAD (Fox et al. 1997; Frommelt et al. 1991; 
Haltia et al. 1994; Kennedy et al. 1995b; Mayeux, Stem, & Spanton 1985) they were 
absent in family 102 and 177 as in FAD due to PSEN1 L250S (Harvey et al. 1998a). 
Myoclonus and seizures have not been reported in the French LI53V family (Raux et 
al. 2000).
The main phenotypic difference between these three families and the majority 
of PSEN1 kindreds appears to be a very early AAO: 40 years in family 102, 37.4 
years in family 105/160, and 35.3 years in family 177. In a review of 38 published 
pedigrees with 22 different PSEN1 mutations, only seven pedigrees had a mean AAO 
in the fourth decade of life (Cmts, Hendriks, & Van Broeckhoven 1996). There does 
not seem to be a clear correlation between AAO and site of the mutation. Even for the 
TM2 mutation cluster, where the thirteen known mutations are in close juxtaposition, 
there is a 23-year range in AAO. Data for this cluster are available for 25 of the 29 
published pedigrees (see Table 4.6): eleven had a mean AAO in the fourth decade of 
life; fourteen in the fifth decade; and for one family the mean AAO was in the sixth 
decade of life. The nature of individual mutations may account for a degree of this 
variation as illustrated by the two mutations at codon 143: a non-conservative change 
(I143T) has a mean AAO of 35 years, whereas a semi-conservative change (I143F)
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has a mean AAO of 55 years. However, this would not account for the variation seen 
in AAO for the same mutation and even within some families.
For APP families the dose of APOE s4 alleles has been shown to reduce the 
AAO (Alzheimer’s Disease Collaborative Group 1993; Mullan et al. 1993). Because 
this effect has been shown to be absent in multiple PSEN1 families (Lendon et al. 
1997; Van Broeckhoven et al. 1994a) further unidentified genetic factors have been 
proposed for these families (Axelman, Basun, & Lannfelt 1998; Fox et al. 1997). 
However, in family 105/160 APOE may modulate the disease. Patient 105/160.V.16 
{APOE s4/e4) had an age at onset of 33 years which was more than one standard 
deviation below the mean age of onset for those of known APOE genotype (36.4±2.3 
years, mean±SD), and more than two standard deviations below the mean age of onset 
for the pedigree as a whole (37.4±1.7 years, mean±SD).
Spastic paraparesis was present in two family members of family 102, but 
absent from all family members of families 105/160 and 177. Patient 102.III.2 had 
presented with dementia in association with a spastic tetraparesis and an intemuclear 
ophthalmoplegia. The spastic paraparesis phenotype is absent from the two other Irish 
DRG families carrying this same E280G mutation (Clark et a l 1995e). A second 
reported mutation at codon 280, found in a large Colombian family with the PSEN1 
E280A mutation is not associated with spastic paraparesis (Lopera et al 1997). The 
FAD spastic paraparesis phenotype is associated with “cotton-wool” plaques first 
described in a large Finnish pedigree with a genomic deletion of exon 9 (PSEN1 A9), 
though not all PSEN1 A9 families e.g. DRG family 74 (Hutton et a l 1996; Perez-Tur 
et al. 1995k), and subsequently in other PSEN1 families (Crook et al 1998; Kwok et 
al 1997; Smith et al. 2001; Verkkoniemi et a l 2000). This “cotton wool plaque” 
phenotype is associated with exceptionally high brain Ap concentrations (Houlden et 
al 2000; Steiner et a l 2001). In common with previous reports not all members of 
family 102 with FAD had evidence of spastic paraparesis (Crook et a l 1998; Kwok et 
al 1997; Smith et al. 2001; Verkkoniemi et al. 2000), suggesting that there must be 
genetic modifying factors affecting “classic” and “variant” expression within the same 
family. This is explored in a recently reported family with the E280Q mutation (i.e. 
same codon as family 102) which is similarly associated with spastic paraparesis and 
cotton wool plaques in some of the family members (Rogaeva et al. 2003). They
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excluded an additional AD gene mutation and coding sequence variations in the three 
spastic paraparesis genes as being responsible for this genetic modifying factor.
In family 105/160 disease duration varied from 3 years to 15 years (mean 7.3 
years), in family 1 0 2  the range was 1 0  years to 1 2  years (mean 1 1  years), and in 
family 177 the range was 6  years to 12 years (mean 8.3 years). This is consistent with 
previously published DRG PSEN1 families (Fox et al 1997; Kennedy et a l 1995b) 
and with predicted survival in sporadic AD cases (Bracco et al. 1994). Survival 
appears to be increasing in the later generations. Earlier diagnosis and better care 
undoubtedly contribute to this, but it is unclear in what proportion.
4.3.2 Neuropsychology
There is little neuropsychological data available for family 102. Patient 102.III.9 was 
assessed on the CAMCOG and obtained a score of 71/107 (Roth et a l 1986). Patients 
105/160.IV.15 and 177.III.2 only underwent a limited assessment and presented with 
a global intellectual and memory impairment. Patient 177.III.3 was assessed twice. At 
the first assessment a mild global weakness in her memory functions was 
demonstrated by means of the verbal and visual versions of the RMT (Warrington 
1984). At that time it was interpreted as being insufficient evidence for significant 
cognitive impairment. Today it would be interpreted as being consistent with 
(amnestic) Mild Cognitive Impairment (MCI) (Petersen et al. 2001). Unfortunately 
she was then lost to follow up for several years and when reassessed at the age of 41 
years when she obtained a borderline defective Verbal IQ and a defective 
Performance IQ on the WAIS-R (Wechsler 1981). Her memory functions had gravely 
deteriorated; performance on the RMT for Words was at chance and on the RMT for 
Faces below the 1st percentile. Cases 105/160.V.16, 105/160.V.17 and 105/160.VI.08 
all showed intellectual and memory deficits at the first assessment which became 
more pronounced with disease progression. Intellectual and memory failures have 
often been reported as a common feature of both familial and sporadic AD (Fox et al 
1997; Fox et al. 1998; Karlinsky et al. 1991; Lehtovirta et al. 1996; McKhann et al 
1984; Nee et al. 1983; Sadovnick et al. 1988). In the two less affected cases 
(105/160.V.16 and 105/160.V.17) verbal memory impairment preceded visual 
memory impairment. This finding is in accord with the notion that verbal memory is
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more vulnerable than non verbal memory in FAD (Fox et a l 1997; Fox et a l 1998; 
Kennedy et a l 1995b; Newman et a l 1994).
Patients 177.III.3, 105/160.VI.08 and 105/160.V.16 presented with cognitive 
deficits extending beyond intellectual functioning and memory. In all three cases 
perceptual and spatial skills were more affected than naming skills. In patient 
105/160.VI.16 perceptual and spatial skills deteriorated across assessments whilst 
naming skills remained static at a superior level. This pattern has previously been 
reported in a single FAD case, from a chromosome 14 linked pedigree (Newman et al 
1994) and our findings of relatively well preserved naming skills support the notion 
that this could be a common feature in FAD (Duara et al. 1993; Fox et a l 1997; 
Kennedy et a l 1995b; Newman et a l 1994; Warrington et al. 2001). Visuo-spatial 
and naming impairments have been reported in the context of mild SAD (Hodges & 
Patterson 1995; Jacobs et al. 1995; Kaskie & Storandt 1995; Morris et al. 1991).
In cases 105/160.V.16, 105/160.VI.08 and 177.III.3 calculation skills were 
more impaired than reading skills, a finding in accord with previous reports (Fox et a l 
1997; Karlinsky et a l 1991; Kennedy et al. 1993; Kennedy et a l 1995b; Nee et al 
1983). In patient 105/160.V.16 spelling skills remained entirely preserved, whereas a 
spelling impairment was documented by Newman et a l (1994). It may be that these 
subtle differences between FAD pedigrees reflect disease severity or genotypic 
differences.
4.3.3 Neuroimaging
Patient 177.III.3 had a brain MRI at the time of her second assessment at the age of 41 
years when her MMSE was 12/30. The MRI showed biparietal atrophy. In family 
105/160 patient IV. 15 had brain atrophy demonstrated indirectly by means of a 
lumbar air encephalogram. Cases 105/160.V. 10 and 105/160.V.16 had brain CT 
scans, which demonstrated brains smaller than expected for age. These cases were 
already relatively far advanced in the disease process. Case 105/160.V.17 was imaged 
early in the disease process when her MMSE was still 27. Her brain MRI scan was 
reported as normal as were subsequent brain MRI scans 13 and 22 months later. 
Comparison of these scans however revealed evidence of early cerebral atrophy.
Cranial MRI performed on patients with PSEN1 FAD typically reveals 
evidence of medial temporal lobe atrophy without significant white matter 
abnormalities. However, in family 102 two patients had brain MRI scans performed
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that yielded rather different results to those seen in the other two families. Significant 
white matter abnormalities were seen on cranial MRI in patient 102.III.9 (see Figure 
4.13), who had spastic paraparesis. Family member 102.III.3 also had white matter 
abnormalities on cranial MRI, in the absence of spastic paraparesis. Patient 102.III.2 
also had spastic paraparesis, but unfortunately only had brain CT which was reported 
as normal. In the absence of significant risk factors for cerebrovascular disease, we 
propose that the white matter abnormalities seen on cranial MRI in these FAD 
patients most likely reflect an ischaemic leucoencephalopathy due to amyloid 
angiopathy affecting meningocortical vessels. This theory is supported by the 
prominent amyloid angiopathy on the brain biopsy specimen from patient 102.III.2. A 
previous study has shown no significant differences in white matter hyperintensity 
scores on cranial MRI between patients with EOAD and an aged-matched control 
group, when vascular risk factors were excluded (Scheltens et al. 1992a). There is a 
report of linear signal abnormalities within white matter in the parieto-occipital lobes 
of a patient with FAD due to PSEN1 A285V (Aoki et al. 1997). Spastic paraparesis 
was not described and the lesions were attributed to cortical amyloid angiopathy.
4.3.4 Neuropathology
Neuropathological findings in patients 105/160.V. 10, 105/160.VI.08 and 177.III.3 
showed features of severe AD, including extensive formation of neuritic plaques, 
neurofibrillaiy tangles and neuropil threads. The deposition of p-amyloid was 
particularly prominent in the cortical ribbon. Patient 177.III.3 did not have amyloid 
angiopathy, but the two patients from family 105/160 had particularly severe amyloid 
angiopathy. In these two patients the amyloid was noted to spread from the vascular 
walls into the surrounding cerebral parenchyma to correspond to the classical picture of 
dyshoric angiopathy.
Although the general histological features of sporadic and familial cases of AD 
are the same, recent investigations have revealed differences in the severity of P-amyloid 
(AP) deposition, depending on the causative gene mutation. In cases due to APP717 
mutations, the P-amyloid plaques are predominantly composed of APm2(3) with 
relatively little APi^o present. The total amount of Ap 1^2(3) is considerably greater than 
in sporadic AD (Mann et al. 1996b). Similarly, in brains with FAD due to PSEN1 
mutations, ApM2(3) was the main component of plaques. Moreover, the total amount of
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Ap 1 4 2(3) and Api4 o was more than twice the amount deposited in cases of sporadic AD 
of similar duration, although the ratio between the extent of the deposition of the two 
amyloid species was the same compared with sporadic Alzheimer’s disease (Mann et al. 
1996a). In a recent neuropathological study of 30 patients carrying 10 different 
presenilin 1 and 2 mutations, including patient 105/160.V. 10, enhanced deposition of 
total P-amyloid and Ap 142(3), although not of AP1 4 0 , in the superior temporal gyrus was 
noted when compared to sporadic cases (Gomez-Isla et al 1999). Moreover some of the 
PSEN1 mutations (Ml39V, I143F, G209V, R269H and E280A) were also associated 
with faster rates of neurofibrillary tangle formation and an accelerated neuronal loss 
when compared with sporadic cases.
Cases 105/160.V. 10 and 177.III.3 had significant Lewy body pathology in 
addition to the hallmark lesions of AD. In patient 105/160.V. 10 several Lewy bodies 
were present in the pigmented nuclei of the brain stem and in restricted areas of the 
cerebral cortex whereas in patient 177.III.3 there was sufficient Lewy body pathology 
(see Figure 4.10) to consider a secondary diagnosis of dementia with Lewy bodies 
(transitional or limbic type) (McKeith et al. 1996). Although the co-existence of Lewy 
body and Alzheimer lesions is recognized in sporadic AD it is more common in FAD. 
In a series of 74 FAD cases 22% were complicated by Lewy bodies when using a- 
synuclein immunostaining to define them (Lippa et al. 1998). The Lewy body 
pathology in our cases, even 177.III.3, is negligible when compared with the 
Alzheimer changes, and there was no clinical Lewy body symptomatology to support 
the diagnosis. The Newcastle criteria could not be maintained in the light of a- 
synuclein immunostaining and have been revised (McKeith, Perry, & Perry 1999). 
For these reasons we feel a secondary diagnosis of dementia with Lewy bodies cannot 
be justified in either case.
The neuropathology of patient 102.III.2 was quite different to that of the other 
two families. Although only a brain biopsy specimen was obtained this revealed 
numerous, large, non-cored, “cotton-wool” plaques (see Figure 4.14). In this variant 
of FAD, although Ap is deposited, almost no congophilic amyloid cores form in the 
brain parenchyma and therefore, as discussed in section 1 .4 .2 , it has been postulated 
that the major determinant of dementia must lie upstream of these deposits in the 
pathogenic cascade (Crook et al. 1998; Kwok et al. 1997).
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4.3.5 Molecular genetics
PSEN1 comprises 13 exons, of which exons 3-12 code for a 467 amino acid length 
protein (Clark et a l 1995e; Cruts et a l 1995). This serpentine protein is believed to 
comprise six to eight transmembrane (TM) domains, where mutations tend to be 
concentrated. The LI53V mutation in family 177 is part of and extends a previously 
described mutation cluster on TM2 (see Table 4.6). The mutations in the TM2 cluster 
occur every third or fourth amino acid. Consequently it has been suggested that they 
line up on the same side of an a-helix, disrupting the structure and function of PSEN1, 
(Hardy 1997) a hypothesis that has since been extended for TM 1, 3, 4 and 6  (Hardy 
& Crook 2001).
The E280G mutation is located in the other major PSEN1 mutation cluster 
which is in exon 8 , near the PSEN1 cleavage site (Cruts, Hendriks, & Van 
Broeckhoven 1996). Together the TM2 and exon 8  mutation clusters account for over 
50% of PSENl mutations (Cruts & Van Broeckhoven 1998). The majority of PSEN1 
mutations have been missense mutations leading to the hypothesis that mutant 
proteins result in disease by toxic gain-of-function (Scheuner et al 1996).
By contrast the PSENl intron 4  mutation was thought to result in FAD by 
haploinsufficiency of full-length PSENl (Tysoe et a l 1998). However, it has since 
been shown that the intron 4  mutation produces three different transcripts, two 
deletion transcripts (PSENl A 4  and A 4 cry p t ic )  and one insertion transcript (insjAc), by 
aberrant splicing (De Jonghe et al 1999b). De Jonghe and co-workers demonstrated 
that the latter transcript was due to the insertion of a TAC triplet between exons 4  and 
5 of the PSEN1 (insjAc) and resulted in the insertion of a Threonine after amino acid 
113 (T113-1 Mins) (De Jonghe et a l 1999b). In contrast to the insertion transcript, the 
truncated proteins were not detectable in vivo in brain homogenates or lymphoblast 
lysates of mutation carriers. Similarly De Jonghe and coworkers demonstrated that in 
vitro AP42 secretion was increased in human embryonic kidney cells (HEK-293) 
overexpressing the insertion transcript, but not in those overexpressing the deletion 
transcripts. Increased Ap4 2 :Ap4o ratios in brain homogenates were also demonstrated. 
Thus in common with previous missense mutations and in frame splice mutants, the 
pathogenic effect of the intron 4  mutation appears to be mediated by increased Ap42(3) 
formation which is emerging as a general mechanism in presenilin and APP 717 
mutation FAD (Duff et a l 1996; Scheuner et a l 1996).
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Table 4.6 Presenilin 1 transmembrane domain-2 mutation cluster.
Mutation Family Code Mean Age at Ethnicity 
Onset (yrs)
Reference
N135D - 35 Mexican-American (Crook et al. 1997)
Ml 391 AD 1674 - American (Boteva et al. 1996)
M139K ALZ 034 37 French (Dumanchin et al. 1998)
M139T CAE 010 49 French (Campion et al. 1995b)
M139V F148 44 English (Clark et al. 1995e)
F206 38 English (Clark et al. 1995e)
AD1421 - American (Boteva et al. 1996)
- 40 German (Sandbrink et al. 1996)
#3 32 German (Finckh et al. 2000)
- 43 German (Hull et al. 1998)
1143F F156 55 English (Rossor et al. 1996)
I143T AD/A 35 Belgian (Cruts et al. 1995)
M146I - 44 Danish (Jorgensen et al. 1996)
- - American (Cervenakova etal. 1996)
43 Danish (Essen-Moller 1946; 
Gustafson et al. 1998)
M146L FAD4, Tori .1 40, 43 Italian (Sherrington et al. 1995m)
Oklal 43 American (Clark etal. 1995e)
AR1 39 Argentinian (Morelli et al. 1998)
1,2,3 45,36,35 Italian (Sorbi et al. 1995b)
ALZ 204 43 French (Campion et al. 1999)
M146V Finl 36 Finnish (Clark et al. 1995e)
Man92/20 40 English (Clark etal. 1995e)
NY5201 37 American (Clark etal. 1995e)
T1471 ALZ 047 42 French (Campion et al. 1999)
LI 53V - 36 French (Raux et al. 2000)
Y154C F369 41 English (Janssen et al. 2003)
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5. A study of plasma amyloid-p peptide in familial 
Alzheimer’s disease
5.1 Background
Familial AD was thought to be generally associated with an increased synthesis of 
more amyloidogenic AP4 2 . However, a number of important variations of APP 
processing have now been described in conditioned media: increased total Ap 
synthesis (AP40 > AP42) for Swedish APP, increased levels of both Ap4o and AP42 for 
Flemish APP, an increased ratio of AP42 to AP40 for French APP, and reduced AP42 
levels for the three pathogenic mutations at codon 693 (Scheuner et al. 1996 ; Ancolio 
et al. 1999 ; Nilsberth et al. 2001). The ratio of the two Ap isoforms seems as 
important as the absolute amount(s). In the Arctic APP mutation at codon 693 the 
generated amount of Ap42 is reduced, but it results in faster and greater protofibril 
formation than wild type Ap, suggesting that protofibrils may accelerate the buildup 
of insoluble Ap (Nilsberth et al. 2001). As prospects for AD disease modifying drugs 
improve, the value of biomarkers with surrogate and pre-symptomatic diagnostic 
potential becomes increasingly important. The advent of sensitive Ap assays has 
stimulated interest in Ap as an AD biomarker, particularly since it is found in both 
plasma and CSF. The presence of AP in plasma reflects synthesis in platelets as well 
as clearance from CSF. The latter may be reduced in AD, reflecting the lower CSF Ap 
levels in AD patients. This chapter reports a small pilot study which investigates the 
suitability of plasma Ap as a biomarker for FAD.
5.2 Subjects
All subjects were recruited from the longitudinal FAD study and from FAD patients 
attending the Specialist Cognitive Disorders Clinic at the National Hospital. All FAD 
patients and “at risk” family members were considered for inclusion in this study. 
Specific informed consent was obtained from each study entrant as previously 
outlined. Some family members had undergone predictive or diagnostic testing the 
results of which they had elected to make available allowing the patients to be 
categorized as follows: symptomatic FAD, pre-symptomatic FAD (positive predictive
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genetic test), “at risk” (not genotyped) and non carriers (negative predictive genetic 
test).
5.5 Methods
Blood was collected into sodium ethylenediaminetetraacetic acid (EDTA) using 
polypropylene tubes and centrifuged immediately at 4000 rpm for three minutes. As 
soon as the centrifuge automatic locking mechanism allowed, supernatants were 
collected taking care to avoid disturbing the buffy coat. The plasma so obtained was 
then divided into aliquots (polypropylene tubes) of approximately 1 ml and 
immediately frozen in dry ice. The frozen samples were then transferred to a -70°C 
freezer until the time of analysis. These samples were then couriered to Dr Eric 
Southam (Glaxo Smith Kline, UK) on dry ice. The p-amyloid assays were performed 
by Dr Southam using commercially available enzyme linked immunosorbent assays 
(ELISA) without knowledge of diagnostic category. Plasma A(3(M2) was assayed 
using Innotest p-Amyloid (M2) High Sensitivity Test (Innogenetics, Ghent, Belgium) a 
sandwich-type ELISA designed for the measurement of Ap(M2) in plasma and cell 
supernatants (Vanderstichele et al. 2000). Plasma A p^o) was determined using the 
BioSource Signal Select Human Ap(i-40) ELISA kit (BioSource, Nivelles, Belgium).
5.4 Results
Twenty three patients were recruited: 11 “at risk” family members (7 APP and 4 
PSENl), 3 pre-symptomatic FAD patients (1 APP and 2 PSENl), 6  FAD patients (2 
APP and 4 PSENl) and 3 non carriers. There was no difference in the age of the 
patients between the groups. Plasma Ap(4o> levels were almost identical in all groups 
(see Figure 5.1). Plasma Ap(M2) was higher in symptomatic FAD individuals (52.8 ± 
3.2 pg.ml'1) than family members who were non-carriers (29.6 ± 7.4 pg.mf1; p<0.02). 
Plasma Ap(M2) in pre-symptomatic FAD cases (55.2 ± 8.0 pg.mf1) tended to be 
higher than that in non-carriers (p<0 .1 ) but was indistinguishable from symptomatic 
FAD (see Figure 5.2). Average plasma Ap(M2) concentrations in “at risk” family 
members (37.3 ± 2.2 pg.mf1) were midway between those of FAD mutation carriers 
(both symptomatic (p<0.01) and pre-symptomatic) and non-carriers. Unfortunately 
the small sample number dictated that APP and PSENl mutations be grouped together 
(no obvious differences were apparent). The numbers of patients were too small to
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test whether Ap(M2) levels changed with disease duration in patients or age in pre- 
symptomatic subjects (no obvious differences were apparent). Unfortunately APOE 
status was not known for the majority of subjects in this study.
5.5 Discussion
There was no difference in plasma Ap(40) between the four groups of patients and this 
is in keeping with earlier observations. A degree of uncertainty surrounds many 
previous determinations of plasma Ap(42) because most available assays lacked the 
required sensitivity. With the introduction of more sensitive assays greater 
consistency in plasma Ap(42> determinations is expected to emerge. The number of 
individuals included in this study is small and the findings must be interpreted with 
caution. However, the observation that plasma Ap(42) is elevated in those with FAD 
mutations, including those without symptoms, is supported by earlier work (Scheuner 
e ta l  1996).
One of the more intriguing findings to emerge from this study was that the 
average plasma Ap42 concentration in at risk subjects was midway between the values 
obtained for carriers and non-carriers, perhaps suggesting that this group consisted of 
a combination of the two. It is, therefore, tempting to speculate that the individuals 
within this group who have the higher levels of Ap42 in their plasma are carriers of 
familial Alzheimer's disease mutations. As the genetic status of this group becomes 
clear, either by genotyping or by the emergence or otherwise of disease symptoms, it 
will be interesting to determine whether this turns out to be the case.
A previous study of two well characterised extended Belgian families AD/A 
and AD/B, respectively segregating PSENl I143T and G384A, used the same 
sensitive Ap(i_4 2 ) ELISA (De Jonghe et al. 1999a). Interestingly they showed that 
Ap(i_42) levels detected in plasma were proportional to the individual PSENl 
mutation’s effect on Ap(i_4 2) secretion in stable transfected human embryonic kidney 
cells (HEK-293). In family AD/A the I143T mutation resulted in only a modest 
increase in AP(M2) secretion in HEK-293 cells and there was no difference in plasma 
AP(i-42) levels between mutation carriers, patients or escapees. However, in family 
AD/B there was a more than fivefold increase in Ap(M2) secretion in HEK-293 cells 
and a significant difference between mutation carriers, patients and escapees. 
Unfortunately the effect of individual family mutations on APP processing is not
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known for the the patients included in this study, nor are their numbers sufficient to 
perform a similar analysis.
Levels of CSF Ap(42) are reduced in sporadic AD (for reviews see Andreasen 
and Blennow 2002, and Verbeek, de Jong and Kremer, 2003), possibly due to 
sequestration in neuritic plaques, but it remains open to question whether AP(42) levels 
are elevated in their plasma (Fukumoto et al. 2003).
These preliminary results do suggest that plasma Ap(42) concentrations may be 
a biomarker capable of identifying those individuals in whom FAD is present, even in 
the absence of symptoms, though that it may be dependent on the effect of individual 
FAD mutations on APP processing. It may have a role as a biomarker to facilitate the 
testing of novel anti-Alzheimer medicines, particularly in those whose symptoms are 
very mild or absent, providing the effect of their individual mutation on APP 
processing is known.
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6. A volumetric MRI study of the progression of 
Alzheimer’s disease
6.1 Background
The rate of cerebral atrophy in AD is significantly increased compared with age- 
matched control subjects. Furthermore there is considerable variation in the rate of 
brain atrophy between AD patients. One possible explanation for this degree of 
heterogeneity is that the different atrophy rates may reflect differences in the rates of 
clinical deterioration among AD patients, and in this context it is of note that rates of 
cerebral atrophy have previously been found to correlate with rates of change in 
MMSE scores in AD patients (Fox et al. 1999). Another possibility is that the rate of 
brain atrophy in AD might vary over time in line with the nature of the progression of 
the disease process. Accordingly changes in the rate of pathological involvement of 
the cerebral cortex would manifest as changes in the atrophy rate.
Previous longitudinal studies of AD have measured rates of brain atrophy 
across a single time interval (Chan et al. 2001a; DeCarli et al. 1992; Fox, 
Freeborough, & Rossor 1996; Jobst et al. 1994; Shear et al. 1995). Less is known 
about rates of cerebral atrophy occurring over sequential time intervals spanning 
several years. Demonstration of the changes in the rates of brain atrophy over time is 
important for understanding the natural history of AD and for assessment of disease 
modifying treatments.
In order to address the issue of longitudinal progression of brain atrophy in 
AD, the study in this chapter evaluated cerebral atrophy rates and ventricular 
enlargement in AD patients who have had multiple scans over a number of years.
6 .2  Subjects and methods
Between January, 1992, and December, 1998, twelve early onset AD patients were 
recruited (see table 6.1). All patients provided written informed consent. The patients 
consisted of nine FAD patients from the longitudinal FAD study and three sporadic 
AD patients recruited through the Specialist Cognitive Disorders Clinic at the 
National Hospital for Neurology and Neurosurgery. All patients had probable AD 
(NINCDS-ADRDA criteria) by the end of the study (McKhann et al. 1984). In the
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FAD group five patients were known to have PSENl mutations, the remaining four 
having APP mutations. The sporadic AD patients had no family history of AD and 
previously performed APP, PSENl and PSEN2 mutation screening had been negative. 
The APOE genotype was known for all patients. In four FAD patients MRI scans 
were also obtained during the presymptomatic phase of the illness. All patients were 
assessed as previously described. The MMSE was used as a simple measure of 
dementia severity. Each patient underwent repeated MMSE testing, performed at the 
time of MRI scanning. All subjects were scanned on one of three 1.5T GE Signa MRI 
scanners (General Electric, Milwaukee, Wisconsin, USA) and T1-weighted 
volumetric images were obtained using a spoiled gradient echo technique as 
previously described to provide 124 contiguous 1.5mm thick slices in the coronal 
plane. All repeat scans were performed on the same scanner.
Only scans without substantial movement or intensity inhomogeneity 
problems were analysed. Image data were transferred to a Sun workstation (Sun 
Microsystems, Mountain View, California, USA). The scans were registered using a 
nine degrees-of-ffeedom algorithm, incorporating three linear scaling factors, to 
compensate for interscan variations in voxel dimensions (Fox & Freeborough 1997). 
Rates of whole brain atrophy were calculated following registration of each subject’s 
pair of scans. Rates of atrophy were measured using three different techniques:
• First, the total brain volume (TBV) was delineated from CSF using a semi­
automated process based on a signal intensity thresholding algorithm, with 
non-brain structures excluded by manual editing. Volume loss was represented 
by a difference in TBV across two scans. TBV measurements were corrected 
for total intracranial volume (TIV), to control for potential changes in voxel 
size due to scanner drifts over time, and to allow comparisons between 
individuals with different head sizes (Whitwell et a l 2001). All TIVs in this 
project were measured by Jennifer Whitwell.
• Second, cerebral atrophy was determined using the previously described and 
validated BBSI technique, which calculates from each registered (positionally 
matched) scan pair the shift in the position of the brain-CSF boundary, 
integrated over the entire brain surface to provide a measure of volume loss 
(Fox & Freeborough 1997).
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• Third, atrophy was assessed by measuring enlargement of ventricular CSF 
volume corrected for TIV. Ventricles were measured by me as previously 
described (see Appendix 4) and corrected for TIV to control for potential 
changes in voxel size and to correct for head size (Whitwell et al 2 0 0 1 ).
6 .3  Statistical analysis and modelling
At the time of the initial scan the severity of AD in individual patients ranged from 
the presymptomatic stage of disease through to moderate dementia. To assess changes 
in atrophy rates with varying disease severity, atrophy rates were documented relative 
to the time when every patient obtained an MMSE score of 23/30, a score 
representing mild dementia and attained by all patients during clinical/research 
follow-up. Statistical analysis was performed by Chris Frost and Hillary Watts.
To allow for repeated within individual measurements, a hierarchical mixed 
quadratic regression model relating brain volume (as a proportion of TIV) to time 
(relative to when MMSE = 23), was used to determine the variation in atrophy rates 
over time. All modelling was done in MLwiN (MLwiN , Institute of Education, 
University of London). Brain volumes were log-transformed to model percentage 
changes. Linear and intercept terms were allowed to vary between individuals 
(random effects) while the quadratic term was fixed, with the logarithm of the rate of 
change of percentage yearly brain loss given by twice this term. This variation of 
linear and intercept terms allowed for true interindividual variability and for any 
inaccuracy in specifying the time when MMSE equalled 23.
A related model was used for BBSI-derived changes in volume. The outcome 
variable was the logarithm of the ratio of brain volumes at the end and start of follow- 
up, with the ratio at the end of this period calculated from the BBSI and brain volume 
at the start. This BBSI-derived percentage change in brain volumes was related to the 
difference in visit times (random effects) and the difference in visit times squared 
(fixed effects). The model allowed for errors introduced during measurement of 
changes and at the beginning and end of the measurement periods. Equations for both 
models are given in Figure 6.1.
The same hierarchical mixed quadratic regression model used to relate brain 
volume (as a proportion of TIV) to time (relative to when MMSE = 23) was also used 
to determine changes in ventricular CSF volumes over time.
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6.4 Results
At the time of first MRI the mean age of the patients was 47 years (SD 7.8; range 35 -  
59) and mean MMSE was 26 (range 16 - 30). The male: female ratio was 5:7. The 
average period from first to last scan was 43.2 months (range 15.8 -  66.3). The mean 
number of usable scans per patient was 5.2 (SD 2.4; range 3-11). In the nine patients 
with FAD four were known to have APP mutations, and five had PSENl mutations. 
Apolipoprotein E 3/3 and 3/4 genotypes were found in seven and five patients 
respectively.
6.4.1 Cerebral atrophy
Atrophy rates were similar whether estimated from directly measured brain volumes 
(Figure 6.2; Table 6.2) or BBSI. The change in rates (ie, rise per year in annual 
percentage brain volume loss) was estimated to be 0.32% (95% Cl 0.15-0.50) from 
measured brain volumes and 0.31% (95% Cl: 0.19 - 0.43) from BBSI.
6.4.2 Ventricular enlargement
Ventricular CSF volumes increased with time as shown in Table 6.2, with an 
estimated acceleration of 0.009% (95% Cl: 0.0000 -  0.0175; P= 0.05) per annum.
6.4.3 Effect of genotype
In view of the borderline significance for ventricular enlargement only cerebral 
atrophy measures were assessed for the effects of APOE and FAD genotypes (Table 
6.3). Comparing APOE e4/e3 with e3/e3 revealed no differences, with similar results 
for TBV and BBSI. There was no difference in atrophy rates between the FAD and 
SAD patients, again with similar results for TBV and BBSI.
6.5 Discussion
Individual patients exhibited a gradual acceleration in cerebral atrophy rates and 
ventricular enlargement from the presymptomatic stages through to moderately severe 
disease. The relation between the two measures of whole brain change accords with 
previous work showing that BBSI values equate to about 80% of brain volume loss
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(Fox & Freeborough 1997). Previous studies have shown that atrophy is higher in 
patients with greater disease severity, which could be consistent with acceleration 
(Murphy et al. 1993; O'Brien et al. 2001).
Although there was borderline evidence that the rate of ventricular 
enlargement increases i.e. a non-linear trend, this was not as convincing as for whole 
brain derived measurements. This would suggest that cerebral tissue atrophies faster 
than ventricles enlarge. This may be due to the relative absolute volumes, but it seems 
more likely that this is because ventricular enlargement reflects only a small 
proportion of cerebral atrophy. It does, however provide further evidence that whole 
brain derived measures are more sensitive than ventricular measurements.
This is the first study to use multiple timepoints and between-individual and 
within-individual changes in atrophy rates to assess changes in atrophy rates. 
Pronounced between-individual variability in atrophy rates was also demonstrated, 
with a two-fold variation in atrophy rates between patients, as derived from fitted 
values at the time MMSE equalled 23. This finding is in keeping with the clinical 
variability in the rate of functional decline, which has been shown to correlate with 
rates of cerebral atrophy (Fox et al. 1999).
There were no statistically significant differences in rates of cerebral atrophy 
between patients with FAD and SAD, nor according to APOE genotype. This is 
perhaps unsurprising since the number of patients is modest, so moderate sized 
differences in the rates could be missed. The estimated rate of atrophy is somewhat 
higher in FAD compared to SAD, and interestingly somewhat lower in those with 
APOE 3/4 genotype compared to APOE 3/3 genotype. The confidence intervals 
reflect the limits of uncertainty. So although the demonstrated between-individual 
differences in cerebral atrophy may have a genetic basis, the small size of the cohort 
did not permit assessment of the effect of specific genotypes on rates of atrophy.
Enrolling patients with early onset AD facilitated serial assessment and 
scanning over several years. The fact that the nine FAD patients had a definite genetic 
diagnosis of AD adds validity to the study findings. However, caution must be 
exercised in extrapolation of these results to the entire population with AD: first, the 
natural history of late onset sporadic AD might differ from that noted in this study; 
second, these results were based on data obtained during the early stages of AD and 
therefore do not necessarily apply to the severe disease stage. These results could
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indicate true acceleration of atrophy in already affected brain regions, disease spread 
to a greater proportion of the cerebral cortex, or both.
The acceleration in atrophy was apparent only over several years; over one to 
two years, the progression of atrophy was approximately linear. The relative 
constancy of the atrophy rate over shorter time periods is important for the use of 
cerebral atrophy rates as biomarkers of disease progression. The near-linearity of 
atrophy progression can be used to model AD treatment effects over periods of less 
than two years, with attenuation of disease progression in treated patients represented 
by a reduction in brain atrophy rate. Increasing rates of atrophy, as demonstrated in 
this study, means that trials attempting to demonstrate a drug effect on AD 
progression would possess greater statistical power, and would require smaller sample 
sizes, by enrolling moderately affected rather than mildly affected patients.
Finally, the demonstration that neuronal loss is already evident at a 
presymptomatic stage of AD, and that there is a subsequent accelerating cascade of 
tissue atrophy, reinforces the need for early diagnosis and therapeutic intervention in 
AD.
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Table 6.1 Study patient demographics
ID Sex Diagnosis ApoE Gene Age at
onset
(vrs)
No.
scans
T1
(days)
T2
(days)
MMSE1 MMSE2
DB M FAD 3/3 PS1 39 6 -527 1195 23 25
HB F FAD 3/3 PS1 35 3 551 480
H I
26 16
CG F FAD 3/3 PS1 39 5 1821 1002 16 0
AH F FAD 3/4 APP 50 8 1538 1616 23 7
CL F FAD 3/3 PS1 39 11 -962 2016 30 25
VL F SAD 3/3 N/A 55 6 2357 1766 2 H | 15
JM M FAD 3/4 PS1 48 7 2437 1678 25 8
DN M 1 FAD 3/3 APP 56 5 1138 847 27 15
AS F FAD 3/4 APP 48 5 -447 1970 30 17
KS F SAD 3/4 N/A 53 1171 602 27 26
WU M SAD 3/3 N/A 59 4 977 1260 22 16
AW M FAD 3/4 APP 47 4 -97 1343 19
U
Patient details: M = male; F = female. FAD = familial AD; SAD = sporadic AD. T1 = 
time of initial scan relative to estimated date of symptom onset; T2 = time of final 
scan relative to first scan. MMSE1 = MMSE score at time of initial scan; MMSE2 = 
MMSE score at time of final scan.
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Table 6.2 Estimated annual rates of progression
Time from 
MMSE of 
23/30 (years)
Brain atrophy rate (% 
per year) derived from 
TBV* measurements
Brain atrophy rate (% 
per year) derived from 
BBSI measurements
Percentage Rate of 
increase in Ventricles/ 
TIV
- 2 2.17(1.58-2.75) 1.60(1.23 - 1.96) 0.173 (0.132 to 0.214)
-1 2.49(1.97-3.00) 1.90(1.59-2.21) 0.181 (0.143 to 0.220)
0 2.80 (2.32-3.29) 2.21 (1.91-2.50) 0.190 (0.153 to 0.227)
1 3.12(2.60-3.64) 2.51 (2.84-2.18) 0.199 (0.161 to 0.237)
2 3.44 (2.84-4.03) 2.81 (2.41-3.21) 0.208 #
Table 6.3 Effect of genotype on rates of cerebral atrophy
Comparison groups Measurement used to 
determine atrophy
Difference in rate of 
atrophy as percentage of 
brain volume lost per year 
(95% Cl)
FAD v. SAD TBV* 0.10 (-1.24 to 1.41)
FAD v. SAD BBSI 0.33 (-0.49 to 1.14)
APOE 3/4 v APOE 3/3 TBV* -0.32 (-1.37 to 0.72)
APOE 314 \  APOE 3/3 BBSI -0.24 (-0.85 to 0.37)
FAD -  familial AD, SAD -  sporadic AD, TBV* = total brain volume corrected for 
total intracranial volume, BBSI = brain boundary shift integral, # = Cl could not be 
estimated
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Figure 6.1 Equations used for modelling atrophy
Result* were derived from  fitting die following two equations:
Log of brain volume over T IV  for subject i at v is it/,
log {Volume, tT W , } * (0  +at ) + 0  +bt )!/► > ^
where rg*tim e  of Ah scan few participant j  and «„■ -  .V(0,cr?) and ~ Ar [ { q ) * ( ^
BBS! measured difference between brain volumes in tim e point* and k  for participant £ 
tVahmu, BBSIM \
°*\— Paw---- )SS®4*<K,*-V+ *<**rv ) + s  + d*
where 6„* -  xV{0,o#), nsV~ A tO ,# .}, and d#, -  N (0 ,a j}
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Figure 6.2 Progression o f brain atrophy derived from total 
brain volum e corrected for intracranial volum e
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Tim e from  MMSE of 23/30 (y ea rs)
Progression in rates of brain atrophy over time, as determined by serial measurements 
of total brain volume, represented as a proportion of total intracranial volume. Patients 
are individually colour-coded. Time is plotted relative to the time (t=0) when a score 
of 23/30 was obtained on MMSE.
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7. A volumetric MRI study of the site of earliest change in 
familial Alzheimer’s disease
7.1 Background
As previously discussed neuropathological studies suggest that AD pathology begins 
in the medial temporal structures and, in particular, the entorhinal cortex (EC) and 
hippocampus (Braak & Braak 1991), leading to atrophy of these structures that can be 
visualised in vivo using MRI (Chan et al. 2001b). Measures of the volumes and rates 
of atrophy of these structures in individuals at risk of FAD due to the autosomal 
dominant inheritance of mutations in APP or PSEN1 should therefore be a sensitive 
means of detecting the earliest changes in the disease. By obtaining serial imaging 
from the pre-symptomatic stage through to the development of earliest symptoms it 
may be possible to determine the earliest structural changes occurring at the onset of 
FAD.
In this study changes in volumes and atrophy rates were studied using global 
(whole brain and ventricle) and regional measures (temporal lobe, hippocampus and 
EC) in cohorts of subjects at risk for FAD and age-matched controls. By comparing 
these groups over the period that the patients developed symptoms, we aimed to 
determine those regions undergoing change at the earliest stages of AD. By 
extrapolation, we estimated how long prior to symptom onset medial temporal lobe 
atrophy had occurred.
7.2 Subjects and Methods
7.2.1 Subjects
All subjects were seen at the National Hospital for Neurology and Neurosurgery, 
Queen Square, London. The study received local ethics committee approval, and all 
subjects gave informed, written consent. As part of the longitudinal study individuals 
at risk of developing FAD underwent annual MR imaging, standardised MMSE and 
detailed clinical and neuropsychological assessments as previously described. During 
this time period five subjects (three male, two female) exhibited early symptoms of 
the disease and eventually went on to fulfil NINCDS-ADRDA criteria for the 
diagnosis of probable AD. All have since been shown to carry FAD mutations (two in
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APP; three in PSEN1). Two patients had four MRI and clinical assessments, one 
patient had three assessments and two patients had two assessments; all exhibited 
progressive cognitive impairment over the period of investigation, and went on to 
fulfil NINCDS-ADRDA criteria for the diagnosis of probable AD. Twenty age- 
matched controls had two serial volumetric MR scans and MMSE assessments.
7.2.2 MRI acquisition and registration
T1 -weighted volumetric MR brain scans were acquired on a 1.5 Tesla Signa unit 
(General Electric, Milwaukee, USA), as previously described. This sequence yielded 
124 contiguous 1.5mm coronal slices, which were transferred to a Sun workstation 
(Sun Microsystems Inc., Mountain View, CA., USA) for analysis using the MIDAS 
image analysis program as previously described (Freeborough, Fox, & Kitney 1997). 
Axial T2-weighted scans were also acquired. For each subjects, follow-up scans were 
performed on the same scanner, and accurately registered onto baseline images, using 
a nine degrees of freedom rigid body registration protocol.
7.2.2 Volumetric analysis
With the exception of whole brain and ventricular segmentation, baseline and 
registered repeat scans were analysed as a pair for each subject. The first 
segmentation was performed using the MIDAS package. The resulting region was 
then pasted onto the remaining scan and edited using intensity thresholding and 
manual tracing. To prevent potential laterality bias, the scans were flipped across the 
mid sagittal line to produce two scans, each a mirror-image of the other; segmentation 
was always performed on the same side of the presented image. Each substructure 
was outlined by a single investigator who was blind to diagnosis, left-right 
orientation, and to whether the scan was the baseline or repeat image.
Total intracranial volume (TIV) was measured according to a previously 
described protocol and was used to normalize for differences in head size (Jenkins et 
al. 2000). Rates of whole brain atrophy were calculated directly from the TIV 
corrected brain volumes, and using the Brain Boundary Shift Integral (BBSI) as 
described earlier. Mean intra-rater reproducibility (calculated as the mean value of the 
absolute difference between a pair of measurements divided by their mean for each 
segmented region) for the investigators, using the protocols described below, was:
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whole brain segmentation and ventricles < 1 %; for temporal lobes and hippocampi 
<3%; and for EC 5%.
7.2.3 Brain segmentation
Whole brain segmentation (see Appendix 3) was performed using a semi-automated 
iterative morphologic technique with the threshold for the boundary between brain 
and CSF set at 60% of mean brain image intensity. The inferior cut-off for the brain 
volume was taken through the brainstem at the level of the most inferior point of the 
cerebellum. Each brain region was then checked and manually edited where 
necessary.
7.2.4 Ventricular segmentation
Ventricular volumes were measured (see Appendix 4) on the baseline and repeat 
images for each subject using 60% image intensity thresholds calculated from each 
brain region. Ventricular volumes included the lateral ventricles and temporal horn of 
the lateral ventricles but not the third or fourth ventricle.
7.2.5 Temporal lobe segmentation
A threshold of 60% of mean brain intensity was employed to improve consistency of 
cerebrospinal fluid-brain delineation. The posterior boundary of the temporal lobe 
was taken to be the slice where the longest length of the fornix was visible (Chan et 
a l 2001b). One temporal lobe region was outlined on all slices including temporal 
lobe tissue. This region was then pasted on to the second image and edited to 
accommodate any structural changes.
7.2.6 Hippocampal segmentation
A consistent threshold of 70% of mean brain intensity was applied for hippocampal 
segmentation. Measurements were taken from coronal slices from the posterior to 
anterior boundaries using a standard neuroanatomical atlas (Duvemoy & Bourgoin 
1998). The posterior limit of the hippocampus was defined as the coronal slice where 
the longest length of the fornix is seen (Watson et al. 1992). This measurement 
method excludes the posterior part of the hippocampal tail in order to achieve 
satisfactory reproducibility of segmentation. The rostral border was taken to be at the
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junction with the amygdala. The hippocampus was bounded superiorly, medially, and 
laterally by the ambient cistern, and inferiorly by the subjacent white matter.
7.2.7 Entorhinal cortex segmentation
Segmentation of the entorhinal cortex (EC) was undertaken using a modification of 
the protocol of Insausti et al. (Insausti et al. 1998). White matter was not included 
within this measurement. Rostrally the EC extended as far as the rostral extreme of 
the sulcus semiannularis and the caudal end of the EC was taken as the end of the 
gyrus inffalimbicus. Superiorly the EC was bounded by the white matter separating it 
from the amygdala (rostrally) and the hippocampus (caudally). The inferomedial 
boundary of the EC was taken to be the ambient cistern, and laterally the EC was 
measured as far as the medial lip of the collateral sulcus. The portion of the EC that 
extended along the medial bank of the collateral sulcus was not included in the 
measurement because of the variation between individuals in the position of the 
lateral border of the EC.
7.2.8 Statistical methods
Whole brain volume and volumes of brain regions were standardised to the geometric 
mean TIV in controls. This was done by fitting linear regression models to the control 
patients (both visits) relating each volume (whole brain, ventricular, left and right 
temporal lobe, left and right hippocampal, left and right entorhinal) to TIV, with all 
variables on logarithmic scales.
Analyses of all TIV adjusted volumes other than those of the ventricles were 
carried out on a logarithmic scale. Baseline TIV adjusted volumes were compared 
between cases and controls using unpaired t-tests allowing for unequal variances in 
cases and controls. Comparisons were made for whole brain, ventricle, left and right 
temporal lobe, left and right hippocampus and left and right EC volumes, together 
with the geometric mean of all four hippocampal and EC volumes. Ratios of left to 
right EC volumes and left to right hippocampal volumes were calculated for each 
subject and compared between cases and controls, as was the ratio of the geometric 
means of the (TIV adjusted) EC volumes and hippocampal volumes.
Percentage changes in whole brain volume were estimated both as the ratio of 
the BBSI to the baseline brain volume, and directly from the TIV-corrected brain 
volumes. Absolute changes in ventricular volume, percentage changes for the other
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structures, the geometric mean for the combined hippocampal and EC volumes, the 
ratios of the left to the right EC and hippocampal volumes and the ratio of the 
geometric mean of the EC volumes to that of the hippocampal volumes were 
calculated from the directly measured volumes. Atrophy rates were calculated by 
relating changes (on a log-scale for proportions) to follow-up time. Atrophy rates 
were compared between cases and controls using unpaired t-tests allowing for 
unequal variances in cases and controls. The ratios of left to right EC atrophy rate, left 
to right hippocampal atrophy rate and EC to hippocampal atrophy rates were also 
compared using unpaired t-tests allowing for unequal variances in cases and controls.
Mean baseline levels and atrophy rates in cases and controls were used to 
extrapolate to ‘points of divergence’ under the assumption of linear (on a logarithmic 
scale) rates of decline prior to the start of follow-up. Under this assumption the point 
of divergence is equal to the ratio of the difference in mean levels at baseline to the 
difference in atrophy rates. A slightly modified version of Fieller’s theorem 
(Buonaccorsci 1998; Fieller 1940) that allows for the relatively small number of 
subjects was used to calculate a confidence interval for these ratios. The modification 
involved the replacement of the 97.5 percentile of the Normal distribution with that 
from a t-distribution with the same number of degrees of freedom as used in the t-test 
comparing baseline levels for each structure in the confidence interval formulae. All 
statistical analyses were carried out using STATA version 6.0 (Stata Corp., College 
Station, TX, USA).
7.3 Results
During the course of the study, all five of the at-risk subjects developed probable 
Alzheimer’s disease according to conventional NINCDS-ADRDA criteria. Table 7.1 
shows characteristics of these five cases, and those of the 2 0  control subjects.
7.3.1 Brain and brain sub-structure volumes at baseline
Whole brain and substructure volumes (ventricles, temporal lobes, hippocampi and 
EC) were calculated from the baseline scan, and are shown, corrected for differences 
in TIV in Table 7.2. There were no significant differences in ventricular, left temporal 
lobe and right temporal lobe volumes between patients and controls. Both left and 
right hippocampal volumes were lower in cases than controls, although only the 18%
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difference in right hippocampal volumes achieved statistical significance (p=0 .0 0 2 ). 
EC volumes were significantly lower in patients than controls (left, p=0.009; right, 
p=0.04). There was no evidence of EC asymmetry and the difference between 
disease-associated reduction in hippocampal and EC volumes was also not 
statistically significant. Averaging results from the four hippocampal and EC volumes 
resulted in an estimated overall difference of 16.6% (p=0.03) between patients and 
controls.
7.3.2 Atrophy Rates
Figure 7.1 shows the TIV adjusted whole brain, ventricular and left and right temporal 
lobe volumes for each subject at each follow-up visit. Subject specific volumes are 
expressed relative to mean baseline level in cases and controls. Figure 7.2 shows 
equivalent data for left and right hippocampal and left and right EC volumes. In the 
three subjects with more than two scans, there is little indication of non-linearity.
Table 7.3 shows atrophy rates for patients and controls and the differences 
between them for each brain region. In controls, there was a small but statistically 
significant reduction in whole brain volume. Using both BBSI and TIV corrected 
brain volumes whole brain annual atrophy rates were 1 % greater in patients than in 
controls. This difference was statistically significant (p=0.004) for the BBSI derived 
atrophy rates. There was a significant increase in the measure of ventricular volume 
increase for both controls (0.44ml per year, p<0.05) and patients (2.35ml per year, 
p<0.001). The difference between the rates in cases and controls was also significant 
(p<0.05)
For all measured brain regions, atrophy rates were significantly increased in 
the patients compared with controls (p<0.05). For both left and right temporal lobe 
volumes, the difference in rates was around 2 % per year, whilst for both the left and 
right hippocampus it was around 3% per year, with no evidence of asymmetry in 
rates. The largest differences were observed for the EC. The atrophy rate for the right 
EC (8.9% per year) was greater than that for the left (4.9% per year) but this 
difference did not achieve statistical significance (p=0.1). Combining results from the 
left and the right (TIV adjusted) volumes EC atrophy rates were statistically 
significantly greater than hippocampal rates in the AD cases (5.7% per year greater, 
p=0.02). However EC atrophy rates were also statistically significantly greater than 
hippocampal rates in controls (1.7% greater, p<0.001) and comparison of the excess
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rate in cases with that in controls gave a borderline statistically significant result 
(p=0.056). Averaging results for the four hippocampal and EC atrophy rates, resulted 
in an overall difference of 5.05% (p=0.002) between cases and controls.
Figure 7.3 illustrates the construction of the point of divergence for the 
averaged medial temporal lobe measurements. At baseline, measurements in cases 
were on average already 16.6% below that in controls with a rate of decline that was 
5.05% greater than that in controls. Making the assumption that atrophy rates were 
constant prior to the start of follow-up this suggests an average point of divergence 
3.5 years prior to the start of the study, at which time all patients were asymptomatic. 
Confidence intervals around this and the points of divergence for whole brain and the 
individual structures are however wide (Table 7.4).
7.4 Discussion
These results show that measures of temporal lobe sub-structure volumes, and atrophy 
rates derived from longitudinal scanning can distinguish groups of patients with very 
early AD from controls.
At the commencement of the study, both left and right hippocampal and left 
and right EC volumes were already smaller in cases than in controls. Combining 
results from these four medial temporal lobe regions showed that volumes were 
16.6% lower in cases than controls. By contrast whole brain volumes and ventricular 
size were similar between patients and controls. These findings imply that medial 
temporal lobe atrophy must be occurring prior to symptom onset, and as such are in 
concordance with previous DRG studies (Fox et al. 1996; Scahill et al. 2002). 
Pathological studies suggest that the EC should be expected to show more prominent 
volume changes than the hippocampi early in the disease process (Braak, Braak, & 
Bohl 1993). Imaging data support this, with relatively greater losses in the EC than in 
the hippocampus when mild AD (Bobinski et a l  1999) and “questionable AD” 
subjects (Killiany et al. 2000; Killiany et al. 2002) were compared with controls. The 
results reported here were directionally consistent with this hypothesis but the effect 
was not statistically significant. The lack of statistical significance probably reflects a 
lack of power resulting from the small numbers in this study, the relatively large inter­
subject variability and errors inherent in boundary definition, reflected by the wide 
confidence intervals. The higher measurement error for EC (5%) volume measures
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compared with that for the hippocampus (3%) is evidence for the increased difficulty 
in reliably defining the EC. Differences in measurement reliability led Xu et al. (Xu et 
al. 2 0 0 0 ) to conclude that despite theoretical considerations, there was no practical 
benefit of EC over hippocampal measures in distinguishing patients with MCI, early 
AD and controls; a conclusion that may be altered if improved image acquisition and 
analysis make the EC easier to measure.
This study has demonstrated significant increases in whole brain atrophy as 
measured using both the BBSI and a measure of increased ventricular volume in 
normal controls. These findings are likely to reflect the inevitable mild global atrophy 
(secondary to neuronal loss) associated with normal ageing, even in this age-group 
(Pakkenberg & Gundersen 1997); it is likely that these changes would be larger still in 
a more elderly cohort. However, such changes are clearly different in scale to the 
significantly greater atrophy seen in AD as demonstrated in several previous 
longitudinal imaging studies (Fox & Freeborough 1997; Luxenberg et al. 1987). This 
is confirmed in this study of younger subjects with FAD, with excess whole brain 
atrophy occurring in the pre-symptomatic AD group at a rate of around 1% per year. 
The study was not designed to detect differences in atrophy rates between regions in 
controls. Nonetheless it is interesting to observe that the largest atrophy rates are seen 
in the EC, although given the small number of subjects and the wide confidence 
intervals this result needs to be viewed with some caution.
Significantly increased rates of temporal lobe, hippocampal and EC atrophy 
were demonstrated in patients compared to controls, indicating that regional atrophy, 
particularly affecting medial-temporal lobe structures occurs very early in the disease 
process. Such longitudinal comparisons, by using patients as their own controls, are 
less likely to be influenced by inter-individual differences than cross-sectional 
analyses, even if in the latter corrections are made for TIV. Although not significantly 
different, the fact that rates of atrophy for the EC are considerably higher than those 
from the hippocampus or temporal lobe, suggests that EC atrophy rates might be the 
most sensitive method of discriminating early AD from controls.
This study was not designed to assess all candidate regions within the brain. 
Whilst it is recognized that medial temporal lobe structures bear the brunt of the 
disease process in early AD, recent imaging studies have highlighted that neocortical 
areas, and in particular the posterior cingulate cortex may also be involved from the 
earliest stages of the disease (Baron et a l  2001; Callen et al. 2001; Scahill et al.
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2002). Such regions have proved difficult to delineate and quantify reliably, and at 
present medial temporal lobe volumes and atrophy rates continue to be more widely 
assessed as potential diagnostic and disease progression measures in AD.
As discussed in Chapter 6  there is evidence to suggest that rates of atrophy 
accelerate as the disease progresses. This also seems to be true for earliest stages of 
AD (Jack et a l 2000), which is biologically plausible given that there must be a 
transition from the atrophy rates of normal ageing to the increased rates described 
here. If rates of atrophy increase very gradually, then this accelerating degenerative 
process may have begun very many years earlier. If however, one assumes that initial 
rates of atrophy had been constant in the period prior to the start of volume 
measurement a minimum estimate of the onset of pathological atrophy may be 
calculated. Using this model, with the assumption that rates of medial temporal lobe 
atrophy are constant at this early stage the calculated mean time from the start of 
medial temporal lobe atrophy to the start of the study was 3.5 years (see Figure 7.3). 
The 95% confidence interval around this estimate (0.7 -  7.5 years) is wide and this 
result must be interpreted cautiously. Of the patients reported two had baseline 
MMSE scores below 27, probably indicative of the presence of early cognitive 
impairment. However, all subjects were thought to be asymptomatic at the start of 
follow-up, and would not have come to medical attention without a family history 
FAD. The wide confidence intervals reported in this study are therefore likely to in 
part reflect subtle differences in disease stage, even prior to symptom manifestation
Extrapolating these results to all patients with AD requires considerable 
caution, since these calculations are based on a small number of patients with FAD. 
Not only are these patients considerably younger that patients with sporadic AD 
(SAD), but the progression of their disease may also be different. Indeed, in addition 
to differences between FAD and SAD, there are also phenotypic differences between 
FAD patients with different mutations. However, within the older SAD group there is 
considerable heterogeneity and the advantage of the FAD cohort is the certainty of 
diagnosis, the lack of co-morbidity and the feasibility of assessment from a 
presymptomatic stage.
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Table 7.1: Characteristics of subjects
Subject characteristics (mean ± SD)
Age
(years)
Baseline
MMSE
Final
MMSE
Follow-up
(days)
Cases
(n=5, 3 male)
42.9 ± 4.5 28.4 ±2.3 25.6 ±4.3 864 ± 244
Controls 
(«=2 0 , 1 0  male)
45.8 ± 6 . 8 29.4 ± 0.8 29.3 ± 0.8 515 ±293
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Table 7.2: Mean baseline volumes in ‘at risk9 subjects
Brain Region
Geometric mean volumes in cases (N=5) as a % o f  
that in controls (N=20) at baseline, after 
adjustment for differences in total intracranial 
volume (95% confidence intervals)
Whole Brain 98.2 (95.1,101.5)
Left Temporal Lobe 101.3 (93.9, 109.2)
Right Temporal Lobe 98.9 (92.4, 105.9)
Left Hippocampus 92.1 (81.4, 104.1)
Right Hippocampus 81.9 (70.9, 94.6)
Left Entorhinal Cortex 76.7 (55.0, 107.0)
Right Entorhinal 83.7 (71.1,98.6)
Cortex
Mean 83.4 (71.8, 97.0)
Brain Region
Mean volumes (ml) in cases (N=5) and controls 
(N=20) at baseline, after adjustment for  
differences in total intracranial volume (95% 
confidence intervals)
Ventricles
Cases (N=5) Controls (N=20) Difference 
13.2 (9.9, 16.4) 14.3 (10.2, 18.4) -1.1 (-5.9, 3.6)
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Table 7.3: Annual changes in measured brain regions
Brain Region
Percentage change in volume per year
Cases (N=5) Controls (N=20) Additional change in 
Rate (95% Cl) Rate (95% Cl) cases (95% Cl)
Whole brain: 
using baseline +BBSI 
using TIV correction
-1.23 (-1.72, -0.74) -0.28 (-0.41, -0.14) -0.96 (-1.44, -0.48) 
-1.08 (-2.64, 0.49) -0.12 (-0.63, 0.39) -0.96 (-2.48, 0.58)
Left Temporal Lobe -2.08 (-3.37, -0.78) -0.13 (-0.54, 0.27) -1.95 (-3.21,-0.68)
Right Temporal Lobe -1.95 (-3.10, -0.79) 0.05 (-0.27, 0.37) -2.00 (-3.13,-0.86)
Left Hippocampus -2.76 (-4.66, -0.82) 0.45 (-0.26, 1.17) -3.19 (-5.05,-1.30)
Right Hippocampus -3.31 (-5.98, -0.57) -0.21 (-1.51, 1.12) -3.11 (-5.76, -0.38)
Left Entorhinal Cortex -5.97 (-7.63, -4.24) -1.16 (-2.34, 0.03) -4.86 (-6.64, -3.05)
Right Entorhinal 
Cortex
-10.73 (-16.21,-4.89) -1.99 (-3.10, -0.86) -8.92 (-14.44, -3.04)
Mean -5.74 (-7.83, -3.62) -0.73 (-1.24, -0.22) -5.05 (-7.11,-2.95)
Brain Region
Change in mis per year
Cases (N=5) Controls (N=20) Additional change in 
Rate (95% Cl) Rate (95% Cl) cases (95% Cl)
Ventricles 2.35 (0.71, 4.00) 0.44 (0.04, 0.84) 1.91 (0.31, 3.52)
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Table 7.4: Estimated points of divergence (95% Cl) in atrophy rates 
relative to baseline
Brain Region
Estimated points o f  divergence (years) relative to 
start o f  follow-up (95% confidence interval)
Whole Brain -1.83 (-4.05,2.55)
Ventricles 0.59 (-1.78, 5.87)
Left Temporal Lobe 0.64 (-3.70, 5.88)
Right Temporal Lobe -0.54 (-4.05, 3.85)
Left Hippocampus -2.55 (-7.75, 1.60)
Right Hippocampus -6.32 (-409.12,-1.48)
Left Entorhinal Cortex -5.32 (-17.42, 1.19)
Right Entorhinal -1.90 (-5.63, -0.15)
Cortex
Mean -3.50 (-7.54, -0.66)
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Figure 7.1: Brain volumes (brain, ventricles and temporal lobes) over time presented relative to mean baseline levels.
All volumes corrected for total intracranial. Squares represent cases (n=5) and circles controls (n=20).
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Figure 7.2: Brain volumes (hippocampal and entorhinal cortex) over time presented relative to mean baseline levels.
All volumes corrected for total intracranial. Squares represent cases (n=5) and circles controls (n=20).
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168
8 The onset and progression of Alzheimer’s disease 
imaged with voxel compression mapping of serial MRI
8.1 Background
The study presented in the previous chapter assessed medial temporal lobe structures 
which from cross-sectional studies are thought to bear the brunt of the 
histopathological changes in Alzheimer’s disease (AD) (Braak & Braak 1991). 
However, because of these a priori assumptions Chapter 7 could not address where 
the disease process of familial AD (FAD) begins nor how it progresses, which is 
important for developing therapeutic strategies aimed at prevention. To answer this 
question requires longitudinal follow-up of individuals from a presymptomatic stage 
using in vivo measures. To achieve this previous studies have included those at higher 
risk of “converting” to AD either by enrolling those with mild cognitive impairment 
(Petersen et al. 2001) or by recruiting elderly individuals who were APOEe4 
hetero/homozygotes (Reiman et al. 1996; Small et al. 1995). The “at risk” offspring 
of patients with FAD are at 50% risk of the disease at a relatively predictable age at 
onset. These individuals provide a group that may be studied longitudinally with a 
reasonable chance of identifying the earliest manifestations of the disease. 
Comorbidity such as vascular disease is rare in these individuals because of their 
young age at disease onset. Furthermore because of their known genetic risk of AD 
the diagnosis is relatively secure in life without histological confirmation (Fox et al. 
1998). Although there are differences between FAD and sporadic AD, most notably 
an earlier age at onset in FAD, the significant clinical, pathological and 
neuropsychological similarities support the use of FAD as a model of the disease that 
is amenable to presymptomatic study.
8.2 Introduction
Neuronal damage at the cellular level is accompanied by macroscopic structural 
readjustments: deformations, positional shifts as well as volume loss. This complex
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and dynamic process is inadequately captured with a single imaging snapshot of the 
brain. Serial imaging adds a fourth dimension, change over time, to 3D MRI. 
Sensitive methods are necessary to visualise and quantify subtle brain changes that 
may have occurred over the interval between scans. Digital subtraction of the serial 
imaging provides that sensitivity as long as accurate positional matching - registration 
- is first achieved. Rigid-body registration methods are now capable of bringing serial 
imaging into sub-voxel alignment, allowing meaningful subtraction of an individual’s 
later scan from their earlier scan. Registration that treats the brain as a rigid body can 
match the brain as a whole and can be used to quantify whole brain atrophy 
(Freeborough, Woods, & Fox 1996). However, because of structural readjustment, the 
sites of tissue loss cannot be accurately determined. A non-linear registration 
algorithm is needed in order to track local cerebral losses and deformations (Sowell et 
al. 1999). A compressible viscous fluid model provides a plausible model of the 
structural changes associated with cerebral degeneration and has previously been used 
to visualise developmental change (Thompson et al. 2000). Non-linear registration 
methods, incorporating this model, can also be used to match serial MR scans from 
individuals with degenerative dementia (Freeborough & Fox 1998). This matching 
provides voxel-by-voxel maps of volume change, Voxel Compression Maps, that can 
localise regions of atrophy.
8.3 Methods
Subjects
Twenty clinically diagnosed individuals with sporadic and familial AD, fulfilling 
NINCDS-ADRDA criteria (McKhann et al. 1984), were recruited from the Specialist 
Cognitive Disorders Clinic at The National Hospital for Neurology and Neurosurgery; 
median (range) age 53 (38-76) years and median initial mini-mental state examination 
(MMSE) (Folstein, Folstein, & McHughs 1975) 22/30 (8-27). Twenty healthy control 
subjects were recruited from patients' spouses; median age 51 (39-71) years, median 
initial MMSE 30/30 (28-30). Four individuals at risk of FAD from the DRG 
longitudinal study, who were initially asymptomatic but subsequently became 
affected during follow-up, were also studied. These subjects came from FAD families 
with known autosomal dominant mutations (APP V717G, PSEN1 Ml39V and PSENl 
intron 4). However, none of the at-risk individuals nor the researchers involved in the 
clinical or MRI assessments knew any individual's mutation status. All subjects were
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assessed annually with full history, examination and comprehensive 
neuropsychometry as described earlier (Newman et al. 1994). Informed consent was 
obtained from all subjects and the study had the approval of the Local Research Ethics 
Committee.
At baseline the median age of the at-risk subjects was 43.4 (39-51) years and 
they had MMSE scores of 27, 29, 29 and 30/30. The at-risk subjects were 
asymptomatic in that neither they nor their close informants felt there were symptoms 
of memory loss or other cognitive decline. Performances on stringent tests of verbal 
and visual recognition memory (Warrington 1984) were normal apart from one 
individual who scored below the fifth percentile on both, who nonetheless fulfilled 
entry criteria as asymptomatic. Other cognitive functions were normal on the 
previously described extensive battery of neuropsychological tests. The four subjects 
were followed for between five and eight years and all became symptomatic and 
subsequently progressed to fulfill established criteria for AD. Two individuals 
developed symptoms of memory loss by the time of their second scan and the other 
two developed symptoms 1-3 years after their second scan.
Magnetic resonance imaging acquisition
Serial, approximately annual imaging, was acquired on all subjects together with 
additional scans with intervals varying from hours to months. Three-dimensional Tl- 
weighted MRI were performed on a 1.5 Tesla Signa unit (General Electric, 
Milwaukee) using a fast SPGR (spoiled gradient-recalled acquisition in the steady 
state) sequence yielding 124 contiguous 1.5mm coronal slices of 256 x 256 voxels 
(acquisition parameters: TR/TE/NEX/FLIP - 35/5/1/35).
Image postprocessing
Scans were presented for analysis in a random order, and performed by operators 
blind to the subject’s details. As a pre-processing step the brain was segmented from 
non-brain structures in each scan using a semi-automated algorithm followed by 
manual editing (Freeborough, Fox, & Kitney 1997). For each pair, the later scan was 
accurately aligned to the baseline scan using an automatic image registration 
technique which optimised the match for brain to sub-voxel accuracy (Freeborough, 
Woods, & Fox 1996). In the case of multiple scans all repeat scans were registered to 
the baseline image. A voxel scaling correction was applied during registration to
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accommodate variation in the calibration of scanner voxel dimensions (Freeborough, 
Woods, & Fox 1996). Accurate measures of global brain atrophy were computed 
using the Brain Boundary Shift Integral (Fox & Freeborough 1997).
Fluid matching algorithm
Local structural changes were detected by matching the rigidly registered image pairs 
using a highly non-linear registration algorithm (Freeborough & Fox 1998). This 
registration uses a viscous fluid model to compute a voxel-level deformation field 
constrained to be continuous, topology-preserving and one-to-one. The computation is 
iterative and can be completed in a few hours on a contemporary desktop workstation. 
Voxel Compression Maps can be derived from the deformation field by computing 
the determinant of the Jacobian matrix at each point to provide a point-estimate of 
volumetric change. These maps are combined with the structural images as colour 
overlays to allow association of patterns of change with neuroanatomically significant 
regions (See Figure 8.2).
8.4 Results
The rigid body registration and subtraction revealed cerebral volume losses in all 
subjects over time. The median (range) global rates of loss in the subjects with mild to 
moderate AD were significantly greater than those in the healthy controls, 2.20 (0.82- 
4.19) % vs 0.24 (-0.35-0.64) % per year (Wilcoxon rank-sum, p<0.001). The median 
initial rate of atrophy for the four at-risk individuals was 1.0 (0.78-1.88) % per year, 
which was significantly greater than the control rate (Wilcoxon rank-sum, p<0.001). 
In addition the subtraction images confirmed that in AD the brain undergoes 
considerable deformation and positional shifts as atrophy progresses, for example the 
corpus callosum elevates and individual gyri are subject to rotational deformations. 
Fluid registration was able to resolve local structural brain changes and demonstrate 
far superior matching to rigid body registration (see Figure 8.1). Derived voxel 
compression maps were markedly different between the AD cases and normal 
controls (see Figure 8.2). In regions on the MR images where the image appears 
homogenous and featureless such as cerebrospinal fluid within the ventricles, the 
volume changes are appropriately shown to be diffuse. Consistent patterns of loss 
were seen in the AD cases with both widespread grey and white matter regions 
undergoing diffuse volume losses. These losses were marked in medial temporal lobe
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and neocortical association areas and by contrast, the primary motor and sensory 
cortices, brain stem and cerebellum were spared (see Figure 8.3). The small global 
volume losses seen in the healthy controls were shown in the voxel compression maps 
as diffuse loss with minor enlargement of both sulcal and ventricular spaces. As a 
control, fluid registration and voxel compression mapping were also applied to pairs 
of scans of affected individuals acquired on the same day, which confirmed the 
stability of the technique in that little overall change was visible compared with 
intervals of months or years.
The four at-risk subjects had increased rates of cerebral atrophy prior to 
fulfilling the clinical criteria for Probable AD. Furthermore, fluid registration of 
images spanning the onset of symptoms revealed diffuse losses involving the medial 
temporal lobe but also showed increased rates of atrophy in the infero-lateral temporal 
lobe, the parietal lobe and the posterior cingulate (see Figure 8.4). In one at-risk 
individual a series of 1 2  scans spanning a three year symptom-free phase and four 
years of cognitive decline had been acquired. Analysis of the presymptomatic scans 
suggest accelerating atrophy rates starting five years prior to diagnosis (see Figure 
8.5). Even at the very earliest stages, increased atrophy with involvement of the 
medial temporal lobe was present. As the individual became clinically affected, 
atrophy rates increased and changes became widespread, eventually becoming 
comparable to the patterns and rates seen in established sporadic AD.
8.5 Discussion
The distribution of atrophy in both preclinical and established AD as revealed by 
voxel compression mapping accords well with the pattern of cognitive deficits and the 
distribution of observed histological changes at autopsy. Braak and Braak (1991) 
reported neurofibrillary tangles in the hippocampus and entorhinal cortex in elderly 
controls at post-mortem and more extensive medial temporal lobe changes in mildly 
memory impaired subjects. If these cross-sectional data are viewed as a continuum 
this implies the locus of initiation of Alzheimer’s disease is in the medial temporal 
lobe. The voxel compression mapping provides longitudinal data compatible with 
this. Although cytoskeletal changes, i.e. neurofibrillary tangles and neuritic plaques, 
are rare in the primary cortices and cerebellum, diffuse plaques and amyloid 
deposition are not, suggesting that the neuritic component of the histopathological 
changes are essential for neuronal disintegration and atrophy. The reason for the
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topographical vulnerability is not clear.
The presymptomatic individuals represent a unique cohort because serial 
imaging was acquired many years before they would have presented clinically. 
However some caution is needed in generalising results found in FAD to the more 
common sporadic AD. The finding of increased rates of atrophy in the subjects in this 
study is consistent with evidence of significant hippocampal atrophy in very mild 
sporadic and familial AD and in minimal cognitive impairment (de Leon et al. 1993b; 
Jack et al. 1997).(de Leon et al. 1993b) Subtle memory defects may predate the 
diagnosis of AD by several years (Linn et al. 1995) and abnormalities in cerebral 
glucose metabolism or brain activation during memory tasks have been reported to be 
detectable even earlier in cognitively normal individuals with a family history of 
Alzheimer's disease or with a increased genetic risk of AD (Bookheimer et al. 2000; 
Kennedy et al. 1995a; Reiman et al. 1996; Small et al. 1995). We cannot be certain 
when structural changes are first detectable but it appears that atrophy rates increase 
several years before symptoms. This study cannot address the issue of when 
histological changes (plaques, tangles and cell loss) start but it seems reasonable to 
suggest that they are likely to precede the macroscopic, atrophic changes 
demonstrated in this study.
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Figure 8.1 Coronal MRI scans and subtraction images in familial AD
Images of 54 year old woman w ith FAD
a)=Baseline MRI. b)=Repeat MRI after 14 month interval. c)=Subtraction image after 
rigid-body registration o f the repeat scan onto the baseline image. Well matched areas 
appear grey while points of difference between the two scans are lighter or darker 
(e.g. ventricular enlargement is shown by a rim o f high signal).d)=Subtraction image 
following fluid registration showing very good image matching.
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F igure 8.2 C orona l M R Is w ith  voxel-com pression-m apping colour overlay
a)=48 year old male control with voxel compression mapping (VCM) colour overlay 
showing change over a period of 11 months. 2b)=46 year old female with FAD with 
VCM colour overlay showing change over a 14 month period.
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Figure 8.3 M RI with voxel-compression-mapping colour overlay in FAD 
over a 3-year period during which symptoms developed
51 year old familial AD case with a 3 year interval during which time symptoms 
developed. VCM colour overlay in the a) axial b) coronal and c) sagittal views.
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Figure 8.4 Coronal MRI slices showing VCM colour overlay in a 38 year old 
female familial AD case at symptom onset, but prior to clinical diagnosis.
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Figure 8.5 Change in brain volume in FAD
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Legend: Change in brain volume as a percentage of intracranial volume over time in a 
familial AD patient, who was 36 years old at baseline (for normal range see Whitwell 
2001). Fluid registered images relative to base line for time points a (scan 3), b (scan 
4), and c (scan 11) are shown in the lower panel.
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9 Mapping the onset and progression of atrophy in 
familial frontotemporal lobar degeneration
9.1 Background
Atypical forms of AD are well described and presentations that overlap with 
frontotemporal lobar degeneration (FTLD) are recognised (for review see Galton et 
al. 2000). In the presenium clinical diagnosis is further complicated by the similar 
incidence of AD and FTLD (Harvey, Skelton-Robinson, & Rossor 2003; Ratnavalli et 
al 2002). This chapter contains a detailed case report of an initially asymptomatic 
patient who went on to develop familial FTLD. Although it will not be possible to 
generalise the findings reported to other FTLD patients per se, these prospectively 
collected data present a unique opportunity for studying the onset and progression of 
non-AD familial dementia and comparing it with FAD. To perform a similar study in 
sporadic FTLD patients would be difficult in the absence of known risk factors. 
Furthermore, this study permits additional assessment of the biological validity of the 
non-linear serial MRI registration technique (fluid registration).
The clinical and neuropsychological features of a patient with familial FTLD 
are correlated with the anatomical changes (as defined by means of fluid registration) 
and compared with FAD.
9.2 Methods
9.2.1 Clinical
Patient IV.3 was from DRG family 306, a British kindred with seven individuals 
affected with FTLD spanning three generations (see Figure 9.1). She was enrolled 
into the prospective longitudinal “at risk” study aged 51 years. Approval was received 
from the ethics committees of both the National Hospital for Neurology and 
Neurosurgery, and St. Mary’s Hospital, and the patient gave informed, written 
consent. Assessments were conducted at approximately yearly intervals, at the 
Dementia Research Group and Department of Neuropsychology at the National 
Hospital.
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Each assessment on patient IV.3 was standardised as described in chapter 2, 
including clinical interview, neurological examination, volumetric brain MRI, MMSE 
and neuropsychological assessment as described in Chapter 2.
Frozen blood for DNA extraction was only available from two family 
members and therefore formal linkage studies were not possible. Genomic screening 
for tau (MAPT) mutations was performed by Dr Huw Morris, Institute of Neurology, 
as previously described (Morris et al. 1999).
9.2.2 Neuroimaging
Seven T1-weighted volumetric MRI scans were acquired over a period of 6 8  months, 
using two scanners (the first three scans were performed on one scanner; the 
subsequent four scans on another). Both scanners were 1.5T GE Signa Units (General 
Electric, Milwaukee, WI). Scans were acquired using a spoiled gradient-echo 
technique and transferred to a Sun Enterprise 250 workstation as previously 
described. Each MRI scan was reported by an experienced neuroradiologist. Image 
processing was performed using the MIDAS software tool (Freeborough, Fox, & 
Kitney 1997). A semi-automated technique, using intensity thresholding and a series 
of erosions and dilations, was applied to delineate brain tissue. Total intracranial 
volumes (TIV) were measured for each scan (Whitwell et a l 2001). A rigid-body 9 
degrees of freedom registration was performed to align the repeat scan onto the 
baseline image (Freeborough, Woods, & Fox 1996). Brain volumes for each scan 
were calculated directly from the MIDAS software tool, and corrected for TIV. 
Whole brain atrophy rates were calculated between intervals from the registered scans 
using a validated automated technique, the brain boundary shift integral (BBSI) (Fox 
& Freeborough 1997; Freeborough & Fox 1997). The previously described fluid 
registration model uses the rigidly-aligned repeat scan as a starting point to generate a 
voxel-level deformation field (Crum, Scahill, & Fox 2001; Freeborough & Fox 1998). 
The determinant of the Jacobian matrix from the deformation field gives a measure of 
volume change at the voxel level, and voxel compression maps are created by using a 
colour overlay to signify this volume change.
9.2.3 Neuropathology
Neuropathological examination was performed on patient IV. 1 by Professor Lantos of 
the MRC Neurodegenerative Diseases Brain Bank at King’s College Hospital. Further
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immunohistological studies were performed in 2002/3 by Dr Keith Josephs and Dr 
Tamas Revesz at the Institute of Neurology. Blocks of tissue were taken from the 
frontal, temporal (with the hippocampus and the amygdala), parietal and occipital 
lobes, the basal ganglia (to include the caudate nucleus, the lentiform nucleus, the 
claustrum and the nucleus basalis of Meynert), the thalamus with the subthalamic 
nucleus, midbrain, pons, medulla oblongata and from the cerebellar hemisphere and 
vermis. The sections were stained with haematoxylin and eosin, impregnated with 
silver according to the modified Bielschowsky method and luxol fast blue and cresyl 
violet (on selected sections). Antibodies were used to immunostain p-amyloid, glial 
fibrillary acidic protein (GFAP), tau protein and a-synuclein (all from DAKO).
9.3 Results
9.3.1 Family overview
The family tree is shown in Figure 9.1. No information is available about the founders 
of this family. Patients II. 1 and II.7 are thought to have been affected, but no further 
details are available. Patient III.l died aged 57 years of lobar pneumonia, with a 
diagnosis of pre-senile dementia. Patient III.2 died at age 60 years of “cerebral 
sclerosis” in a psychiatric hospital. Patient III.4 died of bronchopneumonia, with an 
underlying diagnosis of pre-senile dementia, in the same hospital at age 58 years. No 
psychiatric in-patient notes survive for either of these two family members.
Patient IV. 1 was assessed at The National Hospital for Neurology when he 
presented aged 56 years with a four year history of personality change, disordered 
social conduct and cognitive decline. Four years after onset, he was wheelchair bound 
and incontinent, laughed in response to questioning or any attempt to engage him in 
conversation, and had no comprehensible speech. Brain CT revealed generalized 
involutional changes particularly prominent over the frontal and temporal areas. He 
died twelve months later and underwent neuropathological examination.
The genomic screen for tau (MAPT) mutations performed on patients IV. 1 
and IV.3 was negative.
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9.3.2 Neuropathology
The brain of patient IV. 1 was severely atrophic with the left frontal and temporal 
lobes most affected. Microscopy revealed no plaques or tangles but showed neuronal 
loss and astrocytosis with status spongiosus in the superficial layers of the temporal 
and especially frontal cortex. Glial fibrillary acidic protein immunocytochemistry 
confirmed the increase in astrocytes in both cortex and underlying white matter. 
Immunohistochemistry for ubiquitin revealed a small number of intracytoplasmic 
inclusions in the hippocampal dentate granule cells. A moderate number of abnormal 
neurites and intracytoplasmic inclusions were noted in the superficial layer of the 
frontal and temporal lobe cortices as well as a moderate number of intranuclear 
inclusions in the limbic cortices. Tau and a-synuclein immunohistochemistry was 
negative. The postmortem diagnosis was of a familial FTLD with ubiquitin positive 
(tau and synuclein negative) inclusions.
9.3.3 Prospective study of patient IV.3
During the period of study patient IV.3 attended for nine clinical visits. 
Neuropsychological assessments were performed at six of these time-points, and MRI 
was performed at seven. Details of these assessments at each time point are presented 
below, with an overview shown in Figure 9.2. The neuropsychological scores are 
summarized in Table 9.1.
At the commencement of the study (visit 1) patient IV.3 was 51 years old, and 
had been working as a librarian for 26 years, having initially trained as a nurse. She 
was left-handed. She did not smoke and only rarely drank alcohol. She reported no 
cognitive or behavioural symptoms, and the clinical assessment was unremarkable, 
with no objective evidence of cognitive impairment. She scored 29 on the MMSE.
At neuropsychological assessment (1), on the shortened version of the WAIS-R, she 
scored at an average level on the Verbal scale (IQ 97), and at the upper end of the low 
average range on the Performance scale (IQ 87). She performed at an average level on 
the Advanced Progressive Matrices, a test of nonverbal abstract reasoning (Raven
1965). Her premorbid optimal level of functioning was estimated using the NART to
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be in the superior range (123) (Nelson & Willison 1991). There was a significant 
discrepancy between the estimated premorbid and current performance on tests of 
general intelligence. This indicates a significant intellectual decline (Nelson & 
O'Connell 1978). There was however no evidence for deficits in memory, 
visuoperceptual or frontal executive function.
Cross-sectional MRI (1) was reported as normal; however the initial calculated 
brain volume was slightly small at 1099ml or 82% of total intracranial volume 
(normal range: 83-89%).
Visit 2 (14 months)
At the second assessment, she reported no cognitive or behavioural changes. The 
clinical assessment was unremarkable; she scored 28 on the MMSE. There was no 
evidence for decline on neuropsychological testing (2 ); she scored at a slightly higher 
level on both the verbal and performance sections of the WAIS-R. Her performance 
on the Advanced Progressive Matrices remained in the average range (Raven 1965). 
All other test scores were essentially unchanged.
The MRI (2) was reported as normal.
Applying fluid-registration to MRIs (1) and (2) revealed very focal left sided 
frontal atrophy almost completely confined to the pars opercularis occurring over the 
first 14 month period. (Figure 9.3).
Visit 3 (26 months)
At the third assessment the patient remained well and she reported no cognitve or 
behavioural changes. Clinical assessment was normal and she scored 29 on the 
MMSE.
The third neuropsychological assessment revealed that her verbal and 
performance IQs remained static at an average level. Despite intact naming skills she 
performed remarkably poorly on a verbal phonemic fluency task. However, her 
performance remained unimpaired on three further frontal tasks (Wisconsin card 
sorting test, Cognitive Estimates test, Trail Making test). Performance on other focal 
cognitive tasks including memory remained unchanged.
The MRI (3) was reported as normal. Using rigid body registration and the 
brain boundary shift integral (BBSI) we demonstrated that over the time period
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spanning the first three assessments there was 22.9ml brain volume loss (assuming 
constant brain loss this equates to 0.96% of brain volume/year).
Fluid-registration was applied to MRIs (2) and (3). Over this 12 month period 
diffuse left sided frontal lobe atrophy had developed, though the pars opercularis was 
still losing volume at the greatest rate. There was now clear, but lesser involvement of 
the pars triangularis, the pars orbitalis and the middle frontal gyrus. The anterior 
caudate was slightly involved, but the primary motor cortex, paracentral lobule, 
temporal lobe structures (including the hippocampi) and cerebellum remained 
unaffected (see Figure 9.4 and 9.5).
Visit 4 (45 months)
At the fourth assessment 19 months later, for the first time the patient reported 
symptoms. She was having difficulties expressing herself, and felt that her childhood 
stammer had re-emerged, although this was not apparent during the interview. She 
reported some difficulties with mental arithmetic. She denied any difficulties learning 
or speaking her lines when acting, or any difficulties at work. The abnormalities in the 
clinical assessment were confined to higher mental function; throughout the interview 
she appeared more jocular than previously, and laughed inappropriately on occasion. 
She scored 29 on the MMSE, although she was no longer able to serially subtract 7s, 
and achieved this score by spelling “WORLD” backwards.
Neuropsychological testing (4) revealed that her scores remained within the 
average range in the verbal and performance part of the WAIS-R, and in the Ravens 
Advanced Matrices. Her spelling had declined slightly from the high average/superior 
to the average level, and arithmetic was now in the low-average range. Nonetheless, 
memory, naming, speed and attention, visual perceptual and visuospatial skills were 
unchanged. She obtained an impaired score on a test of frontal lobe function (the 
Hayling sentence completion test). Despite good scores on tests of speed and attention 
her performance on the Trail Making Test was slow.
For the first time her volumetric MRI (4) was abnormal. It was reported as 
showing enlarged lateral ventricles and widening of the Sylvian fissure on the left.
Visit 5 (51 months)
By the time of the fifth assessment, six months later, the patient reported significant 
deterioration. She now had clear difficulties with expressive language, had stopped
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using the telephone, and could no longer work. She reported that she had become 
“much quieter” at social occasions. She was remarkably unconcerned by her 
symptoms, and by the fact that she had been referred from her work for an 
occupational health assessment. The clinical examination was now clearly abnormal. 
She had speech production difficulties and made several phonemic errors in both 
spontaneous speech, and when reading a prose passage. She laughed inappropriately 
on several occasions, and manifested bilateral limb dyspraxia, most marked when 
miming meaningless gestures with the right hand. She had orofacial dyspraxia; she 
could neither whistle nor cough; when asked to yawn she repeated the word “yawn”. 
She was unable to perform bimanual movements, an alternating coin test, nor a 
conflicting tapping test. She scored 26 on the MMSE.
Neuropsychological testing (5) revealed a decline in her verbal and 
performance IQ. Her memory and naming continued to be unaffected, although her 
single word comprehension had declined slightly to the average level. Her spelling 
had declined further to the low end of the average range. Calculation was now 
defective. There was impairment on the Cube Analysis subtest of visuospatial 
function, although visual perceptual skills were normal. There was evidence of 
further frontal executive impairment, with decline on the Wisconsin card sorting and 
Trail Making tests. Her performance on tests of speed and attention remained normal.
Standard MRI (5) demonstrated further cerebral atrophy, with increasingly 
prominent lateral ventricles and widening of the left peri-sylvian fissure.
Visit 6 (56 months)
At the sixth assessment she was seen at the Specialist Cognitive Disorders Clinic. 
She had previously been keen to attend alone not wanting to burden her husband with 
taking part in a research project. Her husband was therefore for the first time able to 
provide a corroborative history. He had been aware of his wife’s problems expressing 
herself verbally for about a year. Her childhood stammer had reappeared and her 
arithmetic had declined. She had become less tidy and on occasions had left the 
kitchen tap running. On no occasion had she got lost. Her husband also reported that 
she laughed inappropriately. There was no change in religiosity nor libido. Her food 
preferences had changed, e.g. she no longer liked potatoes. Speech production 
difficulties were evident. Her spontaneous speech was characterised by phonemic
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errors and echolalia. There was evidence of orofacial apraxia, and she failed bedside 
tests sensitive to frontal lobe dysfunction. She scored 26/30 on the MMSE.
Neuropsychological assessment (6 ) revealed further decline in verbal and 
performance IQ to a borderline defective level. For the first time there was evidence 
of language and verbal memory impairment. Verbal recognition memory scores had 
declined to a defective level and her verbal recall memory to a low average level. In 
contrast visual memory remained at a good average level. She failed to score on tests 
of calculation and spelling. She was almost unable to score on a test of visuospatial 
skills. Her visuoperceptual skills had declined to a low average level. She failed all 
frontal executive tests, with the exception of the Weigl colour form sorting test. Her 
performance on two tests of speed and attention remained within normal limits. 
Subsequently she was no longer able to tolerate formal neuropsychological testing.
The MRI scan (6 ) was clearly abnormal with prominent ventricles, and asymmetric 
left temporal lobe atrophy. Rigid body registration and calculation using the BBSI, 
revealed that over the eleven month interval between scans four and six, 43.8ml of 
brain volume was lost (i.e. 4.5% of brain volume/year, assuming linear decline).
Fluid-registration of MRIs (4) and (6 ) revealed increasing atrophy particularly 
involving the left orbito-ffontal region and right anterior frontal lobe, including the 
operculum over the 11 month period. There was more widespread atrophy diffusely 
involving the left temporal lobe, with the inferior temporal lobe gyrus, and to a lesser 
extent the middle temporal gyrus being affected. There was also involvement of the 
left parietal lobe and both frontal lobes, with relative sparing of the orbito-ffontal gyri. 
The primary sensory and motor cortices, superior temporal gyri, hippocampi, 
amygdalae and cerebellum remained unaffected (see Figure 9.6, 9.7 and 9.8).
Visit 7 (57 months)
One month later the patient was admitted for investigation at the National Hospital for 
Neurology and Neurosurgery the following month, by which time she had gained 
weight and had developed a clear, new preference for sweet foods. Clinical 
examination revealed her to be perseverative, and to exhibit utilization behaviour and 
bilateral grasp reflexes; there were no fasciculations, and the remainder of the 
examination was unchanged from her previous assessment. The MMSE was now 
21/30. Screening blood tests for reversible causes of dementia were normal or
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negative, including electrolytes, glucose, renal function, liver function, thyroid 
function, full blood count, erythrocyte sedimentation rate, clotting studies, vitamin 
B12, folate, an autoantibody screen, and treponemal serology. The CSF was acellular, 
the protein and glucose were normal, and there were no oligoclonal bands in CSF or 
serum. The EEG was normal with preservation of a rhythm. Neuropsychological 
testing was not repeated. She was diagnosed with familial FTLD.
Visit 8 (66 months)
By this stage the patient was practically mute, and could no longer cope with the 
demands of formal neuropsychological assessment. She occasionally said “yes” when 
asked a question, but not always appropriately. She was no longer able to shop by 
herself, but did wander without getting lost.
Visit 9 (69 months)
At this final assessment, the only vocalization was a giggle. She had deteriorated 
significantly and was now occasionally incontinent of urine. She no longer recognized 
her friends. Her sense of humour had become puerile, but she continued to enjoy 
simple comedy shows on television. She now had severe oro-facial apraxia which 
interfered with mastication.
The cross-sectional MRI (7) revealed further asymmetric left temporal 
atrophy. However, despite very disabling symptoms, there was sparing of the 
hippocampi, mesial temporal lobe, anterior superior temporal gyri, occipital poles and 
cerebellum, and even at this stage frontal lobe atrophy was not prominent. Using rigid 
body registration and the BBSI to compare scans six and seven (an interval of thirteen 
months) 76.3ml of brain volume was lost (8 % of brain volume/year).
9.4 Discussion
This study reports the clinical, neuropsychological and imaging findings of a patient 
with familial FTLD over the time period she progressed from being asymptomatic to 
being profoundly affected. Fluid registration demonstrates early left-sided focal brain 
atrophy with subsequent progressive clinical and neuropsychological decline. It seems 
reasonable to assume that this focal atrophy is responsible for the observed deficits, 
and that these changes represent early manifestations of the disease process, years
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before the disease would have presented clinically had she not been followed on the 
basis of her family history. In addition, the focal left sided atrophy with associated 
speech production deficits is compelling evidence that our patient, despite being left- 
handed, was left hemisphere dominant.
Arnold Pick first described focal brain atrophy in 1892 (Pick 1892). Since that 
time multiple pathological studies have shown that degenerative dementias may be 
associated with relatively focal, lobar atrophy. Neuroimaging studies have allowed 
these changes to be delineated in vivo, and correlated with concomitant cognitive 
deficits. Magnetic resonance imaging has been used to demonstrate strikingly 
different patterns of regional atrophy within the subgroups of FTLD (Chan et al. 
2001b; Perry & Hodges 2000). However, such cross-sectional studies cannot 
demonstrate the progression of atrophy, one of the hallmarks of a neurodegenerative 
disease. Analysis of serial scans from the same patient can provide an accurate 
measure of change within an individual over time. Such methodologies have been 
used to demonstrate significantly increased rates of global atrophy in individuals with 
AD and FTLD (Chan et a l 2001a; Fox, Freeborough, & Rossor 1996) when 
compared with control subjects. In this study excess global atrophy was occurring 
from the start of the study, and accelerated during the course of the disease in line 
with both the clinical and neuropsychological progression.
The development of fluid registration allows visualization of the progression 
of regional brain atrophy in vivo. This technique has been validated in both AD and 
control subjects (Freeborough & Fox 1998).
At this patient’s first visit, despite the reported lack of symptoms or abnormal 
clinical findings, it is notable that neuropsychological testing revealed significant 
intellectual impairment in the setting of well-preserved cognitive skills. This finding 
indicates that intellectual impairment was present even at this very early stage. Recent 
studies have shown that the performance on tests of general intelligence, in particular 
tests of fluid intelligence such as the Advanced Matrices, is related to brain function 
in the lateral prefrontal cortex (Gray, Chabris, & Braver 2003). Thus patient IV.3’s 
impaired performance on tests of general intelligence may suggest early frontal 
dysfunction. However, Geschwind et al. have shown that frontal executive 
impairment may be present in patients destined to get FTLD decades before the onset 
of symptoms (Geschwind et al. 2001), and in patient IV.3 there was evidence of 
further neuropsychological decline only at the third assessment. It is therefore is
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unclear whether the documented intellectual impairment represented the onset of the 
disease process, or was longstanding.
Fluid-registration of the first and second MRI scans revealed highly selective 
left sided frontal atrophy almost completely confined to the pars opercularis. This 
change was accompanied neither by clinical nor neuropsychological evidence of 
decline. By the third scan this atrophy pattern had progressed and extended to involve 
the pars triangularis, the pars orbitalis, and, to a lesser extent, the middle frontal 
gyrus. This increased, but still focal, atrophy was not accompanied by clinical 
evidence of decline. However, neuropsychological testing revealed consistent 
evidence of a new selective verbal (phonemic) fluency deficit. Since Broca’s first 
descriptions of focal dominant frontal lesions causing expressive language 
dysfunction, numerous neuropsychological studies have demonstrated that the left 
frontal lobe is implicated in the organisation and generation of verbal output (Milner 
1982; Robinson, Blair, & Cipolotti 1998; Troyer, Moscovitch, & Winocur 1997). A 
recent review of the literature has proposed that lesions of the dominant pars 
opercularis may impair the ability to sequence words syntactically, and that lesions of 
the pars triangularis may impair the ability to generate words (Taubner, Raymer, & 
Heilman 1999). Positron emission tomography studies have also shown activation of 
left dorsolateral prefrontal cortex, Broca’s area and anterior cingulate during word 
generation tasks (for a review see Nathaniel-James & Frith 2002). In conclusion it is 
likely that the demonstrated atrophy pattern is responsible for the observed 
impairment in verbal fluency, but that there was evidence of very focal atrophy in this 
region that preceded any clinical or neuropsychological evidence of progressive 
impairment.
The reported findings findings are broadly in keeping with previous functional 
neuroimaging studies of speech production in normal volunteers (Blank et al. 2002) 
and after stroke (Blank et al. 2003). However, relatively focal cerebral 
hypometabolism was demonstrated in the left anterior insula in a group study 
comparing PA and AD patients (Nestor et al. 2003). Since the PA patients already 
fulfilled diagnostic criteria, by definition the demonstrated focal metabolism was later 
in the disease process than the presymptomatic focal left opercular atrophy in our 
patient. Furthermore this difference may be contributed to by the heterogeneity of 
age, disease duration and possibly the underlying neuropathophysiology of the PA
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patient group. So although these studies are clearly complementary they are not 
directly comparable.
The subsequent course of this patient’s disease was characterized clinically by 
a progressive decline in speech production, and the emergence of increasing frontal 
executive and dominant parietal dysfunction. These findings were confirmed on 
neuropsychological testing. At visit 4, impairment on the Hayling sentence 
completion test and probable decline on the Trail Making test were documented, with 
subsequent failure on the Wisconsin card-sorting and Trail Making tests at assessment 
5 illustrating clear progression of frontal dysexecutive impairment. Increasing 
deterioration of calculation and spelling was confirmed over visits 4-5, consistent with 
increasing dysfunction of the left parietal lobe. By the final neuropsychological 
assessment (6 ), there was further significant deterioration of intellectual function, with 
by now marked global impairment of executive function and severe dyscalculia and 
dysgraphia. Speech production difficulties were by now prominent. At this stage, 
performance on a demanding series of memory tests remained broadly within normal 
limits. Similarly, her naming, verbal comprehension and speed and attention were 
satisfactory.
Fluid registration over the time period of scans (4)-(6) revealed increasing 
atrophy centred around the left frontal and left parietal lobes, findings consistent with 
those from clinical assessment and neuropsychological testing. No significant 
atrophy was seen in the hippocampi and medial temporal lobes, areas implicated as 
neuronal substrata of verbal and visual memory function (Cipolotti et al. 2001; Milner
1966), compatible with the patient’s well-preserved memory. The re-emergence of 
primitive reflexes, generally implicated in frontal lobe disease, in the absence of long- 
tract or cerebellar signs is also compatible with the observed atrophy pattern. The 
increasing rates of global brain atrophy over the period of follow-up are in keeping 
both with the increasing regional atrophy demonstrated using fluid registration, and 
the progression of the disease as assessed by clinical and neuropsychological testing. 
Importantly, there were no abnormalities visible on cross-sectional imaging until scan 
(4), 45 months into the study, and 31 months after clear focal changes had been 
demonstrated using fluid-registration. When abnormalities did become present on 
conventional imaging, they were entirely in keeping with a diagnosis of FTLD.
This study has a number of limitations. The patient attended alone (at her
• tilrequest) until the 6  assessment, and the history given may therefore be incomplete.
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However, when she was accompanied by her husband, his account of her illness was 
broadly in keeping with our clinical assessment. We have no information concerning 
the early course of the disease in other affected family members. This patient’s 
brother was not assessed until late in his disease, at which time many of the reported 
clinical features appear to be consistent with FTLD. Given this, the family history, 
and similar young age at onset, it is highly likely that despite differing phenotypes, 
both siblings were suffering from the same disease process. A recent study suggested 
that in FTLD, ubiquitin positive intranuclear inclusions are specific for familial FTLD 
with ubiquitin inclusions, and may even identify a subset of families with a common 
molecular pathogenesis (Mackenzie & Feldman 2003), providing further support for 
these two siblings being affected by the same disease. However, as FTLD is a 
clinically and neuropathologically diverse entity, the pattern and progression of 
atrophy we describe in this individual are unlikely to be consistent amongst different 
clinical presentations, nor necessarily applicable to sporadic FTLD.
Though the use of two different scanners could result in a systematic bias 
regarding the reported progression of atrophy, the earliest changes were demonstrated 
on the first scanner and no “cross scanner” calculations or analyses were performed. 
Furthermore all reported atrophy results are corrected for headsize (TIV) which can 
reasonably be assumed to remain constant.
The neuropsychological battery used in this study, although comprehensive 
was initially designed to detect the earliest changes in FAD, and not FTLD per se. 
Accordingly the selected tests were not specifically targeted to detect early speech 
production deficits. It is therefore possible that with closer assessment, subtle speech 
production dysfunction might have been present even earlier than was detected.
In summary the onset and progression of familial FTLD is markedly different 
from the findings reported in Chapter 8  for FAD with initially highly selective left 
sided frontal atrophy, then more prominent left sided frontal atrophy, followed by 
involvement of the left parietal lobe. Unlike AD no significant atrophy was seen in 
the hippocampi or medial temporal lobe structures. This study provides support for 
the biological validity of the fluid registration technique with atrophy reflecting the 
different clinical presentation and different pathophysiological processes.
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Table 9.1 Neuropsychological assessments of patient 306.IV.3.
A ssessm ents 1 . 2 3 4 i 5 6
Feb 1996 May 1997! Apr 1998 Nov 1997 ! May 2000 Oct 2000
Month 0 14 26 45 51 56
Verbal IQ 97 108 ! 103 ! 97 | 85 75
Performance IQ 87 96 ! 89 92 85 72
Advanced Matrices 7/12 n.t. 6/12 I 6/12 n.t. n.t.
NART IQ 123 n.t. n.t. n.t. n.t. n.t.
I 48/50 : 48/50 !: 49/50 i48/50 (75-! 42/50 i 33/50
RM Words | (>75%ile) (>75%ile);(=90%ile) 90%ile) ; (=50%ile) ! (<5%ile)
49/50 I 47/50 (= , 50/50 47/50 (= I 39/50 (= I 43/50 (50-
RM Faces I (>75%ile) j 75%ile) (>95%ile) 75%ile) 25 % i le) : 75%ile)
28/30 23/30
Topographical n.t. n.t. I n.t. n.t. (95%ile) (=50%ile)
24/24 24/24 21/24 (= I 19/24 (= 20/24 (= 20/24
Paired A ssociates 1 : (>90%ile) (>90%ile) I 75%ile) 50%ile) : 75%ile) (>75%ile)
24/24 : 24/24 24/24 22/24 (= 24/24 18/24 (10-
Paired A ssociates 2 (>90%ile) (>90%ile) (>90%ile) : 25%ile) | (>75%ile) 25%ile)
25/30 (75- 24/30 (75-! 27/30 25/30 (75-; 24/30 (75- 20/30 (25-
GD Naming Test 90%ile) 90%ile) (=95%ile) 90%ile) j 90% lie) ! 50%ile)
47/50 47/50 47/50 (75- 44/50 (50-1 42/50 27/50 (1-
Synonyms 4 -  (>75- (75- ■ 90%ile) 75%ile) (=50%i!e) 5%ile)
; 27/30 29/30 29/30 22/30 (50- 7/30 (10-
GD Spelling Test (>90%ile) (>90%iIe) (>90%iIe) 75%ile) t 25%ile) L 0/30
11/24 (= 10/24 (25- 10/24 (25- 5/24 (10- - 3/24
GD Arithmetic Test a 50%ile) 50%ile) 50%ile) 25%ile) j J=5%ile) 0/24
Silhouettes
: 23/30 (= 
j 50%ile)
! 22/30 (25- 24/30 (50-24/30 (50- 
! 50%ile) ! 75%ile) ! 75%ile)
20/30 (25- 
50%i!e)
17/30 (10- 
! 25%ile)
10/10 ! 10/10 ; 9/10
Cube Analysis
i (>5% cut-
J ofl)
(>5% cut­
off)
(>5% cut-8/10 (>5%[ 6/10 (<5% 
1 off) : cut-off) i cut-off)
| 2/10 (<5% 
cut-off)
WCST P ass P ass P ass
!---------------^
n.t. Fail n.t.
Cognitive Estim ates 
"S" words
4
:.......n.t........
3
i_....n.t.....__
2
i.......9
n.t i 
8
n.t. n.t.
; .....1
Trail Making A n.t. n.t
53 (25- 
i 50%ile)
52 (25- 
! 50%ile) ;
76 (10- 
25%ile)
[ Unable to 
complete
I 89 (25- 120 (25- 160 Failed
Trail Making B n.t. n.t. ! 50%ile) : 50%ile) (=10%ile) : practice
Hayling
Weigl
n.t.
n.t.
n.t.
n.t.
n.t.
n.t.
1 (fail) : 
n.t. i
3 (poor) 
n.t.
3 (poor) 
P ass
Digit Copying
40 (50- 
75%ile)
42
(=50%ile)
39 (50- 
75%ile) !
41 (50- 
75% lie)
45 (50- 
75%ile)
56 (10- 
25%ile)
Cancelling 0 's 64 48
(mean;sd) . 67 (46; 14) j (46; 14) (46; 14) 51 (46; 14) 64 (46; 14) ; 51 (46; 14)
Legend: RM = Recognition Memory; GD = Graded-Difficulty; WCST = Wisconsin 
Card Sorting Test; n.t. = not tested
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Figure 9.1 Family tree of family 306
11.811.711.5
IV. 1 IV.2 IV.3
Patient enrolled in prospective longitudinal study marked with arrow. Circles 
represent females, squares males, and diamonds are anonymised individuals. 
Deceased family members are marked with a diagonal slash
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gure 9.2 Overview of assessments that patient IV.3 underwent during the course of the study
Feb May April Nov May Oct Nov Sep Dec
1996 1997 1998 1999 2000 2000 2000 2001 2001
Month 0 14 26 45 51 56 57 66 69
MMSE 29 29 29 29 26 21
MRI
Scans reported normal Increasingly abnormal scans
0.96% brain volume loss/year 4.5% brain volume loss/year
Fluid 
Registration 1 
Very focal left 
frontal atrophy
Fluid 
Registration 2 
Increasing left 
frontal atrophy
Fluid Registration 3 
Increasing frontal and left parietal 
lobe atrophy
8% brain volume loss/year
Clinical
Working
Increasing speech impairment
Orofacial and generalized dyspraxia
Primitive reflexes
Unable to work
N-Psych
Moderate intellectual 
deficit; otherwise 
cognitively well 
preserved
Onset of 
verbal 
fluency 
deficit
Increasing left frontal & parietal 
lobe dysfunction. Memory, speed 
and attention normal
Not testable
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Figure 9.3 Voxel compression map time period one (sagittal)
c o n t r a c t i n g e x p a n d i n g
Sagittal MRI of patient 306.IV.3 with colour overlay over time period one, showing 
very focal anterolateral left frontal lobe atrophy, particularly centred around the pars 
opercularis
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Figure 9.4 Voxel compression map time period two (sagittal)
c o n t r a c t i n g e x p a n d i n g
Sagittal MRI of patient 306.IV.3 with voxel-compression-mapping overlay over time 
period two, showing focal anterolateral left frontal lobe atrophy, extending from, but 
still centred around the pars opercularis.
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Figure 9.5 Voxel compression map time period two (coronal)
c o n t r a c t i n g e x p a n d i n g
Coronal MRI o f patient 306.IV.3 with voxel-compression-mapping overlay over time 
period two, showing marked asymmetric (Left >Right) frontal lobe atrophy at this 
stage
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Figure 9.6 Voxel compression map time period three (coronal-parietal)
e x p a n d i n gc o n t r a c t i n g
Coronal MRI of patient 306.IV.3 with voxel-compression-mapping overlay over time 
period three showing focal left parietal lobe atrophy. The right parietal lobe is much 
less affected, and with no significant change seen within the cerebellum.
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Figure 9.7 Voxel compression map time period three (coronal-frontal)
c o n t r a c t i n g e x p a n d i n g
Coronal MRI of patient 306.IV.3 with voxel-compression-mapping overlay over time 
period three, showing bilateral frontal lobe atrophy, more prominent on the left. 
There is focal atrophy of the left inferior, and to a lesser extent the left middle, 
temporal lobe gyrus. The left superior temporal, fusiform and parahippocampal gyri 
and the hippocampal formation are notably spared.
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Figure 9.8 Voxel compression map time period three (sagittal)
e x p a n d i n gc o n t r a c t i n g
Sagittal MRI of patient 306.IV.3 with voxel-compression-mapping overlay over time 
period three, showing atrophy of the left operculum, middle and inferior temporal 
lobes and inferior parietal lobule. The primary motor and sensory cortices, occipital 
lobe and cerebellum are spared.
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10. A volumetric MRI study comparing familial and 
sporadic Alzheimer’s disease
10.1 Background
Although familial AD has an earlier age at onset than sporadic AD, it shares the same 
neuropathological signature lesions. Some neuropathological studies suggest that 
some FAD mutations may progress faster than SAD (e.g. Gomez-Isla et al. 1999). In 
this chapter two studies comparing FAD and SAD prospectively are reported to 
compare the rate of progression in vivo.
10.2 Subjects
10.3.1 Study 1
Thirty two patients with probable AD (NINCDS-ADRDA criteria) and 18 normal 
controls (NC) were recruited from the Specialist Cognitive Disorders Clinic and the 
FAD longitudinal study. The AD group comprised of 14 SAD subjects and 18 patients 
with FAD (six with APP and twelve with PSEN1 mutations. The FAD and SAD 
patients were severity matched based on their MMSE score at the time of initial MRI. 
The control patients were selected from the DRG pool of control patients and age and 
sex matched to the FAD group. All subjects underwent at least two volumetric MRI 
scans at approximately annual intervals.
10.3.2 Study 2
Twenty two patients with probable AD (NINCDS-ADRDA criteria) were recruited 
from the Specialist Cognitive Disorders Clinic and the FAD longitudinal study. The 
study group comprised of 11 SAD subjects (4F:7M) and 11 patients with FAD 
(5F:6M) from pedigrees with known APP or PSENJ mutations. All subjects 
underwent at least three volumetric MRI scans at approximately annual intervals.
10.3 Methods
10.3.1 Study 1
T1 weighted volumetric MRI assessments were performed on the same 1.5 T Signa 
unit (General Electric, Milwaukee, WI). The individual MRI scans provided 124
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contiguous 1.5 mm coronal slices through the head, which were transferred to a Sun 
workstation (Sun Microsystems Inc., Mountain View, CA) for examination using the 
MIDAS image analysis programme. The scan pairs were registered by positional 
matching of the later scan onto the baseline scan. The ventricular cerebrospinal fluid 
(CSF) space was identified on the earlier scan using a semi-automated technique 
using manually placed seeds and defined as having a voxel intensity of between 0  and 
60% of mean brain voxel intensity. Ventricular volumes included the lateral ventricles 
and temporal horn of the lateral ventricles but not the third or fourth ventricle. All 
segmentations were performed by myself; mean intrarater reproducibility was 
>99.5%. The baseline ventricular CSF volume was then "copied and pasted" onto the 
later scan where it was edited. This has the advantage that like is compared with like 
and that the same assumptions to exclude extraneous CSF are made for both sets of 
images. Further details of the ventricular segmentation protocol are given in Appendix 
4.
10.3.2 Study 2
Neuroimaging was performed as described above and the sequential scan pairs were 
registered by positional matching. The difference in brain volumes was calculated 
using the brain boundary shift integral (BBSI) as previously described.
10.4 Results
10.4.1 Study 1
The ages (mean ± SD) of the subjects were: FAD = 46.7 ± 7.4 years, NC = 47.9 ±8.1 
years and SAD = 67.3 ± 9.5 years. Their MMSE scores (mean ± SD) at baseline were: 
FAD = 22.9 ± 6.1, SAD = 19.6 ± 3.9 (NS) and NC = 29.1 ± 0.6 (P<0.005). The scan
interval (mean ± SD) was 1.60 ± 0.54 years for the FAD subjects, 1.16 ± 0.24 years
for the control group and 1.09 ± 0.36 years for the SAD patients. Baseline ventricular 
volumes (mean ± SD) were: FAD = 24.1 ± 16.8 ml, NC 16.3 ± 10.8 ml and SAD 48.7 
± 28.4 ml. Ventricular volumes (mean ± SD) increased by: FAD = 5.7 ± 4.9 ml/yr, 
NC = 0.5 ± 0.8 ml/yr and SAD = 6.1 ± 3.2 ml/yr. There were no significant 
differences between baseline ventricle volumes. The rate of increase in both FAD and 
SAD ventricle volumes was significantly greater than for NC (P<0.05), but there was 
no significant difference between the FAD and SAD groups.
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10.4.2 Study 2
The ages (mean ± SD) of the subjects at their first scan were FAD = 46.5 ± 7.8 and 
SAD = 64.6 ± 6.7 years. MMSE scores (mean ± SD) were: FAD = 21.8 ± 8.2 and 
SAD = 20.3 ± 5.2. The BBSI (mean ± SD) for interval one were: FAD = 29.8 ± 14.3 
mis and SAD = 14.3 ± 9.8 mis, and for interval two: FAD = 26.4 ± 12.9 mis and SAD 
= 13.3 ± 5.9 mis. The annualised rates of atrophy (mean ± SD) expressed as a 
percentage of brain volume at first scan for interval one were: FAD = 2.73 ± 2.58 
%/yr, SAD = 2.51 ± 1.15 %/yr (NS). Interval two: FAD = 3.42 ± 2.30 %/yr, SAD = 
2.00 ± 1.05 %/yr (P<0.05). However, there was one outlier in the FAD group with 
atrophy rates of 9.94 %/yr and 9.49 %/yr for intervals one and two. These were more 
than twice as high as the next individual in either group skewing the data. This patient 
had severe FAD, with a MMSE of 5/30 at baseline and 0/30 at the third scan 12 
months later. Excluding this patient reduces the respective FAD rates of atrophy 
(mean ± SD) to 2.01 ± 1.03 %/yr and 2.81 ± 1.17 %/yr for interval one and two which 
were not significantly different from those for SAD patients. There were no 
significant differences in the rates of atrophy between the intervals within the FAD 
and SAD groups.
10.5 Discussion
Older SAD subjects had larger baseline ventricles than the younger FAD and NC 
subjects. There was overlap between the groups, especially between FAD and NC and 
therefore this finding did not reach statistical significance. However, rates of 
ventricular enlargement in Study 1 were significantly greater in both FAD (5.6ml per 
year) and SAD (6.1ml per year) compared to NC (0.5ml per year) and the results were 
similar to those obtained in other recent high resolution MRI which demonstrate a 
broad consensus (~5-8ml per year) as to the magnitude of ventricular enlargement in 
AD (see Table 1.2). Discrepancies between these results are likely to be due to 
protocol differences and inter-subject variation. The changes in AD are substantially 
higher than those seen in normal ageing. In Study 1, normal controls underwent 
ventricular change of 0.5ml per year, which compares well with reports from Wang et 
al. (2002) who found 0.4ml per year, Schott et al. (2003) who found ventricular 
expansion of 0.44 ml per year, and Scahill et al. (2003) who reported change of
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0.65ml per year. Importantly there was no difference in the current study in the rate of 
change of ventricular CSF volume between the FAD and a similarly severely affected 
SAD group despite a 20 year difference in age.
Although there is some evidence for more rapid progression in Study 2, when the 
BBSI is used as a measure of brain atrophy this was entirely due to a single individual 
with severe FAD (MMSE 5/30) skewing the data. Removal of that outlier resulted in 
there being no significant difference between the FAD and SAD group. The rate of 
cerebral atrophy in Study 2 was between 2.0-2.8 % per year which is in accord with 
previous data (see Table 1.2). Furthermore there appeared to be no significant 
differences between the first and second intervals, in keeping with data from Chapter 
6  suggesting that progression in AD is linear over 1-2 years.
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11 Conclusions
The data presented in this thesis were collected as part of an ongoing collaborative 
study involving many people. This thesis addresses several related questions about 
familial AD. Past genetic screening of the DRG collection of families had identified a 
causative FAD mutation in only a minority of families. Against this background 
Chapter 3 reports a mutational analysis of the three known FAD genes. Multiple 
mutations, both novel and previously reported, were identified. Three different 
PSEN1 mutation families are reported in detail in Chapter 4 to assess whether there is 
a specific PSEN1 FAD phenotype. Although the clinical features were broadly of 
early onset AD in all families, family 102 (E280G) additionally had spastic 
paraparesis and unusual “cotton wool” plaques at neuropathology. With advances in 
symptomatic AD treatments and the particular relevance of possible amyloid p 
immunotherapy to FAD families, Chapter 5 is a pilot study which confirms earlier 
reports of increased plasma amyloid p peptide as a biomarker for FAD. Relatively 
little is known about the progression of cerebral atrophy using MRI beyond one to 
two years and whether progression is linear or whether it accelerates - this is 
addressed in Chapter 6 . Based on the neuropathological studies of Braak and Braak 
(1991) AD is thought to start in the medial temporal lobes. This region’s involvement 
is confirmed in vivo in subjects who were initially asymptomatic using volumetric 
MRI studies in Chapter 7. However, confirming the involvement of the medial 
temporal lobe early in FAD does not equate to this being the locus of disease onset. 
This is addressed in Chapter 8  which investigates the earliest MRI changes in FAD 
without a priori assumptions using fluid registration. This in vivo study showed pre- 
symptomatic posterior cingulate, neocortical temporo-parietal and medial temporal 
lobe atrophy which accords well with Braak and Braak (1991). We had the 
opportunity to also assess the onset of non-AD by prospectively studying a 
presymptomatic “at risk” family member belonging to a familial FTLD pedigree. 
Fluid registration revealed very focal left frontal lobe atrophy, clearly different from 
FAD, which correlated well with the patient’s clinical presentation. Relatively little is 
known about the difference between cerebral atrophy in FAD and sporadic AD 
patients and this is addressed in Chapter 10. These studies are summarized below 
using the specific questions stated at the beginning of this thesis in “the problem”.
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11.1 What proportion o f  FAD is accounted for by mutations in known 
genes?
A mutational analysis of the APP, PSEN1 and PSEN2 genes in 31 probands with 
probable or definite AD from DRG families with an AAO <61 years is described in 
Chapter 3. In 21 (6 8 %) probands eight novel PSEN1 mutatiions, eight previously 
reported PSEN1 mutations, a novel APP mutation (H677R) and two known APP 
mutations were identified. Nine of the eleven (82%) probands with 
neuropathologically confirmed AD, who additionally fulfilled recognised criteria for 
autosomal dominant inheritance, were associated with a sequence variant in APP or 
PSENL The ten patients, in whom it was not possible to identify a mutation in APP, 
PSEN1 or PSEN2, were over ten years older (P=0.001) than the probands with 
mutations. No mutations in PSEN2 were detected. The proportion of PSEN1 and APP 
mutations described in the present study is much higher than the 18% reported by 
Cruts et al. (1998) who used the same criteria to define autosomal dominant 
inheritance as in the present study. However, the findings from this study are in 
accord with a French FAD study in which 24/34 (71%) families fulfilling stricter 
three generational criteria to define autosomal dominant inheritance were found to 
have mutations in APP or PSEN1 (Campion et al. 1999). The combined post-study 
DRG FAD mutation prevalence is 8 8 % and the likelihood of a fourth FAD locus 
existing would appear to be much diminished. However, several large kindreds in the 
DRG collection of FAD families remain without an identified mutation.
11.2 Is there a specific PSEN1 FAD phenotype?
Three neuropathologically verified PSEN1 FAD families are described in Chapter 4. 
The phenotype of family 105/160 (Intron 4) was remarkably similar to previously 
described PSEN1 pedigrees and shares their early AAO, the presence of myoclonus 
and generalised seizures, and a relative preservation of naming skills until late in the 
disease. Family 177 (LI53V) similarly had an early AAO, myoclonus and relatively 
preserved naming, but no reported generalized seizures. In view of the reduced age at 
onset in patient 105/160.V.16 and APOE s4/s4 homozygosity, APOE s4 may 
modulate AAO in this pedigree. The neuropathology of family 105/160 and 177 is 
more severe than sporadic AD and although Lewy bodies were prominent in both
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these families their neuropathology is similar to that of other PSEN1 cases. Family 
102 (E280G) however, was associated with significant white matter abnormalities on 
cranial MRI and/or progressive spastic paraparesis. The characteristic 
neuropathological findings of diffuse, non-cored, “cotton-wool” amyloid plaques and 
prominent amyloid angiopathy associated with the FAD spastic paraparesis phenotype 
were seen in a third affected family member. Neither spastic paraparesis nor 
significant white matter abnormalities on cranial MRI have been previously described 
in association with the E280G mutation. Although all three families have an early 
AAO and broadly have FAD phenotypes there is a remarkable clinical and 
neuropathological phenotypic heterogeneity in PSEN1 FAD.
11.3 Is plasma amyloid fi peptide a useful biomarker o f  FAD?
The common mechanism of action for FAD mutations is through modulation of APP 
processing which alters the synthesis p-amyloid peptides, key components of neuritic 
plaques. As prospects for the first AD modifying drug improve, the value of a 
peripheral disease marker with surrogate and pre-symptomatic diagnostic potential 
becomes increasingly important. Since p-amyloid peptide synthesis occurs in blood 
platelets as well as the CNS the suitability of plasma p-amyloid peptides as 
biomarkers of familial AD is described in Chapter 5. Plasma AP42 concentrations 
were determined using the highly specific and sensitive Innotest AP(l-42) ELISA. 
Plasma Ap42 concentrations (pg.ml-1 ) were elevated in both symptomatic (52.8 ± 3.2, 
n = 6 ; P<0.02) and pre-symptomatic (55.2, n = 3; P<0.1) subjects who possess FAD 
mutations when compared with asymptomatic family members who did not possess 
such mutations (29.6, n = 3). The mean plasma Ap42 concentration in “at risk 
subjects” of unknown genotype (37.3 ± 2.2, n = 11) was midway between those of 
FAD mutation carriers (P<0.01) and non carriers. These findings are in accord with a 
previous report (Scheuner et a l 1996) and suggest that Ap42 peptide may be a useful 
biomarker for FAD, even in the absence of symptoms.
11.4 Is the progression o f cerebral atrophy in EOAD linear?
In Chapter 6  a longitudinal neuroimaging study is described. Twelve early onset AD 
patients (nine familial and three sporadic patients) with at least three scans obtained 
over a period of up to six years were recruited. Brain atrophy was estimated from
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sequential brain volume measurements, and also using the brain boundary shift 
integral (BBSI), a direct estimate of volume loss (between temporally adjacent scan 
pairs). Ventricular enlargement, an indirect measure of brain atrophy was also 
assessed. The data were presented relative to the fixed datum of MMSE 23, which 
relates to mild to moderate disease, and which was reached by all patients during the 
course of the study. Cerebral atrophy rates appeared approximately linear but were 
better represented by a quadratic than by a linear relationship with time. When 
atrophy was derived from sequential measurements of whole brain volume, the 
estimated increase in rate of atrophy was 0.25% per year (95%CI 0.08 to 0.43). Two 
years before MMSE 23 cerebral atrophy was estimated at 2.17% of brain volume per 
year increasing to 3.18% four years later. The values obtained using the BBSI were 
similar: the estimated increase in rate of atrophy was 0.28% per year (95% Cl 0.17 to 
0.39), with an estimated rate of atrophy of 1.73% of brain volume per year initially 
and 2.84% four years later. Ventricular CSF volumes also increased with time from 
0.173 % per year (95% Cl 0.132 to 0.214) to 0.208 % per year over four years. There 
was only borderline evidence for acceleration of ventricular enlargement which was 
estimated at 0.009% per year (95% Cl: 0.0000 -  0.0175; P= 0.05), probably because 
ventricular enlargement reflects only a small proportion of cerebral atrophy. No 
significant differences were observed between sporadic and familial AD patients, nor 
was APOE genotype found to affect rate of cerebral atrophy. Brain atrophy rates 
therefore gradually increase in AD with increasing disease severity, an observation 
with important implications for the understanding of disease progression in AD, and 
for the use of brain atrophy as a biomarker of disease severity.
11.5 Is there pre-symptomatic medial temporal lobe atrophy in FAD?
Chapter 7 is a volumetric MRI study of patients with FAD during the period that they 
developed symptoms. Five patients with presymptomatic FAD (three with PSEN1 and 
two with APP mutations) and 20 normal controls had two or more annual volumetric 
MRI brain scans. All five FAD “at risk” subjects subsequently developed probable 
AD. Volumes of brain, ventricles, temporal lobes, hippocampi, and entorhinal cortices 
were measured. Rates of volume change were calculated from serial scans. There 
were no significant differences in baseline measures of whole brain, temporal lobe, or 
ventricular volume between patients and controls. However, baseline averaged
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volumes of medial temporal lobe structures (hippocampi and entorhinal cortices) were 
16.6% (95% confidence interval [Cl], 3.3-28.0%) lower in the patient group. Atrophy 
rates for brain, temporal lobe, hippocampus, and entorhinal cortex were significantly 
increased in patients compared with controls (p < 0.05). Averaged atrophy rates from 
both hippocampi and entorhinal cortices were 5.1% (95% Cl, 3.0-7.1%) greater in 
patients than controls. Linear extrapolation backward suggested medial temporal lobe 
atrophy commenced 3.5 years (95% Cl, 0.7-7.5 years) prior to the commencement of 
the study, when all patients were asymptomatic. In conclusion increased medial 
temporal lobe atrophy rates are an early and distinguishing feature of FAD and 
pathological atrophy is probably occurring several years before the onset of symptoms 
in FAD.
11.6 Where does cerebral atrophy in FAD begin?
This question is addressed in Chapter 8 using “fluid” registration, a technique that 
treats the brain as a viscous liquid rather than a rigid body. It addresses the criticisms 
generally levelled at volumetric imaging studies where a priori assumptions are made 
about areas involved in AD neurodegeneration. Serial imaging was acquired in four 
asymptomatic “at risk” individuals from FAD families (families 19, 105/160, and 148, 
respectively carrying the causative APP V717G, PSEN1 intron 4 and PSEN1 Ml39V 
mutations). All four subjects became symptomatic over a period of five to eight years 
during research follow-up. In addition 20 individuals with a clinical diagnosis of 
probable AD and 20 control subjects underwent serial brain MRI. A non-linear fluid 
matching algorithm was applied to register repeat scans onto baseline imaging. 
Jacobian determinants were used to create a voxel compression map, allowing 
localisation of volume change in an individual over time. Using fluid registration 
progressive atrophy was revealed in presymptomatic “at risk” FAD individuals with 
posterior cingulate and neocortical temporo-parietal cortical losses as well as medial 
temporal lobe atrophy. In established cases atrophy was widespread but spared the 
primary motor and sensory cortices and cerebellum, reflecting the clinical 
phenomenology. Voxel compression maps confirmed early involvement of the medial 
temporal lobes but also showed posterior cingulate and temporo-parietal cortical 
losses at the /^sym ptom atic stage. This distribution of atrophy in both preclinical 
and established AD accords well with the pattern of cognitive deficits and the
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distribution of observed histological changes at autopsy (Braak & Braak 1991). If 
Braak & Braak’s (1991) cross-sectional neuropathological data are viewed as a 
continuum the locus of initiation of Alzheimer’s disease can be considered to be in the 
medial temporal lobe. The voxel compression mapping data provide longitudinal data 
compatible with this. However, this study cannot determine the stage at which 
structural changes are first present, only that atrophy rates increased several years 
before symptom onset. Similarly this study cannot address the issue of when 
histological changes (plaques, tangles and cell loss) start but it seems reasonable to 
suggest that they are likely to precede the macroscopic, atrophic changes 
demonstrated.
11.7 Is the onset and progression o f  cerebral atrophy different in non- 
AD dementia?
Fluid registration was also applied in Chapter 9 to demonstrate the onset and 
progressive pattern of in vivo atrophy in familial FTLD. An asymptomatic “at risk” 
family member of DRG family 306, a neuropathologically confirmed FTLD family 
with ubiquitin positive and tau negative inclusion bodies, was recruited for a 
longitudinal clinical, neuropsychological and neuroimaging study. The patient was an 
asymptomatic 51 year old woman studied over a period of 69 months with 
approximately annual clinical, MRI and neuropsychological assessments. Over the 
first 26 months of the study, she remained asymptomatic, but subsequently developed 
progressive speech production difficulties, and latterly severe orofacial dyspraxia, 
dyscalculia, frontal executive impairment and limb dyspraxia. Regional atrophy was 
present prior to the onset of symptoms, and was initially centred on the left 
dorsolateral prefrontal cortex and the left middle frontal gyrus. Latterly, there was 
increasing asymmetric left frontal and parietal atrophy. Medial temporal lobe 
structures, the sensorimotor cortices and the cerebellum were unaffected. 
Neuropsychological evaluation revealed mild intellectual impairment prior to the 
onset of these clinical symptoms; frontal executive and left parietal impairment 
subsequently emerged, culminating in widespread cognitive impairment. Fluid 
registered MRI allowed the emerging atrophy patterns to be delineated and the 
neuropsychological and clinical data to be correlated with structural change. Fluid 
registration therefore revealed initially very focal left frontal lobe atrophy, clearly
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different from FAD, which correlated well with the patient’s clinical presentation.
11.8 Does cerebral atrophy in FAD progress faster compared with 
SAD?
Early onset AD, and FAD in particular, is generally believed to be more severe than 
SAD. Chapter 10 consists of two studies comparing rates of atrophy between FAD 
and SAD. The first study compares change in ventricular CSF volumes, whereas the 
second study looks at change in total brain volume using the BBSI. Older SAD 
subjects had larger baseline ventricles than the younger FAD and control subjects. 
There was overlap between the groups especially between FAD and control subjects. 
However, rates of ventricular enlargement were significantly greater in both FAD and 
SAD compared to controls. Importantly there was no difference in the rate of change 
between the FAD and a similarly severely affected SAD group despite a 20 year 
difference in age. Although there is some evidence for more rapid progression in the 
second study when the BBSI is used as a measure of brain atrophy this was entirely 
due to a single individual with severe FAD (MMSE = 5/30 at first scan) skewing the 
data. Removal of that outlier resulted in there being no significant difference between 
the FAD and SAD group. On balance there appears to be no difference in the 
progression of cerebral atrophy in FAD and SAD.
11.9 Implication offindings and possible future studies
The majority of DRG FAD families now have an identified mutation. A number of 
mutations were found in families that had previously been screened, suggesting that 
the mutations were outside the sequenced areas. This is unlikely to be an isolated 
finding and historical series in the literature may therefore underestimate the 
proportion of FAD pedigrees accounted for by the known FAD genes. Although the 
whole of PSEN1 was sequenced, only specific exons of PSEN2 and APP were 
analysed. In the first instance the sequencing of the remainder of PSEN2 is planned, 
but it may be that APP needs to be looked at again. Furthermore the families that 
remain without mutations will need careful review of both the clinical and 
neuropathological features, before considering other genetic (single gene or 
multifactorial) or alternative explanations.
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The characterisation of the PSEN1 phenotype(s) has revealed a number of 
similarities, but also marked heterogeneity. In family 105 the patient with the 
youngest AAO was APOE s4/e4 homozygous. Whether APOE s4 modulates AAO in 
this pedigree is worthy of further study. Lewy body pathology was prominent in 
families 105/160 and 177. It is unclear how APP processing influences Lewy body 
pathology, but this is an increasingly recognised finding in FAD. There may be an 
interaction between a synuclein and APP, which may have relevance for AD, 
dementia with Lewy bodies and Parkinson’s disease dementia. The presence of 
spastic paraparesis in family 102 is also of interest. Family 102 is a large pedigree and 
the current “at risk” generation is involved in the DRG longitudinal study, which may 
shed more light on the factors that determine the absence/presence of spastic 
paraparesis. Review of the available neuropathology to see whether cotton wool 
plaques are present in the absence of reported paraparesis would also be important. 
Since families 168 and 183 also carry the PSEN1 E280G mutation it would be of 
interest to review their phenotype and any available brain bank tissue for similar 
reasons.
The small pilot study of plasma Ap42 as a possible FAD biomarker was 
designed when FAD mutations were generally thought to result in the increased 
synthesis of the more amyloidogenic Ap42- There are now a number of important 
exceptions to this general principle. However, if a specific FAD mutation’s effect on 
APP processing is known, then plasma Ap measurements can be interpreted 
appropriately. There may therefore be a limited role for plasma Ap as a biomarker, 
possibly for assessment of the in vivo effects of potential disease modifying agents in 
cultured media, animal models or even human FAD patients.
A number of important findings where described in the imaging chapters. 
Increased pre-symptomatic medial temporal lobe atrophy was demonstrated in FAD 
patients when compared to matched control patients. Baseline FAD medial temporal 
lobe volumes were found to be lower than in control patients suggesting that atrophy 
started several years before symptom onset. Non-linear (fluid) registration was used to 
determine the area where cerebral atrophy starts without a priori assumptions about 
the areas involved in AD neurodegeneration. Posterior cingulate and neocortical 
temporo-parietal cortical losses as well as medial temporal lobe atrophy were the 
earliest changes identified. In established cases atrophy was widespread but spared the
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primary motor and sensory cortices and cerebellum. This data provides important 
biological validity for the registration technique. The rate of cerebral atrophy was 
found to accelerate with increasing disease severity. Equally important was the fact 
that the rate of atrophy was linear over one to two years, the time period used in 
typical drug trials. Whole brain atrophy was a better measure of cerebral atrophy than 
ventricular volumes, almost certainly because of their relative sizes. The acceleration 
of cerebral atrophy could indicate true acceleration of atrophy in already affected 
brain regions, disease spread to a greater proportion of cerebral cortex, or both. This 
question could be addressed with non-linear (fluid) registration. Acceleration of 
disease progression would suggest that for a given drug trial design more statistical 
power could be achieved by the enrolment of more severely affected patients. 
Conversely, over short periods atrophy was linear suggesting that this variable does 
not need to be controlled for over one to two years, and attenuation of cerebral 
atrophy could be due to a treatment effect. Although the imaging studies described in 
this thesis cannot determine when neuropathological or even structural changes first 
occur, the findings accord well with the clinical phenomenology and Braak & Braak’s 
(cross-sectional) neuropathological model (Braak & Braak 1991). It seems reasonable 
to assume that the neuropathological changes predate tissue loss, and therefore 
measurable cerebral atrophy. It then follows that there is significant pre-symptomatic 
disease activity. A comparison of rates of cerebral atrophy between FAD and SAD 
patients showed no difference in the progression of these groups. This needs to be 
looked at in more detail, before concluding that the FAD findings have broader 
implications. Similarly the detailed study of familial FTLD, in which very different 
clinical and imaging changes from FAD were described, may not immediately be 
applicable to sporadic FTD. However, similar conclusions about pre-symptomatic 
changes can be drawn to those listed for FAD. The potential of the registration 
technique(s) would benefit assessment in different dementias. Should specific 
dementia disease modifying drugs become available, early and accurate diagnosis will 
become increasingly important. Serial imaging demonstrating excess atrophy above 
that expected for age may be a useful method of detecting early neurodegeneration 
and the pattern of regional atrophy may prove to be a useful tool in the differential 
diagnosis of degenerative dementias. However, the validation of cerebral atrophy as a 
true surrogate marker of AD (and degenerative dementia in general) must await the 
development of a true disease modifying agent.
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Appendix 1: Tau (MAPT) gene mutation phenotypes
Abbreviations used in table:
3R = three repeat tau
4R = four repeat tau
CBD = corticobasal degeneration
DDPAC = disinhibition dementia parkinsonism amyotrophy complex 
DRG = Dementia Research Group 10+16 families (Janssen et al 2002) 
F = frontal
FTD = ffontotemporal dementia 
MAAD = mean age at death 
MAAO = mean age at onset 
MND = motor neurone disease
MSTD = familial multi system tauopathy with presenile dementia
MT = microtubule
NFT = neurofibrillary tangles
PA = progressive nonfluent aphasia
PHF = paired helical filaments
PPND = pallido-ponto-nigral degeneration
PSG = familial progressive subcortical gliosis
PSP = progressive supranuclear palsy
T = temporal
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Mutation Mechanism Clinical MAAO 
(range) yrs
MAAD (range) yrs Duration
(yrs)
Neuropathology Tau filament 
morphology
First Author
K257T All tau isofbrms 
increased, but mainly 
3R; reduced MT 
assembly
FTD in proband with late semantic 
memory impairment. Not clearly 
autosomal dominant.
P47 51 4 F<T atrophy. Tau immunoreactive Pick bodies in 
neocortex, hippocampus and subcortical areas.
Narrow
irregularly
twisted
filaments
Rizzini, 2000
G272V All tau isofbrms 
increased. Reduced 
MT assembly
HFTD2 family: FTD '46.5 '54.7 8.5(4-16) F-T atrophy. Ballooned cells in cortex and basal 
ganglia, Tau positive inclusions in multiple 
cortical and subcortical areas and in dentate 
gyrus
Hutton, 1998; Heutink, 
1997; Spillantini, 1998a; 
Hasegawa, 1998;
10+3 Increased 4R tau; 
enhanced exon 10 
splicing
MSTD family: disequilibrium, short term 
memory, progressive cognitive decline, 
extrapyramidal syndrome, vertical gaze 
palsy and dysphagia.
49 (39-59) 10 Diffuse atrophy of neocortex, subcortical nuclei, 
brainstem, and spinal cord. Neuronal and glial tau 
inclusions
Twisted ribbons Spillantini, 1997 & 
1998b; Murrell, 1997
10*12 Increased 4R tau; 
enhanced exon 10 
splicing
Kumamoto pedigree: FTD and 
parkinsonism
’53 y F-T atrophy. Neuronal and glial tau inclusions Twisted ribbons Yasuda, 2000
10+13 Increased 4R tau; 
enhanced exon 10 
splicing
Man19 family: FTD 65 Hutton, 1998
10+14 Increased 4R tau; 
enhanced exon 10 
splicing
Family Mo (DDAPC): disinhibition, 
hyperphagia, early memory loss, anomia, 
constructional apraxia, extrapyramidal 
syndrome,
45 (27-56) 57 (35-69) 13(5-23) F-T atrophy. Depigmentation of substantia nigra. 
Ballooned neurones.
Hutton, 1998; Lynch, 
1994
10+16 Increased 4R tau; 
enhanced exon 10 
splicing
Families: Aus1, PSG-1 (FPSG, A), 
FTD002, Man6, Man23, EKR, and DRG 
all FTD
Aus1: 53 (39- 
64); PSG-1: 49 
(41-58); EKR.
48 (48-55), DRG 
50 (37-59)
Aus1: 62 (49-69); 
PSG-1: 60 (54-69); 
EKR 65 (65-75); 
DRG 61 (42-72)
4-14; 7-17; 
DRG 11 (3-22)
F-T atrophy. Neuronal and glial tau pathology in 
PSG-1 and DRG
PSG-1: twisted 
ribbons
Hutton, 1998; Goedert, 
1999a; Dark, 
1997;Poorkaj, 2001; 
Janssen, 2002
N279K All tau isofbrms 
increased, but tau 
positive inclusions are 
mainly 4R; enhanced 
exon 10 splicing
PPND family: progressive parkinsonism 
with dystonia, personality change, 
dementia, ocular motility abnormalities, 
pyramidal tract dysfunction, frontal lobe 
release signs
43 (32-52) 52 (46-63) 9(5-19) Mild F-T atrophy. Depigmentation of substantia 
nigra, pallidum and caudate. Widespread 
neuronal and glial fibrillary tangles.
Twisted and
straight
filaments.
Clark, 1998; D'Souza, 
1999; Reed, 1998; 
Hasegawa, 1999; Hong, 
1998; Wszolek, 1992
delK280 Effect on exon 10 
uncertain; reduced MT 
assembly
Demonstrated in a Dutch FTD patient 
whose father had been diagnosed with 
Parkinson's disease
D'Souza, 1999; Rizzu, 
1999
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Mutation Mechanism Clinical MAAO 
(range) yrs
MAAD (range) yrs Duration
(yrs)
Neuropathology Tau filament 
morphology
First Author
L284L Increased 4R tau; 
enhanced exon 10 
splicing
LKL pedigree; FTD but, early visuospatial 
impairment in proband
52 (47-61) 62 (57-71) 10 (9-10) Symmetrical F>T atrophy. Amyloid and tau 
deposition
D'Souza, 1999
N296N Increased 4R tau; 
enhanced exon 10 
splicing
FTD in proband with late supranuclear 
gaze palsy, orofacial dyspraxia and 
bradykinesia
'56 '69 ’13 Symmetrical F-T atrophy. Swollen achromatic 
neurons and corticobasal inclusion bodies. Glial 
and neuronal tau positive inclusions.
Spillantini, 2000; Brown, 
1996
P301L All tau isoforms 
increased; reduced MT 
assembly
HFTD1 family and Seattle families D, F, & 
G: FTD in all families. Variation in AAO in 
Seattle families not due to ApoE. Family 
MN. FTD and PA phenotypes.
HFTD1: 50.4; 
D: 49 (41-57); 
F: 61 (56-67); 
G: 64 (57-75); 
MN: 58 (55-63)
HFTD1: 58.6; D: 
56 (46-63); F: 68 
(56-77); G: 72 (65- 
80); MN: 65 (62- 
68)
HFTD1: 8.5 (4 
16); D: 6 (5- 
6); F: 8 (4-13); 
G: 7 (5-11); 
MN: 7 (5-12)
Severe F-T atrophy. Ballooned cells, 
degeneration of substantia nigra. Glial and 
neuronal tau positive inclusions. Seatle D: 
circular NFT in one patient, brainstem NFT 
similar to PSP in the other. Family MN: one 
patient had MND with Pick like bodies
Irregularly 
twisted ribbons
Hutton, 1998; Heutink, 
1997; Spillantini, 1998a; 
Hasegawa, 1998; 
Nacharaju, 1999; Bird, 
1999; Nasreddine, 1999
P301S All tau isoforms 
increased; reduced MT 
assembly
Family P: FTD (n=1) and CBD (n=1); 
German family: FTD, parkinsonism and 
epilepsy in late stage
Family P: 28 
(27-29); 20s
36; 35 (24-46) 7 "■ F-T atrophy. Extensive filamentous pathology of 
hyperphosphorylated tau
Straight
filaments
Bugiani, 1999; Goedert 
1999b; Sperfeld, 1999
S305N
(=102)
All tau isoforms 
increased, but 
inclusions are mainly 
4R; enhanced exon 10 
splicing
Japanese family with FTD; minimal 
parkinsonism in 1/3 patients
35 (29-38) 40 (35-41) 5 (3-6) F-T atrophy: Glial and neuronal tau positive 
inclusions. Unusual ring shaped NFT.
Straight tubules D'Souza, 1999; 
Hasegawa, 1999, lijima, 
1999
S305S Enhanced splicing of 
exon 10
frontal dysexecutive symptoms, 
progressive dementia, limb dystonia, 
parkinsonism, dysarthria, and 
supranuclear gaze palsy
51 (48-55) 54 (51-56) 6 (4-7) NFT concentrated in basal ganglia, gliosis, tufted 
astrocytes, ballooned neurones. Fulfils criteria for 
PSP
Twisted and
straight
filaments.
Stanford, 2000
V337M All tau isoforms 
increased. Reduced 
MT assembly
Early antisocial psychotic symptoms; 
subsequent confusion and progressive 
memory loss; dementia
53 (42-66) 67 (55-78) 15 (4-26) F-T atrophy. NFT in multiple cortical areas. 
Degeneration of amygdala. Glial and neuronal tau 
positive inclusions. No neuritic plaques
PHF Hasegawa, 1998; 
Poorkaj, 1998; Sumi, 
1992; Spillantini, 1996
E342V Increased 4R tau Proband FTD and late parkinsonism 44 (39-48) 50 (45-55) 7 (6-7) F-T atrophy. Glial and neuronal tau positive 
inclusions. Pick bodies (especially in CA1) and 
Pick cells.
PHF Lippa, 2000
G389R All tau isoforms 
ncreased, reduced MT 
assembly; no effect on 
exon 10 splicing.
Family F: PA; case  1 FTD with 
parkinsonism. Two separate mutations: G- 
>C and G->A respectively. Not clearly 
autosomal dominant.
38; 32 43; 37 5;5 F>T atrophy. Severe neuronal loss, astrocytosis, 
marked tissue vacuolation. Pick like inclusions 
(also in dentate fascia). Tau positive "coiled 
bodies" in WM. Increased susceptibility of tau to 
calpain I digestion
C ase 1: straight 
and twisted 
filaments
Murrell, 1999; Pickering- 
Brown, 2000
R406W All tau isoforms 
ncreased. Reduced 
MT assembly
Iowa kindred (Danish origin): FTD, some 
ndividuals with parkinsonism and gaze 
disturbance
55 (45-75) 73 (70-76) 26 (20-35) Mid F-T atrophy. Severe hippocampal atrophy 
with abundant NFT. Depigmentation of substantia 
nigra with abundant NFT. No neuritic placques. 
Neuronal tau positive inclusions. Fulfils criteria for 
PSP
PHF Hutton, 1998; 
Hasegawa, 1998; Reed, 
1997
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Appendix 2: Standardised MMSE
Modified from Folstein et al. (1975)
What is the YeaT 7 (exact)________________________________________________ __( 1)
What is the season of the year? (-1 week, +2 weeks)  (1)
What is the date? (±1 day)  (1)
What is the day of the week? (exacl)  (1)
What is the month? (exact)_________________________________________________(1)
What country are we in? __(1)
What county or city are we in? __U)
What town or area are we in?  (1)
What is the name of this place?  0 )
What floor of the building arc we on?  (1)
I am going to name three objects. After I have said them, I want you to repeat than Remember what 
they are because I am going to ask you to name them again in a few minutes.
BUS DOOR ROSE
Record number of trials:____________________ (Score 1st trial only) (3)
Please start with 100 and count backwards, subtracting 7 each time, go on to spelling of WORLD 
unless serial 7’s are all correct: 93, 86.79, 72.65:
_ _ _ _ _  (-(5))
What were the three objects 1 asked you to remember?
BUS DOOR ROSE _ (3 )
1 am going to give you a word and ask you to spell it forwards and backwards. The word is WORLD. 
First spell it forwards?. Now spell it backwards.
_ _ _ _ _  <-W )
Show a wrist watch. What is this called?  (1)
Show a pencil. What is this called?  (1)
Repeat after me, exactly as I say it: “No ifs ands or huts'’__________________________(1)
I’m going to give you a piece of paper. When I do, take it in your right hand, fold the paper in half with
both hands, and put the paper on the floor.____________________________________ __(3)
Read the words on the page, then do what it says. CTOSE YOUR EYES_____________ __(1)
Write a complete sentence on die piece of paper for me.  (1)
Here is a drawing. Please copy the drawing as accurately as you can.________________ __(1)
TOTAL _  (30)
Sprlag: 1st M ar-31st M ay, Summer: 1st Jim -31st Aug, Autum u: 1st Scp-30th Nov, W in ter: 1st Dec-28th Feb
NHQS: Q ueen Square. H albarne. R u ssell Square, T he City. St M ary's: Paddington. E dgew are R d. Maryiebonc
S erial 7 ’k  Each subtraction may be prompted eg. 93-7. Score mathematical correctness ie 92-7=85. A llow  10-20 secs per 
reply and stop after 2 incorrect answers. Unless all 5 arc correct, go cm to W O RLD backwards.
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CLOSE YOUR EYES
Please write your sentence in the space below:
Please copy this diagram on the bottom half of this page
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Appendix 3: Semi-automated labelling of brain regions
The aim of the procedure is to label all brain voxels while excluding non-brain, for 
example, CSF or dura. The procedure incorporates conditional morphology procedure 
and makes use o f the knowledge that the brain is the largest structure in a 3D scan of 
the head and that it is only weakly connected to adjacent structures, (e.g. the optic 
nerve is a weak connection to the eye). In most cases whole brain segmentation can 
be accomplished by four steps: thresholding, erosion, dilation and internal 
rethresholding.
S t e p  1 - I n t e n s i t y  T h r e s h o l d i n g
Intensity thresholds are set to exclude voxels brighter than brain (e.g. scalp) and 
darker than brain (e.g. CSF). The upper threshold is set first. Anything brighter than 
the upper threshold will be excluded. The aim is chose thresholds to exclude most 
tissues brighter than white matter including susceptibility artefact (esp. inferior 
temporal lobe) while not excluding normal white matter.
Figure A3.1: Initial thresholding w ith lower threshold = 0, upper threshold set 
to exclude high signal (most of scalp).
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The lower threshold is set to include as much of brain as possible while minimising 
inclusion of non-brain. This threshold is typically half the value of the upper 
threshold. The green intensity region should now include most of the brain.
Figure A3.2: Upper and lower thresholds set to include brain and exclude CSF
Ideally the lower threshold should be taken to a high enough value so that in the next 
step only one erosion is needed to remove non-brain and leave only brain. This 
requires the thresholding step to have reduced the size of “bridges” between brain and 
scalp.
The final part o f this step is to set the axial cut off slice. This removes any structures 
below the inferior edge of the cerebellum. This is set when viewing the image in the 
coronal plane - removing all axial slices below the lowest extent of the cerebellum. 
Once this step is completed and Accept clicked Midas searches for the largest 
connected 3-D object in the current region (i.e. brain) and removes any smaller 
objects.
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F i g u r e  A 3 .3 :  T h e  a x i a l  c u t - o f f  s h o u l d  c o i n c i d e  w i t h  t h e  b o t t o m  o f  t h e  
c e r e b e l l u m .  
S t e p  2 - E r o s i o n
The erosion removes edge-voxels from all surfaces of the region. The purpose is to 
break thin connections between brain and scalp. After each erosion the program 
retains only the largest connected region. The minimum erosions necessary to isolate 
brain should be done. The usual range of erosions is [0, 3]. High numbers o f erosions 
remove significant quantities of brain from the region which cannot be recovered in 
the Dilation stage. The erosions are conditional in that a range of signal intensities 
which determines which voxels can be eroded - for instance setting an upper 
threshold at the intensity of white matter will only erode voxels with a signal intensity 
beneath this value. The number of erosions required are increased one at a time. 
Often the brain remains connected to scalp on only a few slices, often around the 
temporal lobes. If connections can be identified visually then they can be broken 
interactively at this stage by striking through them with the mouse while holding
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down the middle button. When all connections between brain and non-brain have 
been removed, all parts of the region external to brain are removed automatically.
F i g u r e  A 3 .4 :  A n  e r o d e d  b r a i n  r e g i o n  d i s c o n n e c t e d  f r o m  s u r r o u n d i n g  
t i s s u e .  
S t e p  3  - C o n d i t i o n a l  D i l a t i o n
The purpose of this step is to recover the brain voxels that has been removed by 
erosion. Each dilation grows out from the edges of the current brain region but only 
into voxels within defined range of intensities which represent brain.. The intensity 
thresholds that appear at this point are automatically set by calculating the mean 
signal intensity over the whole brain region after step 2 and taking 60% and 160% of 
this value. These percentages have been determined to be suitable for T1-weighted 
volumes. The thresholds are re-calculated after each dilation as more voxels are 
recovered. The number of dilations that are needed to recover all brain voxels 
depends on the number of erosions (typically = number of erosions + 2).
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Step 4 - Rethresholding
This step reclaims remaining excluded areas and completes the segmentation. The 
rethresholding box is a box of X voxels that moves across the outlined brain region 
and fills in any area within that region that has been omitted by step 3 subject to the 
following constraints:
• the omitted area must be smaller than the box.
• only those voxels that have a signal intensity of between 60% and 160% of the 
mean brain intensity will be included.
• the missing area must already be internal to the region.
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Appendix 4: Ventricular segmentation
The aim of this protocol is to label areas of ventricular cerebrospinal fluid taking care
not to include extraneous CSF spaces. Before the process can begin ensure that the
corresponding brain region is loaded from the brain database and that the coronal
view can be seen in the MIDAS window.
Step 1 - Preparing the image
1. The initial step is to calculate the upper threshold to be used in the segmentation 
process. This is done by highlighting the brain region and choosing Measure 
:Simple Mean. This calculates the mean voxel intensity over the whole region and 
computes 60% and 160% of the mean. The values can be seen in the Log 
window. Make a note of the 60% value.
2. The next step is the removal of the outlined region. This is achieved by clicking 
on Regions followed by Remove. This is the end of the preparation process.
Step 2 - Setting the threshold
1. The segmentation tool required for this procedure is the Irregular Volume 
window which is found in Regions'. Edit: Irregular Volume. Once the window is 
open line up the MIDAS and Irregular Volume windows side by side so that the 
images in both windows can be viewed simultaneously. In the Irregular Volume 
window choose the sagittal view. Set the brightness in the MIDAS window to a 
satisfactory level and increase the magnification of both images until the 
ventricles can be clearly seen.
2. To set the threshold click on Threshold in the Irregular Volume window toolbar 
and move the Upper threshold slide bar to the 60% value. The lower threshold 
remains at zero. This ensures that any voxel with an intensity of above 60% of 
the mean will be excluded (which eliminates all white and grey matter) but 
ensures that all CSF areas are included.
Step 3 - Segmentation
1. Set the starting point by moving the dotted position bar in the MIDAS window so 
that it lies midway across the left lateral ventricle. In the Irregular Volume 
window (which is now showing the corresponding slice in the sagittal plane)
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move the dotted bar anteriorly to a point approximately one third of the ventricle 
length. The image in the MIDAS window will change to the corresponding 
coronal slice.
2. In the Irregular Volume window toolbar click on Seed and, in the MIDAS 
window image, put a seed in the centre of each of the lateral ventricles (achieved 
by clicking on the right mouse button). The area will be highlighted in both the 
coronal and sagittal images. If there are no CSF spaces in the temporal lobes 
(temporal horn) move up one slice. The seeds will be automatically retained. If 
the seed has missed the ventricle, place another seed in the centre and the missing 
area will be highlighted. Continue moving up each slice until the lateral 
ventricles are totally separated from any other CSF areas. When this point is 
reached click on Pgt Up in the Irregular Volume window toolbar and Continue 
when the warning box appears. This will propagate the seeds up through every 
slice anterior to the present slice and highlights the ventricle. Make sure this is 
only used when the ventricles are not joined to any other CSF spaces as 
propagating will result in all adjoining CSF being highlighted. If this does occur, 
the propagation can be cancelled by clicking on Wipe + in the Irregular Volume 
window toolbar. To check the propagation, move the dotted position bar on the 
Irregular Volume image to a couple of points anterior to the highlighted edge of 
the ventricle.
3. Occasionally, the temporal horn will be in view when the procedure is started. If 
this is the case seeds need to be placed in these spaces. The more anterior the 
slice the smaller the temporal horn will become until it is no longer visible.
4. When all slices anterior to the starting slice appear to be highlighted it is time to 
move posteriorly. Take the dotted position bar on the Irregular Volume window 
to the starting position (the first highlighted area). Move down a slice at a time. 
As before, the seeds will be automatically retained. In contrast to point 3, the 
more posterior the slice the more of the temporal horn will be in view. Care 
needs to be taken when highlighting this area as extraneous CSF spaces can often 
be included. To ensure consistency, follow this rule: As you look at either the left 
or right hippocampus in the coronal view, imagine a line following the curve of 
the relative parahippocampal gyrus and then extending up into the hemisphere 
(avoiding the hippocampus) running almost parallel to the corresponding 
ventricle. Any CSF spaces to the left (if viewing the right hippocampus) or right
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(if viewing the left hippocampus) of this line should be included whereas any 
spaces to the right/left respectively will be excluded (see examples Fig A4.1 and 
Fig A4.2).
Figure A4.1 Temporal horn of lateral ventricles manual border shown (i)
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Figure A4.2 Temporal horn of lateral ventricles manual border shown (ii))
5. Moving posteriorly the lateral ventricles and temporal horn will begin to 
converge. As the CSF areas start to appear use as many seeds as possible to 
ensure that all CSF is highlighted. Some apparently dark areas will not be 
included as their voxel intensity is above the 60% threshold. Continue in this 
manner until a slice is reached where no ventricle spaces are seen. Again care 
needs to be taken as some subjects have a single hemisphere lateral ventricle that 
extends far beyond the ventricle in the opposite hemisphere. This area has to be 
included. In cases of uncertainty, check the corresponding slice on the Irregular 
Volume sagittal or axial image using the position bar.
6. Once all slices appear to have been segmented move the coronal image to 
approximately slice 65 or any other central slice where lateral ventricles and 
temporal horn can be seen. Using the position bar, check around each lateral 
ventricle and each temporal horn on both the coronal and sagittal planes to ensure 
that no slice has been missed and no extraneous CSF areas have been included. 
Seeds (unwanted areas) can be removed by clicking the middle mouse button on
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the seed thereby removing it and then Clean. Repeat looking at the coronal and 
axial planes. When the segmentation process is complete, click OK.
7. To database the segmented ventricle region, make sure that the ventricle regional 
database is open {Regions - Show Database - Ventricles). Highlight the region by 
clicking on the blue outline, click on Regions then Database and enter the 
required information including the 60% threshold value.
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Electronic Database Information
URLs for the data in this thesis are as follows:
• GenBank: http://www.ncbi.nlm.nih.gov/Genbank/Genbank Overview.html
• Online Mendelian Inheritance in Man (OMIM): 
http://www.ncbi.nlm.nih.gov/Omim/
• Online Alzheimer Disease & Frontotemporal Dementia Mutation Database: 
http://www.molgen.ua.ac.be/ADMutations
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